[
{
	"jumpto":"ENAS5268_2.3.2.0",
	"name":"(5-HT)3 receptor antagonists, doses [N/V]"
},
{
	"jumpto":"ENAS5407_4.5.0.0",
	"name":"(C)RT regimen, selection [Rectal CA]"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"(FOLFIRINOX), gemcitabine [Pancr]"
},
{
	"jumpto":"interactive_0002491",
	"name":"(Neo)-Adj. systemic treatment choice, tool [EBC]"
},
{
	"jumpto":"ENAS6235_4.4.1.0",
	"name":"(Neo)Adjuvant systemic treatment [EBC]"
},
{
	"jumpto":"ENAS5285_6.2.2.3",
	"name":"1st-line treat., good/intermed. Px [RCC]"
},
{
	"jumpto":"ENAS5643_4.4.0.0",
	"name":"1st line Tx. of NSCLC w/o oncogenic driver"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"3D conformal RT [TETs]"
},
{
	"jumpto":"ENAS5068_5.5.0.0",
	"name":"5-fluorouracil (5-FU)/folinic acid (FA) [Pancr]"
},
{
	"jumpto":"ENAS5062_4.1.0.0",
	"name":"5-fluorouracil (5-FU)[Anal cancer]"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"5-fluorouracil (5-FU) [mCRC]"
},
{
	"jumpto":"ENAS5647_6.1.2.0",
	"name":"5-Fluorouracil [Diarrh.]"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"5-FU, in advanced penile CA [PenCa]"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"5-FU [PenCa]"
},
{
	"jumpto":"ENAS5285_5.2.1.3",
	"name":"5-year disease-specific survival [RCC]"
},
{
	"jumpto":"ENAS5282_3.1.0.0",
	"name":"18F-FDG-PET (Oes CA)"
},
{
	"jumpto":"ENAS5271_4.2.1.0",
	"name":"AAIPI in patients ≤60 years, DLBCL"
},
{
	"jumpto":"ENAS6346_4.0.0.0",
	"name":"ABC, assessment guidelines"
},
{
	"jumpto":"ENAS6346_4.0.0.0",
	"name":"ABC, biopsy guidelines"
},
{
	"jumpto":"ENAS6346_4.0.0.0",
	"name":"ABC, chemotherapy guidelines"
},
{
	"jumpto":"ENAS6346_2.0.0.0",
	"name":"ABC, definitions"
},
{
	"jumpto":"ENAS6346_15.1.0.0",
	"name":"ABC, diagnostic and treatment algorithms"
},
{
	"jumpto":"ENAS6346_5.0.0.0",
	"name":"ABC, ER-positive/HER2-negative"
},
{
	"jumpto":"ENAS6346_3.0.0.0",
	"name":"ABC, general guidelines"
},
{
	"jumpto":"ENAS6346_6.0.0.0",
	"name":"ABC, HER2-positive"
},
{
	"jumpto":"ENAS6346_7.0.0.0",
	"name":"ABC, triple negative"
},
{
	"jumpto":"ENAS6346_15.2.0.0",
	"name":"ABC diagnostic work-up and staging, interactive tool"
},
{
	"jumpto":"ENAS6346_15.1.0.0",
	"name":"ABC follow-up and supportive care, interactive tool"
},
{
	"jumpto":"interactive_0002106",
	"name":"ABC follow-up and supportive care, interactive tool"
},
{
	"jumpto":"interactive_0002107",
	"name":"ABC symptom control, interactive tool"
},
{
	"jumpto":"ENAS6346_15.7.0.0",
	"name":"ABC symptom control, interactive tool"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Abdominal pain (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Abiraterone, palliative care [PC]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Abiraterone, side effects [PC]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Abiraterone, treatment of CRPC [PC]"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"Abiraterone [PC]"
},
{
	"jumpto":"ENAS5304_8.6.4.0",
	"name":"Ablative treatment with or without surgery, summary [mCRC]"
},
{
	"jumpto":"ENAS5268_2.2.3.0",
	"name":"AC-treated female patients, breast cancer [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.2.3",
	"name":"AC-treated female pts. with breast cancer, summary [N/V]"
},
{
	"jumpto":"ENAS5410_3.1.1.0",
	"name":"Acantholytic dysker­ato­sis [irAEs]"
},
{
	"jumpto":"ENAS6344_3.1.0.0",
	"name":"ACC, diagnosis and pathology [ACC]"
},
{
	"jumpto":"ENAS6344_2.0.0.0",
	"name":"ACC, Incidence and epidemiology [ACC]"
},
{
	"jumpto":"ENAS6344_8.5.1.0",
	"name":"ACC, summary [ACC]"
},
{
	"jumpto":"ENAS6344_5.1.2.1",
	"name":"ACC management [ACC]"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"Acquired cystic disease-associated RCCs"
},
{
	"jumpto":"ENAS6341_4.1.4.6",
	"name":"Acupuncture, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.4.6.0",
	"name":"Acupuncture [PCN]"
},
{
	"jumpto":"ENAS6341_4.2.4.0",
	"name":"Acute cerebellar syndrome, summary [PCN]"
},
{
	"jumpto":"ENAS6341_3.4.0.0",
	"name":"Acute cerebellar syndrome [PCN]"
},
{
	"jumpto":"ENAS5268_4.0.0.0",
	"name":"Acute CINV in children, prevention [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.3.0",
	"name":"Acute emesis [N/V]"
},
{
	"jumpto":"ENAS5269_5.9.4.0",
	"name":"Acute myeloid leukaemia [FN]"
},
{
	"jumpto":"ENAS5062_4.4.1.0",
	"name":"Acute pelvic toxicity [Anal cancer]"
},
{
	"jumpto":"ENAS5265_5.1.1.0",
	"name":"Acute treatment, LMWH and UFH [VTE]"
},
{
	"jumpto":"ENAS5265_5.1.1.0",
	"name":"Acute treatment, solid tumours [VTE]"
},
{
	"jumpto":"ENAS5265_5.1.2.0",
	"name":"Acute treatment, thrombolytic therapy [VTE]"
},
{
	"jumpto":"ENAS5265_8.4.1.1",
	"name":"Acute treatment in solid tumours, summary [VTE]"
},
{
	"jumpto":"ENAS5265_8.4.1.1",
	"name":"Acute treatment with LMWH and UFH, summary [VTE]"
},
{
	"jumpto":"ENAS5265_8.4.1.2",
	"name":"Acute treatment with thrombolytic therapy, summary [VTE]"
},
{
	"jumpto":"ENAS5269_5.9.6.0",
	"name":"Acyclovir [FN]"
},
{
	"jumpto":"ENAS5282_2.0.0.0",
	"name":"Adenocarcinomas (Oes CA)"
},
{
	"jumpto":"ENAS5282_4.1.6.0",
	"name":"Adenocarcinomas, management (Oes CA)"
},
{
	"jumpto":"ENAS6369_2.3.0.0",
	"name":"Adenocarcinoma [Cervical CA]"
},
{
	"jumpto":"ENAS5283_4.3.3.2",
	"name":"Adjuvant 5-FU/leucovorin therapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5092_4.2.2.0",
	"name":"Adjuvant ADT [PC]"
},
{
	"jumpto":"ENAS5094_4.3.0.0",
	"name":"Adjuvant chemotherapy [BC]"
},
{
	"jumpto":"ENAS5304_5.7.0.0",
	"name":"Adjuvant chemotherapy [mCRC]"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"Adjuvant chemotherapy [TS/T-NS]"
},
{
	"jumpto":"ENAS6366_2020112710",
	"name":"Adjuvant ChT for early stage disease [EOC]"
},
{
	"jumpto":"ENAS5644_8.3.3.0",
	"name":"Adjuvant therapies, summary [HCC]"
},
{
	"jumpto":"ENAS5644_4.5.0.0",
	"name":"Adjuvant therapies [HCC]"
},
{
	"jumpto":"ENAS6370_8.4.3.0",
	"name":"Adjuvant therapy, summary [Endometrial CA]"
},
{
	"jumpto":"ENAS6343_8.4.2.0",
	"name":"Adjuvant therapy, summary [GEP-NENs]"
},
{
	"jumpto":"ENAS6370_5.3.0.0",
	"name":"Adjuvant therapy [Endometrial CA]"
},
{
	"jumpto":"ENAS6343_5.2.0.0",
	"name":"Adjuvant therapy [GEP-NENs]"
},
{
	"jumpto":"ENAS5283_4.3.3.1",
	"name":"Adjuvant treatment (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.1.3",
	"name":"Adjuvant treatment, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS6344_8.4.2.0",
	"name":"Adjuvant treatment, summary [ACC]"
},
{
	"jumpto":"ENAS5284_7.3.1.6",
	"name":"Adjuvant treatment, summary [Bil]"
},
{
	"jumpto":"ENAS6369_8.3.2.0",
	"name":"Adjuvant treatment, summary [Cervical CA]"
},
{
	"jumpto":"ENAS5068_8.3.4.0",
	"name":"Adjuvant treatment in pancreatic cancer, summary"
},
{
	"jumpto":"ENAS6338_7.3.2.0",
	"name":"Adjuvant treatment of stage II colon cancer [LCC]"
},
{
	"jumpto":"ENAS6338_7.2.2.0",
	"name":"Adjuvant treatment of stage III colon cancer [LCC]"
},
{
	"jumpto":"ENAS6344_5.2.1.0",
	"name":"Adjuvant treatment [ACC]"
},
{
	"jumpto":"ENAS5284_4.3.6.0",
	"name":"Adjuvant treatment [Bil]"
},
{
	"jumpto":"ENAS6369_4.3.1.0",
	"name":"Adjuvant treatment [Cervical CA]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Adjuvant treatment [TS/T-NS]"
},
{
	"jumpto":"ENAS5092_6.0.0.0",
	"name":"ADT [PC]"
},
{
	"jumpto":"ENAS6370_5.2.5.0",
	"name":"Advanced (stage III–IV) and recurrent endometrial cancer [Endometrial CA]"
},
{
	"jumpto":"ENAS5645_6.3.1.0",
	"name":"Advanced-stage disease, overview [HL]"
},
{
	"jumpto":"ENAS5645_11.3.3.0",
	"name":"Advanced-stage disease, summary"
},
{
	"jumpto":"ENAS5645_6.3.1.0",
	"name":"Advanced-stage disease, treatment of cHL"
},
{
	"jumpto":"ENAS6370_8.4.4.0",
	"name":"Advanced and recurrent disease, summary [Endometrial CA]"
},
{
	"jumpto":"ENAS6370_5.4.1.0",
	"name":"Advanced and recurrent disease [Endometrial CA]"
},
{
	"jumpto":"ENAS5268_5.1.0.0",
	"name":"Advanced cancer, antiemetics [N/V]"
},
{
	"jumpto":"ENAS5285_5.2.2.1",
	"name":"Advanced disease, overview [RCC]"
},
{
	"jumpto":"ENAS5285_9.3.0.0",
	"name":"Advanced disease, summary [RCC]"
},
{
	"jumpto":"ENAS6229_4.2.0.0",
	"name":"Advanced metastatic bronchial and thymic NETs, treatment [NETs]"
},
{
	"jumpto":"ENAS6366_202011277",
	"name":"Advanced ovarian cancer [EOC]"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Advanced pancreatic cancer"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Advanced pancreatic cancer, palliative care"
},
{
	"jumpto":"ENAS6235_4.3.1.3",
	"name":"Advances in axillary management [EBC]"
},
{
	"jumpto":"ENAS5304_5.14.4.0",
	"name":"Aflibercept [mCRC]"
},
{
	"jumpto":"ENAS5633_4.1.5.0",
	"name":"Age-adapted protocols [ALL]"
},
{
	"jumpto":"ENAS5633_7.3.1.5",
	"name":"Age related potocols in ALL, summary"
},
{
	"jumpto":"ENAS5284_3.2.1.1",
	"name":"AJCC/UICC staging, cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5284_3.2.2.0",
	"name":"AJCC/UICC staging, gallbladder cancer [Bil]"
},
{
	"jumpto":"ENAS6229_3.0.0.0",
	"name":"AJCC/UICC TNM staging classification system of NETs of the lung [NETs]"
},
{
	"jumpto":"ENAS5269_5.4.0.0",
	"name":"Algo., FN mgmt."
},
{
	"jumpto":"ENAS5269_4.2.0.0",
	"name":"Algo., primary G-CSF prophylaxis [FN]"
},
{
	"jumpto":"ENAS5269_5.10.2.0",
	"name":"Algo., response assessment [FN]"
},
{
	"jumpto":"ENAS5284_4.2.0.0",
	"name":"Algorithm, BTC management [Bil]"
},
{
	"jumpto":"ENAS5285_6.2.2.2",
	"name":"Algorithm, systemic treatment [RCC]"
},
{
	"jumpto":"ENAS6232_2.1.0.0",
	"name":"Algorithm for hereditary GC diagnosis, tool [Hereditary GC]"
},
{
	"jumpto":"interactive_0002497",
	"name":"Algorithm for hereditary GC diagnosis, tool [Hereditary GC]"
},
{
	"jumpto":"ENAS5263_14.4.0.0",
	"name":"Alimentary tract mucositis, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_5.0.0.0",
	"name":"Alimentary tract mucositis [Mucosa]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Alkylating agents [Extra]"
},
{
	"jumpto":"ENAS5633_2.1.0.0",
	"name":"ALL, diagnosis"
},
{
	"jumpto":"ENAS5633_2.2.0.0",
	"name":"ALL, diagnosis and work-up"
},
{
	"jumpto":"ENAS5633_4.1.6.1",
	"name":"ALL, targeted therapies"
},
{
	"jumpto":"ENAS5633_7.1.3.0",
	"name":"ALL cytogentics, summary"
},
{
	"jumpto":"ENAS5633_7.1.2.0",
	"name":"ALL diagnosis, summary"
},
{
	"jumpto":"interactive_0002135",
	"name":"ALL diagnosis and risk assessment, interactive tool"
},
{
	"jumpto":"ENAS5633_3.3.0.0",
	"name":"ALL diagnosis and risk assessment, interactive tool"
},
{
	"jumpto":"ENAS5633_4.1.5.0",
	"name":"ALL in adolescents and young adults"
},
{
	"jumpto":"ENAS5633_4.1.5.0",
	"name":"ALL in adult"
},
{
	"jumpto":"ENAS5633_4.1.5.0",
	"name":"ALL in elderly"
},
{
	"jumpto":"ENAS5633_7.3.1.3",
	"name":"ALL maintenance therapy, summary"
},
{
	"jumpto":"ENAS5633_7.2.2.0",
	"name":"ALL minimal residual disease, summary"
},
{
	"jumpto":"ENAS5633_7.1.4.0",
	"name":"ALL new genetics/genomics, summary"
},
{
	"jumpto":"ENAS5269_5.9.4.0",
	"name":"Allogeneic haematopoietic stem cell transplantation [FN]"
},
{
	"jumpto":"ENAS5636_8.4.4.0",
	"name":"Allogeneic stem cell transplantation, summary [CML]"
},
{
	"jumpto":"ENAS5637_10.4.6.0",
	"name":"Allogeneic stem cell transplantation, summary [MDS]"
},
{
	"jumpto":"ENAS5636_5.4.0.0",
	"name":"Allogeneic stem cell transplantation in CML"
},
{
	"jumpto":"ENAS5637_5.6.0.0",
	"name":"Allogeneic stem cell transplantation [MDS]"
},
{
	"jumpto":"ENAS5410_4.2.6.7",
	"name":"Allograft rejection, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.7.0",
	"name":"Allograft rejection [irAEs]"
},
{
	"jumpto":"ENAS5280_4.6.0.0",
	"name":"AlloSCT"
},
{
	"jumpto":"ENAS5636_5.5.0.0",
	"name":"AlloSCT in advanced stage CML"
},
{
	"jumpto":"ENAS5636_8.4.5.0",
	"name":"AlloSCT in advanced stage CML, summary"
},
{
	"jumpto":"ENAS5280_7.3.6.0",
	"name":"AlloSCT in HCL, summary"
},
{
	"jumpto":"ENAS5637_5.6.0.0",
	"name":"AlloSCT [MDS]"
},
{
	"jumpto":"ENAS5633_7.2.1.0",
	"name":"ALL risk assessment, summary"
},
{
	"jumpto":"ENAS5633_7.1.2.0",
	"name":"ALL screening, summary"
},
{
	"jumpto":"ENAS5262_6.3.3.3",
	"name":"ALT, summary [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.1.0",
	"name":"Alternative therapy, overview [FN]"
},
{
	"jumpto":"ENAS5269_6.4.6.1",
	"name":"Alternative therapy, summary [FN]"
},
{
	"jumpto":"ENAS5262_4.3.5.0",
	"name":"ALT [CVC]"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Amifostine [Mucosa]"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"Amikacin [CVC]"
},
{
	"jumpto":"ENAS5635_3.4.0.0",
	"name":"AML, co-morbidity and other host factors"
},
{
	"jumpto":"ENAS5635_2.0.0.0",
	"name":"AML, diagnosis and pathology"
},
{
	"jumpto":"ENAS5635_4.2.0.0",
	"name":"AML, invasive treatment"
},
{
	"jumpto":"ENAS5635_3.2.0.0",
	"name":"AML, karyotype/cytogenetics"
},
{
	"jumpto":"ENAS5635_3.3.0.0",
	"name":"AML, molecular genetics"
},
{
	"jumpto":"ENAS5635_4.3.0.0",
	"name":"AML, non-invasive treatment"
},
{
	"jumpto":"ENAS5635_3.5.0.0",
	"name":"AML, pre-treatment investigations"
},
{
	"jumpto":"ENAS5635_3.1.0.0",
	"name":"AML, risk assessment"
},
{
	"jumpto":"ENAS5635_3.2.0.0",
	"name":"AML, risk factors"
},
{
	"jumpto":"ENAS5635_4.1.0.0",
	"name":"AML, treatment"
},
{
	"jumpto":"ENAS5635_4.4.0.0",
	"name":"AML, treatment of refractory or relapsed AML"
},
{
	"jumpto":"ENAS5637_10.4.3.0",
	"name":"AML-like chemotherapy, summary [MDS]"
},
{
	"jumpto":"ENAS5637_5.3.0.0",
	"name":"AML-like chemotherapy [MDS]"
},
{
	"jumpto":"ENAS5635_7.2.4.0",
	"name":"AML co-morbidity and other host factors, summary"
},
{
	"jumpto":"ENAS5635_7.1.0.0",
	"name":"AML diagnosis and pathology, summary"
},
{
	"jumpto":"ENAS5635_7.2.2.0",
	"name":"AML karyotype/cytogenetics, summary"
},
{
	"jumpto":"ENAS5635_7.2.3.0",
	"name":"AML molecular genetics, summary"
},
{
	"jumpto":"ENAS5635_7.3.3.0",
	"name":"AML non-invasive treatment, summary"
},
{
	"jumpto":"ENAS5635_7.4.0.0",
	"name":"AML personalised medicine, summary"
},
{
	"jumpto":"ENAS5635_7.2.5.0",
	"name":"AML pre-treatment investigations, summary"
},
{
	"jumpto":"ENAS5635_7.5.0.0",
	"name":"AML response evaluation and follow-up, summary"
},
{
	"jumpto":"ENAS5635_7.2.1.0",
	"name":"AML risk assessment, summary"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"Amphiregulin [mCRC]"
},
{
	"jumpto":"ENAS5262_6.3.3.9",
	"name":"Amphotericin, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.11.0",
	"name":"Amphotericin [CVC]"
},
{
	"jumpto":"ENAS5637_6.3.0.0",
	"name":"Anaemia, first-line treatment in low risk MDS"
},
{
	"jumpto":"ENAS5637_6.4.0.0",
	"name":"Anaemia, second-line treatment in low risk MDS"
},
{
	"jumpto":"ENAS5639_3.4.3.0",
	"name":"Anaemia, treatment [MPNs]"
},
{
	"jumpto":"ENAS5648_9.1.1.1",
	"name":"Anaemia mgmt. of solid tumours or hemat. Malignancies, summary"
},
{
	"jumpto":"ENAS5637_6.2.0.0",
	"name":"Anaemia treatment in low risk MDS"
},
{
	"jumpto":"ENAS5648_5.1.0.0",
	"name":"Anaemia with MDS, management"
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Anal cancer, advanced disease"
},
{
	"jumpto":"ENAS5062_3.3.0.0",
	"name":"Anal cancer, anatomic stage"
},
{
	"jumpto":"ENAS5062_4.5.0.0",
	"name":"Anal cancer, brachytherapy"
},
{
	"jumpto":"ENAS5062_4.4.1.0",
	"name":"Anal cancer, chemoradiotherapy"
},
{
	"jumpto":"ENAS5062_2.1.0.0",
	"name":"Anal cancer, diagnosis"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"Anal cancer, diagnostic work-up"
},
{
	"jumpto":"ENAS5062_7.0.0.0",
	"name":"Anal cancer, follow-up"
},
{
	"jumpto":"ENAS5062_4.1.0.0",
	"name":"Anal cancer, initial mgmt."
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Anal cancer, metastatic disease"
},
{
	"jumpto":"ENAS5062_4.12.0.0",
	"name":"Anal cancer, palliative care"
},
{
	"jumpto":"ENAS5062_4.7.0.0",
	"name":"Anal cancer, post-operative chemoradiotherapy"
},
{
	"jumpto":"ENAS5062_3.3.0.0",
	"name":"Anal cancer, prognostic groups"
},
{
	"jumpto":"ENAS5062_5.0.0.0",
	"name":"Anal cancer, quality of life"
},
{
	"jumpto":"ENAS5062_4.4.2.0",
	"name":"Anal cancer, radiotherapy"
},
{
	"jumpto":"ENAS5062_6.0.0.0",
	"name":"Anal cancer, response evaluation"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Anal cancer, risk assessment"
},
{
	"jumpto":"ENAS5062_3.4.0.0",
	"name":"Anal cancer, risk assessment factors"
},
{
	"jumpto":"ENAS5062_4.9.0.0",
	"name":"Anal cancer, salvage surgical treatment"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Anal cancer, staging"
},
{
	"jumpto":"ENAS5062_4.3.0.0",
	"name":"Anal cancer, surgical treatment"
},
{
	"jumpto":"ENAS5062_7.0.0.0",
	"name":"Anal cancer, surveillance"
},
{
	"jumpto":"ENAS5062_3.2.0.0",
	"name":"Anal cancer, TNM staging"
},
{
	"jumpto":"ENAS5062_4.6.0.0",
	"name":"Anal cancer, treatment of the elderly"
},
{
	"jumpto":"ENAS5062_8.2.0.0",
	"name":"Anal cancer staging, summary"
},
{
	"jumpto":"ENAS5263_11.4.0.0",
	"name":"Analgesics [Mucosa]"
},
{
	"jumpto":"ENAS5409_3.0.0.0",
	"name":"Anaphylaxis, clinical criteria for diagnosis [IRs]"
},
{
	"jumpto":"ENAS5409_3.0.0.0",
	"name":"Anaphylaxis, diagnosis criteria [IRs]"
},
{
	"jumpto":"ENAS6228_3.1.0.0",
	"name":"Anaplastic thyroid cancer [TC]"
},
{
	"jumpto":"ENAS5283_3.3.0.0",
	"name":"Anatomic stage/ prognostic groups (Gastric cancer)"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Angiography, pancreatic arterial"
},
{
	"jumpto":"ENAS5273_4.2.0.0",
	"name":"Ann Arbor classification, FL"
},
{
	"jumpto":"ENAS5271_3.2.0.0",
	"name":"Ann Arbor staging classification, DLBCL"
},
{
	"jumpto":"ENAS5278_3.4.0.0",
	"name":"Ann Arbor staging classification, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5647_6.2.2.0",
	"name":"Anthracyclines [Diarrh.]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Anthracyclines [Extra]"
},
{
	"jumpto":"ENAS5409_11.1.2.0",
	"name":"Anthracyclines [IRs]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Anti-angiogenic therapy [BC]"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"Anti-EGFR monoclonal antibody therapies [mCRC]"
},
{
	"jumpto":"ENAS5086_5.3.0.0",
	"name":"Anti-folate doublet, unresectable mesothelioma"
},
{
	"jumpto":"ENAS6235_7.3.5.0",
	"name":"Anti-HER2 therapy, summary [EBC]"
},
{
	"jumpto":"ENAS6235_4.4.7.1",
	"name":"Anti-HER2 therapy [EBC]"
},
{
	"jumpto":"ENAS6342_4.1.2.0",
	"name":"Anti-infective therapy in non-gastric EMZL [MZLs]"
},
{
	"jumpto":"ENAS5268_5.2.0.0",
	"name":"Anti-secretory drugs [N/V]"
},
{
	"jumpto":"ENAS5304_5.14.4.0",
	"name":"Antiangiogenic [mCRC]"
},
{
	"jumpto":"ENAS5262_6.3.3.3",
	"name":"Antibiotic lock therapy, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.5.0",
	"name":"Antibiotic lock therapy [CVC]"
},
{
	"jumpto":"ENAS5647_14.3.6.0",
	"name":"Antibiotics [Diarrh.]"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"Antibiotic treatment, CVC-related infections [CVC]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Anticancer agents, classification [Extra]"
},
{
	"jumpto":"ENAS6339_11.4.6.0",
	"name":"Anticancer therapeutics associated with risk of HTN management [CVD]"
},
{
	"jumpto":"ENAS6339_5.7.0.0",
	"name":"Anticancer therapeutics associated with risk of hypertension management [CVD]"
},
{
	"jumpto":"ENAS5268_5.2.0.0",
	"name":"Anticholinergics [N/V]"
},
{
	"jumpto":"ENAS5268_2.8.0.0",
	"name":"Anticipatory nausea and vomiting, prev."
},
{
	"jumpto":"ENAS5265_6.0.0.0",
	"name":"Anticoagulation, contraindications [VTE]"
},
{
	"jumpto":"ENAS5265_7.0.0.0",
	"name":"Anticoagulation and prognosis [VTE]"
},
{
	"jumpto":"ENAS5265_8.5.0.0",
	"name":"Anticoagulation contraindications, summary [VTE]"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Antidotes, after extravasation"
},
{
	"jumpto":"ENAS5268_2.3.1.0",
	"name":"Antiemetics, dose [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.1.0",
	"name":"Antiemetics, route of administration [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.1.0",
	"name":"Antiemetics, safety [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.1.0",
	"name":"Antiemetics, schedule [N/V]"
},
{
	"jumpto":"ENAS5268_5.1.0.0",
	"name":"Antiemetics in advanced cancer, overview [N/V]"
},
{
	"jumpto":"ENAS5268_6.4.1.0",
	"name":"Antiemetics in advanced cancer, summary [N/V]"
},
{
	"jumpto":"ENAS5268_6.2.3.0",
	"name":"Antiemetic treatment options, summary [N/V]"
},
{
	"jumpto":"ENAS5268_3.4.0.0",
	"name":"Antiemetic treatment options [N/V]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Antimetabolites [Extra]"
},
{
	"jumpto":"ENAS6343_8.4.3.2",
	"name":"Antiproliferative treatment, summary [GEP-NENs]"
},
{
	"jumpto":"ENAS6343_5.3.3.1",
	"name":"Antiproliferative treatment [GEP-NENs]"
},
{
	"jumpto":"ENAS5639_6.1.0.0",
	"name":"Antithrombotic therapy [MPNs]"
},
{
	"jumpto":"ENAS5635_4.5.0.0",
	"name":"APL, treatment [AML]"
},
{
	"jumpto":"ENAS5635_7.3.5.0",
	"name":"APL treatmane, summary [AML]"
},
{
	"jumpto":"ENAS6370_5.2.3.0",
	"name":"Apparent stage I endometrial cancer [Endometrial CA]"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Aprepitant [N/V]"
},
{
	"jumpto":"ENAS5410_3.6.3.2",
	"name":"Arthralgia management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"ASA [Mucosa]"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Asbestos exposure [MPM]"
},
{
	"jumpto":"ENAS6341_4.2.7.0",
	"name":"Aseptic meningitis, summary [PCN]"
},
{
	"jumpto":"ENAS6341_3.7.0.0",
	"name":"Aseptic meningitis [PCN]"
},
{
	"jumpto":"ENAS5269_6.4.7.0",
	"name":"Assess. of response, summary [FN]"
},
{
	"jumpto":"ENAS6341_4.1.2.1",
	"name":"Assessment/diagnosis, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.2.1.0",
	"name":"Assessment/diagnosis [PCN]"
},
{
	"jumpto":"ENAS6341_2.6.3.0",
	"name":"Assessment/diagnosis [PCN]"
},
{
	"jumpto":"ENAS6338_9.2.3.0",
	"name":"Assessment of baseline status & characteristics, summary [LCC]"
},
{
	"jumpto":"ENAS5647_20.1.0.0",
	"name":"Assessment of diarrhoea, summary [Diarrh.]"
},
{
	"jumpto":"ENAS5407_4.7.2.4",
	"name":"Assessment of distant metastases [Rectal CA]"
},
{
	"jumpto":"ENAS6338_9.2.4.0",
	"name":"Assessment of distant tumour extension, summary [LCC]"
},
{
	"jumpto":"ENAS6338_3.4.0.0",
	"name":"Assessment of distant tumour extension [LCC]"
},
{
	"jumpto":"ENAS5407_4.7.2.3",
	"name":"Assessment of patients planned for surgery [Rectal CA]"
},
{
	"jumpto":"ENAS6338_6.2.0.0",
	"name":"Assessment of recurrence & adjuvant therapy [LCC]"
},
{
	"jumpto":"ENAS6338_9.5.2.0",
	"name":"Assessment of recurrence risk and benefits from adjuvant therapy, summary [LCC]"
},
{
	"jumpto":"ENAS5269_5.10.1.0",
	"name":"Assessment of response [FN]"
},
{
	"jumpto":"ENAS6338_9.5.3.0",
	"name":"Assessment of risk of complications from adjuvant treatment, summary [LCC]"
},
{
	"jumpto":"ENAS5407_4.7.2.1",
	"name":"Assessment of the primary tumour response [Rectal CA]"
},
{
	"jumpto":"ENAS6341_4.1.2.4",
	"name":"Assessment tools – CIPN outcome measurements, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.2.4.0",
	"name":"Assessment tools – CIPN outcome measurements [PCN]"
},
{
	"jumpto":"ENAS6341_2.5.2.0",
	"name":"Assistance with daily living, motor deficit [PCN]"
},
{
	"jumpto":"ENAS6341_2.5.1.0",
	"name":"Assistance with daily living, predominantly sensory damage [PCN]"
},
{
	"jumpto":"ENAS6339_11.5.1.0",
	"name":"Asymptomatic, new laboratory abnormalities [CVD]"
},
{
	"jumpto":"ENAS6339_6.1.0.0",
	"name":"Asymptomatic, new laboratory abnormalities [CVD]"
},
{
	"jumpto":"ENAS5649_6.1.1.0",
	"name":"Asymptomatic patients, overview [WM]"
},
{
	"jumpto":"ENAS5649_10.3.1.0",
	"name":"Asymptomatic patients, summary [WM]"
},
{
	"jumpto":"ENAS6339_11.5.5.0",
	"name":"Asymptomatic patients and an elevation in cardiac troponin [CVD]"
},
{
	"jumpto":"ENAS6339_6.5.0.0",
	"name":"Asymptomatic patients and an elevation in cardiac troponin [CVD]"
},
{
	"jumpto":"ENAS6339_11.5.3.0",
	"name":"Asymptomatic patients and LVEF decrease treated with trastuzumab [CVD]"
},
{
	"jumpto":"ENAS6339_6.3.0.0",
	"name":"Asymptomatic patients and LVEF decrease treated with trastuzumab [CVD]"
},
{
	"jumpto":"ENAS6339_6.2.0.0",
	"name":"Asymptomatic patients and LVEF decrease [CVD]"
},
{
	"jumpto":"ENAS6339_11.5.2.0",
	"name":"Asymptomatic patients and LVEF decrease [CVD]"
},
{
	"jumpto":"ENAS6339_8.1.0.0",
	"name":"Asymptomatic patients with normal cardiac function [CVD]"
},
{
	"jumpto":"ENAS6339_6.4.0.0",
	"name":"Asymptomatic patients with normal LVEF but decrease in average GLS [CVD]"
},
{
	"jumpto":"ENAS6339_11.5.4.0",
	"name":"Asymptomatic patients with normal LVEF but decrease in average GLS [CVD]"
},
{
	"jumpto":"ENAS6228_5.3.1.0",
	"name":"ATC diagnosis and pathology, summary [TC]"
},
{
	"jumpto":"ENAS6228_3.1.0.0",
	"name":"ATCs, diagnosis and pathology [TC]"
},
{
	"jumpto":"ENAS6228_3.4.0.0",
	"name":"ATCs, management of advanced/metastatic disease [TC]"
},
{
	"jumpto":"ENAS6228_3.3.1.0",
	"name":"ATCs, management of local/locoregional disease [TC]"
},
{
	"jumpto":"ENAS6228_3.2.0.0",
	"name":"ATCs, staging and risk assessment [TC]"
},
{
	"jumpto":"ENAS6228_3.3.1.0",
	"name":"ATCs, surgery [TC]"
},
{
	"jumpto":"interactive_0002479",
	"name":"ATCs management recommendations, tool"
},
{
	"jumpto":"ENAS6228_3.3.2.0",
	"name":"ATCs management recommendations, tool [TC]"
},
{
	"jumpto":"ENAS6228_5.3.2.0",
	"name":"ATC staging and risk assessment, summary [TC]"
},
{
	"jumpto":"ENAS6228_3.1.0.0",
	"name":"ATCs [TC]"
},
{
	"jumpto":"ENAS6365_5.5.11.0",
	"name":"ATF [Bone health]"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Atypical mesothelial proliferation, immunohistochemistry (IHC)"
},
{
	"jumpto":"ENAS5062_4.4.2.0",
	"name":"Australasian planning guidelines"
},
{
	"jumpto":"ENAS5098_3.0.0.0",
	"name":"Autoimmune disorders associated with thymoma [TETs]"
},
{
	"jumpto":"ENAS5285_6.2.2.5",
	"name":"Axitinib [RCC]"
},
{
	"jumpto":"ENAS6339_3.1.1.0",
	"name":"Baseline CV risk assessments [CVD]"
},
{
	"jumpto":"ENAS6339_3.3.0.0",
	"name":"Baseline ECG [CVD]"
},
{
	"jumpto":"ENAS6339_3.4.0.0",
	"name":"Baseline evaluation of left ventricular ejection fraction [CVD]"
},
{
	"jumpto":"ENAS6339_3.2.0.0",
	"name":"Baseline measurement of cardiac biomarkers [CVD]"
},
{
	"jumpto":"ENAS5263_10.2.2.0",
	"name":"Basic oral care protocol, example [Mucosa]"
},
{
	"jumpto":"ENAS5094_2.0.0.0",
	"name":"BC, diagnosis"
},
{
	"jumpto":"ENAS5094_8.0.0.0",
	"name":"BC, follow-up"
},
{
	"jumpto":"ENAS5094_8.0.0.0",
	"name":"BC, long term implications"
},
{
	"jumpto":"ENAS5094_4.1.0.0",
	"name":"BC, management of local/ locoregional disease"
},
{
	"jumpto":"ENAS5094_4.4.0.0",
	"name":"BC, Organ preservation therapy"
},
{
	"jumpto":"ENAS5094_5.2.0.0",
	"name":"BC, second-line therapy"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"BC, staging and risk assessment"
},
{
	"jumpto":"ENAS5094_3.2.0.0",
	"name":"BC, TNM staging"
},
{
	"jumpto":"ENAS5094_2.0.0.0",
	"name":"BC, WHO classification"
},
{
	"jumpto":"ENAS5094_9.1.0.0",
	"name":"BC diagnosis, summary"
},
{
	"jumpto":"ENAS5644_3.3.0.0",
	"name":"BCLC staging and treatment options [HCC]"
},
{
	"jumpto":"ENAS5094_5.2.0.0",
	"name":"BC relapse, treatment"
},
{
	"jumpto":"ENAS5094_9.2.0.0",
	"name":"BC staging and risk assessment, summary"
},
{
	"jumpto":"ENAS5648_3.1.0.0",
	"name":"Benefit and risk profiles of treatments [Anaemia]"
},
{
	"jumpto":"ENAS5268_2.8.0.0",
	"name":"Benzodiazepines [N/V]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Benzydamine mouthwash [Mucosa]"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"BEP [TS/T-NS]"
},
{
	"jumpto":"ENAS5304_5.14.10.3",
	"name":"Best supportive care (BSC) [mCRC]"
},
{
	"jumpto":"ENAS5282_4.2.0.0",
	"name":"Best supportive care (Oes CA)"
},
{
	"jumpto":"ENAS5086_5.2.0.0",
	"name":"Best supportive care, MPM"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Bevacizumab [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.4.0",
	"name":"Bevacizumab [mCRC]"
},
{
	"jumpto":"ENAS5285_6.2.2.3",
	"name":"Bevacizumab [RCC]"
},
{
	"jumpto":"ENAS5643_6.3.11.2",
	"name":"Beyond first-line treatment, summary"
},
{
	"jumpto":"ENAS5643_6.3.12.2",
	"name":"Beyond first-line treatment, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5643_4.11.2.0",
	"name":"Beyond first-line treatment [mNSCLC]"
},
{
	"jumpto":"ENAS5643_4.12.2.0",
	"name":"Beyond first-line treatment [mNSCLC]"
},
{
	"jumpto":"ENAS5647_14.3.7.0",
	"name":"Bile acid sequestrants [Diarrh.]"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Biliary obstruction [Pancr]"
},
{
	"jumpto":"ENAS5279_3.2.0.0",
	"name":"BINET system [CLL]"
},
{
	"jumpto":"ENAS5285_4.0.0.0",
	"name":"Biology [RCC]"
},
{
	"jumpto":"ENAS6235_4.4.3.0",
	"name":"Biomarkers in treatment decision-making [EBC]"
},
{
	"jumpto":"ENAS5282_7.1.0.0",
	"name":"Biopsies, summary (Oes CA)"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Biopsy [TETs]"
},
{
	"jumpto":"ENAS5648_9.4.0.0",
	"name":"Biosimilars and follow-on products, summary [Anaemia]"
},
{
	"jumpto":"ENAS5648_6.0.0.0",
	"name":"Biosimilars and follow-on products [Anaemia]"
},
{
	"jumpto":"ENAS5284_3.1.0.0",
	"name":"Bismuth-Corlette classification, peri-hilar cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5285_6.2.2.8",
	"name":"Bisphosphonates, role [RCC]"
},
{
	"jumpto":"ENAS5285_9.4.2.3",
	"name":"Bisphosphonates, summary [RCC]"
},
{
	"jumpto":"ENAS6235_4.4.9.0",
	"name":"Bisphosphonates for early breast cancer [EBC]"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"Bladder ultrasonography [BC]"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"Bleomycin, non-seminoma [TS/T-NS]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Bleomycin, seminoma [TS/T-NS]"
},
{
	"jumpto":"ENAS5097_4.1.0.0",
	"name":"Bleomycin/etoposide/cisplatin (BEP) [TS/T-NS]"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"Blood tests in TS/T-NS"
},
{
	"jumpto":"ENAS5410_3.1.3.2",
	"name":"Body surface area schematic [irAEs]"
},
{
	"jumpto":"interactive_0002870",
	"name":"Bone-targeted treatments in early breast CA, interactive tool"
},
{
	"jumpto":"ENAS6365_6.1.2.0",
	"name":"Bone-targeted treatments in early breast CA, interactive tool"
},
{
	"jumpto":"ENAS6365_4.6.0.0",
	"name":"Bone biomarkers [Bone health]"
},
{
	"jumpto":"ENAS6365_4.4.0.0",
	"name":"Bone biopsy [Bone health]"
},
{
	"jumpto":"ENAS5640_9.1.0.0",
	"name":"Bone disease and spinal cord compression, supportive care [MM]"
},
{
	"jumpto":"ENAS6365_6.4.2.2",
	"name":"Bone health during cancer treatment, interactive tool"
},
{
	"jumpto":"interactive_0002871",
	"name":"Bone health during cancer treatment, interactive tool"
},
{
	"jumpto":"ENAS5640_9.2.0.0",
	"name":"Bone marrow failure, supportive care [MM]"
},
{
	"jumpto":"ENAS5092_6.0.0.0",
	"name":"Bone scan [PC]"
},
{
	"jumpto":"ENAS5096_2.1.0.0",
	"name":"Bowenoid papulosis [PenCa]"
},
{
	"jumpto":"ENAS5096_2.1.0.0",
	"name":"Bowen’s disease [PenCa]"
},
{
	"jumpto":"ENAS5062_8.3.4.0",
	"name":"Brachytherapy in anal cancer, summary"
},
{
	"jumpto":"ENAS5096_4.2.0.0",
	"name":"Brachytherapy [PenCa]"
},
{
	"jumpto":"ENAS5304_8.5.2.0",
	"name":"BRAF, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.1.0",
	"name":"BRAF mutation status [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.2.0",
	"name":"BRAF mutations [mCRC]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"BRCA1 [Pancr]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"BRCA2 [Pancr]"
},
{
	"jumpto":"ENAS5615_3.0.0.0",
	"name":"BRCA testing"
},
{
	"jumpto":"ENAS5268_6.1.7.0",
	"name":"Breakthrough ChT-induced emesis, summary [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.7.0",
	"name":"Breakthrough refractory emesis, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.2.3.0",
	"name":"Breast cancer, AC-treated female patients [N/V]"
},
{
	"jumpto":"ENAS5615_9.4.1.0",
	"name":"Breast cancer treatment in BRCA mutations, summary [BRCA]"
},
{
	"jumpto":"ENAS6365_6.1.1.0",
	"name":"Breast cancer [Bone health]"
},
{
	"jumpto":"ENAS6365_5.5.3.0",
	"name":"Breast cancer [Bone health]"
},
{
	"jumpto":"ENAS6235_4.3.1.1",
	"name":"Breast conserving surgery [EBC]"
},
{
	"jumpto":"ENAS5263_14.8.3.0",
	"name":"Bristol stool chart, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_9.3.0.0",
	"name":"Bristol stool chart [Mucosa]"
},
{
	"jumpto":"ENAS6229_2.1.0.0",
	"name":"Bronchial and thymic NETs, biochemistry [NETs]"
},
{
	"jumpto":"ENAS6229_2.1.0.0",
	"name":"Bronchial and thymic NETs, bronchoscopy [NETs]"
},
{
	"jumpto":"ENAS6229_2.1.0.0",
	"name":"Bronchial and thymic NETs, clinical symptoms [NETs]"
},
{
	"jumpto":"ENAS6229_6.1.0.0",
	"name":"Bronchial and thymic NETs, diagnosis summary [NETs]"
},
{
	"jumpto":"ENAS6229_2.1.0.0",
	"name":"Bronchial and thymic NETs, diagnosis [NETs]"
},
{
	"jumpto":"ENAS6229_6.4.0.0",
	"name":"Bronchial and thymic NETs, follow-up summary [NETs]"
},
{
	"jumpto":"ENAS6229_5.0.0.0",
	"name":"Bronchial and thymic NETs, follow-up [NETs]"
},
{
	"jumpto":"ENAS6229_2.1.0.0",
	"name":"Bronchial and thymic NETs, genetic screening [NETs]"
},
{
	"jumpto":"ENAS6229_2.1.0.0",
	"name":"Bronchial and thymic NETs, imaging [NETs]"
},
{
	"jumpto":"ENAS6229_2.1.0.0",
	"name":"Bronchial and thymic NETs, pathology [NETs]"
},
{
	"jumpto":"ENAS6229_2.1.0.0",
	"name":"Bronchial and thymic NETs, PET, 68GA-dotatate, 18FDG [NETs]"
},
{
	"jumpto":"ENAS6229_6.2.0.0",
	"name":"Bronchial and thymic NETs, staging summary [NETs]"
},
{
	"jumpto":"ENAS6229_3.0.0.0",
	"name":"Bronchial and thymic NETs, staging [NETs]"
},
{
	"jumpto":"ENAS6229_6.1.0.0",
	"name":"Bronchial and thymic NETs, summary of recommendations [NETs]"
},
{
	"jumpto":"ENAS6229_6.3.1.0",
	"name":"Bronchial and thymic NETs, treatment summary [NETs]"
},
{
	"jumpto":"ENAS6229_4.1.1.0",
	"name":"Bronchial NETs, treatment [NETs]"
},
{
	"jumpto":"ENAS6229_2.2.0.0",
	"name":"Bronchial NETs, WHO classification [NETs]"
},
{
	"jumpto":"ENAS6229_2.2.0.0",
	"name":"Bronchial NETs [NETs]"
},
{
	"jumpto":"ENAS6365_5.5.1.0",
	"name":"BTAs [Bone health]"
},
{
	"jumpto":"ENAS5284_4.2.0.0",
	"name":"BTC management algorithm [Bil]"
},
{
	"jumpto":"ENAS5633_2.2.0.0",
	"name":"Burkitt leukaemia [ALL]"
},
{
	"jumpto":"ENAS5068_3.0.0.0",
	"name":"CA 19-9 [Pancr]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Cabazitaxel, treatment of CRPC [PC]"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"Cabazitaxel [PC]"
},
{
	"jumpto":"ENAS5285_6.2.2.6",
	"name":"Cabozantinib [RCC]"
},
{
	"jumpto":"ENAS6365_5.5.9.0",
	"name":"Calcium balance [Bone health]"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Calretinin"
},
{
	"jumpto":"ENAS6340_1.0.0.0",
	"name":"Cancer-related fatigue [CRF]"
},
{
	"jumpto":"ENAS5283_5.0.0.0",
	"name":"Cancer genome atlas (Gastric cancer)"
},
{
	"jumpto":"ENAS6233_4.1.3.0",
	"name":"Cancer treatment, summary [LS]"
},
{
	"jumpto":"ENAS6233_2.4.0.0",
	"name":"Cancer treatment [LS]"
},
{
	"jumpto":"ENAS5262_6.3.3.9",
	"name":"Candida, summary [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.10.0",
	"name":"Candidaemia [FN]"
},
{
	"jumpto":"ENAS5262_4.3.11.0",
	"name":"Candida [CVC]"
},
{
	"jumpto":"ENAS5269_6.4.6.10",
	"name":"Candidiasis, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.10.0",
	"name":"Candidiasis [FN]"
},
{
	"jumpto":"ENAS5267_5.0.0.0",
	"name":"Cannulation [Extra]"
},
{
	"jumpto":"ENAS5283_4.3.2.0",
	"name":"Capecitabine, perioperative chemotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5647_6.1.4.0",
	"name":"Capecitabine [Diarrh.]"
},
{
	"jumpto":"ENAS5263_5.0.0.0",
	"name":"Capecitabine [Mucosa]"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"Capecitabine [Pancr]"
},
{
	"jumpto":"ENAS5304_5.7.0.0",
	"name":"CAPOX [mCRC]"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Carbo-Px [TETs]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"CarboGem [BC]"
},
{
	"jumpto":"ENAS5068_3.0.0.0",
	"name":"Carbohydrate antigen (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"Carboplatin, MPM therapy"
},
{
	"jumpto":"ENAS5268_6.1.4.2",
	"name":"Carboplatin, summary [N/V]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Carboplatin/gemcitabine [BC]"
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Carboplatin [Anal cancer]"
},
{
	"jumpto":"ENAS5268_2.4.2.0",
	"name":"Carboplatin [N/V]"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Carboplatin [TETs]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Carboplatin [TS/T-NS]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Carboplatin [TS/T-NS]"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Carcinoembryonic antigen (CEA)"
},
{
	"jumpto":"ENAS5410_4.2.6.2",
	"name":"Cardiac toxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.2.0",
	"name":"Cardiac toxicity [irAEs]"
},
{
	"jumpto":"ENAS5262_5.3.0.0",
	"name":"Catheter-induced thrombosis, diagnosis [CVC]"
},
{
	"jumpto":"ENAS5262_5.1.0.0",
	"name":"Catheter-induced thrombosis, overview [CVC]"
},
{
	"jumpto":"ENAS5262_5.6.0.0",
	"name":"Catheter-induced thrombosis, prevention [CVC]"
},
{
	"jumpto":"ENAS5262_5.2.0.0",
	"name":"Catheter-induced thrombosis, risk factors [CVC]"
},
{
	"jumpto":"ENAS5262_5.4.0.0",
	"name":"Catheter-induced thrombosis, treatment [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.2.0",
	"name":"Catheter-related infection [FN]"
},
{
	"jumpto":"ENAS5262_5.5.2.0",
	"name":"Catheter-related thrombosis, prevention [CVC]"
},
{
	"jumpto":"ENAS5262_5.5.1.0",
	"name":"Catheter-related thrombosis, treatment [CVC]"
},
{
	"jumpto":"ENAS5647_11.1.0.0",
	"name":"Causes of diarrhoea in cancer pts."
},
{
	"jumpto":"ENAS6342_2.2.0.0",
	"name":"CBL-MZ [MZLs]"
},
{
	"jumpto":"ENAS5646_7.3.4.0",
	"name":"CD30+ lympho-proliferative disorders, summary [PCLs]"
},
{
	"jumpto":"ENAS5269_5.9.6.0",
	"name":"Ceftazidime [FN]"
},
{
	"jumpto":"ENAS5269_6.4.6.7",
	"name":"Cellulitis, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.7.0",
	"name":"Cellulitis [FN]"
},
{
	"jumpto":"ENAS5269_6.4.6.2",
	"name":"Central IV catheters, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.2.0",
	"name":"Central IV catheters [FN]"
},
{
	"jumpto":"ENAS5410_3.6.1.4",
	"name":"Central neurological toxicity mgmt., interactive tool [irAEs]"
},
{
	"jumpto":"ENAS6341_4.2.1.0",
	"name":"Central neurotoxicity, summary [PCN]"
},
{
	"jumpto":"ENAS6341_3.1.0.0",
	"name":"Central neurotoxicity [PCN]"
},
{
	"jumpto":"ENAS5267_9.1.0.0",
	"name":"Central venous access device extravasation, overview"
},
{
	"jumpto":"ENAS5267_12.8.0.0",
	"name":"Central venous access device extravasation, summary [Extra]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Central venous access device [Extra]"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"Cervical intra-epithelial neoplasia (CIN)"
},
{
	"jumpto":"ENAS5304_5.14.5.0",
	"name":"Cetuximab + irinotecan [mCRC]"
},
{
	"jumpto":"ENAS5409_11.2.2.0",
	"name":"Cetuximab [IRs]"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"Cetuximab [mCRC]"
},
{
	"jumpto":"ENAS5283_4.2.0.0",
	"name":"CF, cisplatin/5-fluorouracil (Gastric cancer)"
},
{
	"jumpto":"ENAS5267_6.2.0.0",
	"name":"Chemical phlebitis [Extra]"
},
{
	"jumpto":"ENAS5267_6.3.0.0",
	"name":"Chemical phlebitis [Extra]"
},
{
	"jumpto":"interactive_0002203",
	"name":"Chemo-induced anaemia management, interactive tool"
},
{
	"jumpto":"ENAS5648_3.2.0.0",
	"name":"Chemo-induced anaemia management, interactive tool"
},
{
	"jumpto":"ENAS5304_5.12.0.0",
	"name":"Chemoembolisation [mCRC]"
},
{
	"jumpto":"ENAS5615_5.2.0.0",
	"name":"Chemoprevention [BRCA]"
},
{
	"jumpto":"ENAS5269_6.2.0.0",
	"name":"Chemoprophylaxis, summary [FN]"
},
{
	"jumpto":"ENAS5269_3.0.0.0",
	"name":"Chemoprophylaxis [FN]"
},
{
	"jumpto":"ENAS5283_4.3.3.2",
	"name":"Chemoradiotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5062_4.4.1.0",
	"name":"Chemoradiotherapy, anal cancer"
},
{
	"jumpto":"ENAS5068_5.6.2.0",
	"name":"Chemoradiotherapy, capectabine [Pancr]"
},
{
	"jumpto":"ENAS5068_5.6.2.0",
	"name":"Chemoradiotherapy, locally advanced pancreatic cancer"
},
{
	"jumpto":"ENAS5407_4.8.1.0",
	"name":"Chemoradiotherapy, postoperative indications [Rectal CA]"
},
{
	"jumpto":"ENAS5283_8.3.1.3",
	"name":"Chemoradiotherapy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5062_8.3.3.0",
	"name":"Chemoradiotherapy in anal cancer, summary"
},
{
	"jumpto":"ENAS6369_4.2.5.0",
	"name":"Chemoradiotherapy in LACC [Cervical CA]"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"Chemoradiotherapy [Pancr]"
},
{
	"jumpto":"ENAS5283_4.3.3.3",
	"name":"Chemotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Chemotherapy, definitive [TETs]"
},
{
	"jumpto":"ENAS5637_5.4.0.0",
	"name":"Chemotherapy, low-dose [MDS]"
},
{
	"jumpto":"ENAS5263_10.2.1.0",
	"name":"Chemotherapy, mucositis [Mucosa]"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"Chemotherapy, PenCa"
},
{
	"jumpto":"ENAS5098_5.6.0.0",
	"name":"Chemotherapy, post-op [TETs]"
},
{
	"jumpto":"ENAS5407_4.8.2.0",
	"name":"Chemotherapy, postoperative [Rectal CA]"
},
{
	"jumpto":"ENAS5407_4.7.1.0",
	"name":"Chemotherapy, preoperative [Rectal CA]"
},
{
	"jumpto":"ENAS5283_8.3.1.3",
	"name":"Chemotherapy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5644_8.4.1.1",
	"name":"Chemotherapy, summary [HCC]"
},
{
	"jumpto":"ENAS5265_2.2.0.0",
	"name":"Chemotherapy-associated VTE"
},
{
	"jumpto":"ENAS5647_6.1.1.0",
	"name":"Chemotherapy-induced diarrhoea"
},
{
	"jumpto":"ENAS5647_20.4.0.0",
	"name":"Chemotherapy-induced diarrhoea, summary [Diarrh.]"
},
{
	"jumpto":"ENAS5268_4.0.0.0",
	"name":"Chemotherapy-induced nausea and vomiting in children"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Chemotherapy-induced nausea and vomiting [N/V]"
},
{
	"jumpto":"ENAS5098_5.12.0.0",
	"name":"Chemotherapy for advanced TETs"
},
{
	"jumpto":"ENAS5633_7.3.2.3",
	"name":"Chemotherapy for relapsed ALL, summary"
},
{
	"jumpto":"ENAS5637_5.3.0.0",
	"name":"Chemotherapy in MDS"
},
{
	"jumpto":"ENAS5096_7.3.3.0",
	"name":"Chemotherapy in PenCa, summary"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"Chemotherapy regimens, BEP (TS)"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"Chemotherapy regimens, EP (TS)"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"Chemotherapy regimens, TI-CE (TS)"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"Chemotherapy regimens, TIP (TS)"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"Chemotherapy regimens, VeIP (TS)"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"Chemotherapy regimens, VIP/PEI (TS)"
},
{
	"jumpto":"ENAS5304_8.5.4.0",
	"name":"Chemotherapy sensitivity, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"Chemotherapy sensitivity [mCRC]"
},
{
	"jumpto":"ENAS5644_5.1.1.0",
	"name":"Chemotherapy [HCC]"
},
{
	"jumpto":"ENAS5097_4.1.0.0",
	"name":"Chemotherapy [TS/T-NS]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Chlorhexidine mouthwash [Mucosa]"
},
{
	"jumpto":"ENAS5269_6.4.5.2",
	"name":"Choice of IV antibacterial, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.7.2.0",
	"name":"Choice of IV antibacterial [FN]"
},
{
	"jumpto":"ENAS5284_3.2.1.1",
	"name":"Cholangiocarcinoma, AJCC/UICC staging [Bil]"
},
{
	"jumpto":"ENAS5284_3.2.1.3",
	"name":"Cholangiocarcinoma, distal [Bil]"
},
{
	"jumpto":"ENAS5284_3.2.1.1",
	"name":"Cholangiocarcinoma, intra-hepatic [Bil]"
},
{
	"jumpto":"ENAS5284_3.2.1.2",
	"name":"Cholangiocarcinoma, peri-hilar [Bil]"
},
{
	"jumpto":"ENAS5410_3.6.5.0",
	"name":"Choroidal neovascularisation, treatment"
},
{
	"jumpto":"ENAS5406_5.1.3.0",
	"name":"Chronic obstructive pulmonary disease [Early NSCLC]"
},
{
	"jumpto":"ENAS6235_7.3.4.0",
	"name":"ChT, summary [EBC]"
},
{
	"jumpto":"ENAS5268_2.7.0.0",
	"name":"ChT-induced emesis [N/V]"
},
{
	"jumpto":"ENAS5267_6.3.0.0",
	"name":"ChT drugs, causing local reactions [Extra]"
},
{
	"jumpto":"ENAS6366_2020112711",
	"name":"ChT for epithelial ovarian cancer [EOC]"
},
{
	"jumpto":"ENAS6366_2020112725",
	"name":"ChT in primary ovarian cancer, summary [EOC]"
},
{
	"jumpto":"ENAS6366_2020112728",
	"name":"ChT in recurrent ovarian CA, summary [EOC]"
},
{
	"jumpto":"ENAS5268_2.6.0.0",
	"name":"ChT with low & minimal emetogenic potential, prev. [N/V]"
},
{
	"jumpto":"ENAS6235_4.4.6.0",
	"name":"ChT [EBC]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"CINV, prevention"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"Ciprofloxacin [CVC]"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"Circulating tumour cell (CTC) [mCRC]"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Cisplatin, definitive chemotherapy [TETs]"
},
{
	"jumpto":"ENAS5071_4.2.0.0",
	"name":"Cisplatin, localised SCLC"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"Cisplatin, MPM therapy"
},
{
	"jumpto":"ENAS5096_4.3.0.0",
	"name":"Cisplatin-based chemotherapy [PenCa]"
},
{
	"jumpto":"ENAS5094_4.3.0.0",
	"name":"Cisplatin-based neoadjuvant chemotherapy [BC]"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"Cisplatin-based [PenCa]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Cisplatin-containing combination chemotherapy [BC]"
},
{
	"jumpto":"ENAS5268_6.1.2.2",
	"name":"Cisplatin-treated patients, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Cisplatin-treated patients [N/V]"
},
{
	"jumpto":"ENAS5282_4.1.6.0",
	"name":"Cisplatin/5-FU combined with 41.4–50.4 Gy RT (Oes CA)"
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Cisplatin [Anal cancer]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Cisplatin [BC]"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"Cisplatin [PenCa]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Cisplatin [TS/T-NS]"
},
{
	"jumpto":"ENAS5280_4.2.2.0",
	"name":"Cladribine"
},
{
	"jumpto":"ENAS6233_3.1.2.2",
	"name":"Classical FAP surveillance guidelines [LS]"
},
{
	"jumpto":"ENAS5280_4.2.5.0",
	"name":"Classical HCL: Tx of newly diagnosed"
},
{
	"jumpto":"ENAS5280_4.4.2.0",
	"name":"Classical HCL: Tx of relapsed & refractory, interactive tool"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Classification, anticancer agents [Extra]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Classification [TETs]"
},
{
	"jumpto":"ENAS6232_4.2.1.0",
	"name":"Clinical and molecular diagnosis, summary [Hereditary GC]"
},
{
	"jumpto":"ENAS6233_4.2.1.1",
	"name":"Clinical and molecular diagnosis, summary [LS]"
},
{
	"jumpto":"ENAS6233_4.2.2.1",
	"name":"Clinical and molecular diagnosis, summary [LS]"
},
{
	"jumpto":"ENAS6232_2.4.1.0",
	"name":"Clinical and molecular diagnosis [Hereditary GC]"
},
{
	"jumpto":"ENAS6232_2.2.1.0",
	"name":"Clinical and molecular diagnosis [Hereditary GC]"
},
{
	"jumpto":"ENAS6232_3.1.0.0",
	"name":"Clinical and molecular diagnosis [Hereditary GC]"
},
{
	"jumpto":"ENAS6232_2.5.1.0",
	"name":"Clinical and molecular diagnosis [Hereditary GC]"
},
{
	"jumpto":"ENAS6233_3.2.1.0",
	"name":"Clinical and molecular diagnosis [LS]"
},
{
	"jumpto":"ENAS6233_3.1.1.0",
	"name":"Clinical and molecular diagnosis [LS]"
},
{
	"jumpto":"ENAS6233_2.1.0.0",
	"name":"Clinical and molecular diagnosis [LS]"
},
{
	"jumpto":"ENAS6339_7.1.0.0",
	"name":"Clinical cardiac dysfunction [CVD]"
},
{
	"jumpto":"ENAS6339_11.6.0.0",
	"name":"Clinical cardiac dysfunction [CVD]"
},
{
	"jumpto":"ENAS5643_3.4.0.0",
	"name":"Clinical classification UICC TNM 8 [mNSCLC]"
},
{
	"jumpto":"ENAS5094_6.0.0.0",
	"name":"Clinical mgmt.overview, interactive tool [BC]"
},
{
	"jumpto":"ENAS5098_7.0.0.0",
	"name":"Clinical myasthenia gravis [TETs]"
},
{
	"jumpto":"ENAS6341_4.1.2.1",
	"name":"Clinical pattern, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.2.1.0",
	"name":"Clinical pattern [PCN]"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"Clinical trials [Pancr]"
},
{
	"jumpto":"ENAS5098_7.0.0.0",
	"name":"Clinical trials [TETs]"
},
{
	"jumpto":"ENAS5647_11.1.0.0",
	"name":"Clostridium difficile [Diarrh.]"
},
{
	"jumpto":"ENAS5269_5.9.9.0",
	"name":"Clostridium difficile [FN]"
},
{
	"jumpto":"ENAS5636_2.0.0.0",
	"name":"CML, diagnosis"
},
{
	"jumpto":"ENAS5636_4.4.0.0",
	"name":"CML, first-line therapy"
},
{
	"jumpto":"ENAS5636_6.0.0.0",
	"name":"CML, management of adverse events and quality of life"
},
{
	"jumpto":"ENAS5636_2.0.0.0",
	"name":"CML, pathophysiology"
},
{
	"jumpto":"ENAS5636_5.3.0.0",
	"name":"CML, second- or third-line option"
},
{
	"jumpto":"ENAS5636_3.0.0.0",
	"name":"CML, staging and risk assessment"
},
{
	"jumpto":"ENAS5636_7.0.0.0",
	"name":"CML, treatment-free remission"
},
{
	"jumpto":"ENAS5636_2.0.0.0",
	"name":"CML accelerated phase, definition"
},
{
	"jumpto":"ENAS5636_2.0.0.0",
	"name":"CML blast phase, definition"
},
{
	"jumpto":"ENAS5636_4.1.0.0",
	"name":"CML chronic phase, first-line management"
},
{
	"jumpto":"interactive_0002134",
	"name":"CML chronic phase treatment options, interactive tool"
},
{
	"jumpto":"ENAS5636_4.2.0.0",
	"name":"CML chronic phase treatment options, interactive tool"
},
{
	"jumpto":"ENAS5636_8.3.1.0",
	"name":"CML first-line mgmt., summary"
},
{
	"jumpto":"ENAS5636_8.3.3.0",
	"name":"CML first-line therapy, summary"
},
{
	"jumpto":"ENAS5636_8.5.0.0",
	"name":"CML mgmtt. of adverse events & QoL, summary"
},
{
	"jumpto":"ENAS5636_8.1.0.0",
	"name":"CML pathophysiology and diagnosis, summary"
},
{
	"jumpto":"ENAS5636_8.4.3.0",
	"name":"CML second- or third-line option, summary"
},
{
	"jumpto":"ENAS5636_8.2.0.0",
	"name":"CML staging and risk assessment, summary"
},
{
	"jumpto":"ENAS5636_8.6.0.0",
	"name":"CML treatment free remission, summary"
},
{
	"jumpto":"ENAS5269_5.9.2.0",
	"name":"CNS bacteraemia [FN]"
},
{
	"jumpto":"ENAS5633_7.3.1.4",
	"name":"CNS prophylaxis in ALL, summary"
},
{
	"jumpto":"ENAS5271_7.3.2.0",
	"name":"CNS prophylaxis in DLBCL, summary"
},
{
	"jumpto":"ENAS5633_4.1.4.0",
	"name":"CNS prophylaxis [ALL]"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Coeliac axis (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Coeliac plexus block (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5647_11.3.0.0",
	"name":"Coeliac plexus block [Diarrh.]"
},
{
	"jumpto":"ENAS6338_3.3.0.0",
	"name":"Colon CA, assessment of baseline status & characteristics [LCC]"
},
{
	"jumpto":"ENAS6338_3.1.0.0",
	"name":"Colon CA, diagnosis [LCC]"
},
{
	"jumpto":"ENAS6338_4.1.2.0",
	"name":"Colon CA, diagnostic algorithm [LCC]"
},
{
	"jumpto":"ENAS6338_2.1.0.0",
	"name":"Colon CA, screening [LCC]"
},
{
	"jumpto":"ENAS6338_7.3.1.0",
	"name":"Colon CA, stage II disease [LCC]"
},
{
	"jumpto":"ENAS6338_7.2.1.0",
	"name":"Colon CA, stage III disease [LCC]"
},
{
	"jumpto":"ENAS6338_7.1.0.0",
	"name":"Colon CA, treatment options [LCC]"
},
{
	"jumpto":"ENAS6338_9.2.1.0",
	"name":"Colon CA diagnosis, summary [LCC]"
},
{
	"jumpto":"ENAS6338_9.1.2.0",
	"name":"Colon CA screening, summary [LCC]"
},
{
	"jumpto":"ENAS6338_9.1.2.0",
	"name":"Colonoscopic tests, summary [LCC]"
},
{
	"jumpto":"ENAS6338_2.2.0.0",
	"name":"Colonoscopic tests [LCC]"
},
{
	"jumpto":"ENAS5062_2.1.0.0",
	"name":"Colonoscopy [Anal cancer]"
},
{
	"jumpto":"ENAS5304_5.2.2.0",
	"name":"Colorectal liver metastases (CLM) [mCRC]"
},
{
	"jumpto":"ENAS5304_5.5.0.0",
	"name":"Colorectal liver metastases [mCRC]"
},
{
	"jumpto":"ENAS6233_3.1.2.4",
	"name":"Colorectal surveillance [LS]"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Combination chemotherapy [TETs]"
},
{
	"jumpto":"ENAS5269_5.6.1.0",
	"name":"Combination therapy [FN]"
},
{
	"jumpto":"ENAS5273_5.4.0.0",
	"name":"Combined chemoimmunotherapy in FL"
},
{
	"jumpto":"ENAS5408_3.1.0.0",
	"name":"Combined MIPI [MCL]"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Common hepatic artery (CHA)"
},
{
	"jumpto":"ENAS5267_6.1.0.0",
	"name":"Common initial symptoms, extravasation"
},
{
	"jumpto":"ENAS5267_12.5.1.0",
	"name":"Common initial symptoms, summary [Extra]"
},
{
	"jumpto":"ENAS5647_14.2.2.0",
	"name":"Complicated diarrhea"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"Computed tomography (CT) [BC]"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Computed tomography (CT) [Pancr]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Computed tomography [TETs]"
},
{
	"jumpto":"ENAS5647_20.16.0.0",
	"name":"Conclusions, summary [Diarrh.]"
},
{
	"jumpto":"ENAS5647_19.0.0.0",
	"name":"Conclusions [Diarrh.]"
},
{
	"jumpto":"ENAS5268_6.2.4.0",
	"name":"Concurrent chemoradiotherapy, summary [N/V]"
},
{
	"jumpto":"ENAS5268_3.5.0.0",
	"name":"Concurrent chemoradiotherapy [N/V]"
},
{
	"jumpto":"ENAS5086_5.4.3.0",
	"name":"Conformal radiotherapy"
},
{
	"jumpto":"ENAS5273_5.5.0.0",
	"name":"Consolidation/ maintenance, FL"
},
{
	"jumpto":"ENAS5273_8.3.2.0",
	"name":"Consolidation/maintenance of FL, summary"
},
{
	"jumpto":"ENAS5265_6.0.0.0",
	"name":"Contraindications, anticoagulation [VTE]"
},
{
	"jumpto":"ENAS5265_8.5.0.0",
	"name":"Contraindications to anticoagulation, summary [VTE]"
},
{
	"jumpto":"ENAS5283_4.3.3.2",
	"name":"Conventionally fractionated radiotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5304_8.6.2.5",
	"name":"Conversion strategic treatment goal, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.3.0",
	"name":"Conversion treatment, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.9.0.0",
	"name":"Conversion treatment [mCRC]"
},
{
	"jumpto":"ENAS5268_2.3.3.0",
	"name":"Corticosteroids, doses [N/V]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Corticosteroids [PC]"
},
{
	"jumpto":"ENAS5268_3.3.0.0",
	"name":"Craniospinal irradiation [N/V]"
},
{
	"jumpto":"ENAS5262_4.1.0.0",
	"name":"CRBSI [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.2.0",
	"name":"CRI [FN]"
},
{
	"jumpto":"ENAS5407_9.3.3.0",
	"name":"CRT regimen, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5285_6.1.1.0",
	"name":"Cryoablation [RCC]"
},
{
	"jumpto":"ENAS5092_6.0.0.0",
	"name":"CT, PC follow-up [PC]"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"CT abdomen [Anal cancer]"
},
{
	"jumpto":"ENAS6365_6.4.1.0",
	"name":"CTIBL [Bone health]"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"CT thorax [Anal cancer]"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"CT [PC]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"CT [TETs]"
},
{
	"jumpto":"ENAS5098_7.0.0.0",
	"name":"CT [TETs]"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"Curative treatment (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5646_4.8.1.0",
	"name":"Cutaneous B cell lymphoma, overview [PCLs]"
},
{
	"jumpto":"ENAS5646_7.3.8.0",
	"name":"Cutaneous B cell lymphoma, summary [PCLs]"
},
{
	"jumpto":"ENAS5267_9.2.0.0",
	"name":"CVAD extravasation, steps"
},
{
	"jumpto":"ENAS5262_4.1.0.0",
	"name":"CVC-related infection, overview"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"CVC-related infections, antibiotic treatment [CVC]"
},
{
	"jumpto":"ENAS5262_4.4.0.0",
	"name":"CVC-related infections, prevention"
},
{
	"jumpto":"ENAS5262_4.2.0.0",
	"name":"CVC infections, diagnosis"
},
{
	"jumpto":"ENAS5262_4.3.2.0",
	"name":"CVC infections, management"
},
{
	"jumpto":"ENAS5262_4.3.1.0",
	"name":"CVC infections, treatment"
},
{
	"jumpto":"ENAS5262_4.3.4.0",
	"name":"CVC removal , indications"
},
{
	"jumpto":"ENAS5283_4.2.0.0",
	"name":"CX, cisplatin/capecitabine (Gastric cancer)"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Cyclophosphamide, second-line treatment [SCLC]"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Cyfra 21.1 [MPM]"
},
{
	"jumpto":"ENAS5094_8.0.0.0",
	"name":"Cystoscopy, BC follow-up [BC]"
},
{
	"jumpto":"ENAS5094_7.0.0.0",
	"name":"Cystoscopy, management of BC [BC]"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"Cystoscopy [BC]"
},
{
	"jumpto":"ENAS5636_8.3.4.0",
	"name":"Cytogenetic monitoring, summary [CML]"
},
{
	"jumpto":"ENAS5636_4.5.0.0",
	"name":"Cytogenetic monitoring [CML]"
},
{
	"jumpto":"ENAS5633_2.3.0.0",
	"name":"Cytogenetics/genetics [ALL]"
},
{
	"jumpto":"ENAS5409_4.0.0.0",
	"name":"Cytokine release syndrome [IRs]"
},
{
	"jumpto":"ENAS5304_5.14.7.0",
	"name":"Cytoreduction (Shrinkage) [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.6.0",
	"name":"Cytoreduction [mCRC]"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Cytoreductive nephrectomy [RCC]"
},
{
	"jumpto":"ENAS5304_8.6.6.0",
	"name":"Cytoreductive surgery, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.13.0.0",
	"name":"Cytoreductive surgery [mCRC]"
},
{
	"jumpto":"ENAS5062_4.1.0.0",
	"name":"Cytotoxic agents [Anal cancer]"
},
{
	"jumpto":"ENAS6344_6.1.4.0",
	"name":"Cytotoxic ChT [ACC]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Cytotoxic doublet [mCRC]"
},
{
	"jumpto":"ENAS5647_6.2.1.0",
	"name":"Cytotoxic drugs associated with diarrhoea"
},
{
	"jumpto":"ENAS5647_6.1.1.0",
	"name":"Cytotoxic drugs associated with diarrhoea"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Cytotoxic triplet [mCRC]"
},
{
	"jumpto":"ENAS5269_6.4.7.0",
	"name":"Daily follow-up, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.10.1.0",
	"name":"Daily follow-up [FN]"
},
{
	"jumpto":"ENAS5262_5.5.1.0",
	"name":"Dalteparin [CVC]"
},
{
	"jumpto":"ENAS5262_6.3.3.7",
	"name":"Daptomycin, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.9.0",
	"name":"Daptomycin [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.7.0",
	"name":"Daptomycin [FN]"
},
{
	"jumpto":"ENAS5284_7.3.1.4",
	"name":"dCCA, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.4.0",
	"name":"dCCA [Bil]"
},
{
	"jumpto":"ENAS5278_3.3.0.0",
	"name":"Deauville criteria"
},
{
	"jumpto":"ENAS5633_3.2.0.0",
	"name":"Definition, CR [ALL]"
},
{
	"jumpto":"ENAS5267_2.0.0.0",
	"name":"Definition, extravasation"
},
{
	"jumpto":"ENAS5633_3.2.0.0",
	"name":"Definition, MoICR [ALL]"
},
{
	"jumpto":"ENAS5633_3.2.0.0",
	"name":"Definition, MoIFail [ALL]"
},
{
	"jumpto":"ENAS5633_3.2.0.0",
	"name":"Definition, MoIRel [ALL]"
},
{
	"jumpto":"ENAS5633_3.2.0.0",
	"name":"Definition, MoIR [ALL]"
},
{
	"jumpto":"ENAS5633_3.2.0.0",
	"name":"Definition, relapse [ALL]"
},
{
	"jumpto":"ENAS5267_12.1.0.0",
	"name":"Definition of extravasation, summary"
},
{
	"jumpto":"ENAS5645_5.0.0.0",
	"name":"Definition of Hodgkin lymphoma"
},
{
	"jumpto":"ENAS6338_7.2.4.0",
	"name":"Definition of risk groups in stage III [LCC]"
},
{
	"jumpto":"ENAS5098_8.3.8.0",
	"name":"Definitive chemotherapy, summary [TETs]"
},
{
	"jumpto":"ENAS5098_8.3.7.0",
	"name":"Definitive radiotherapy, summary [TETs]"
},
{
	"jumpto":"ENAS5098_5.9.0.0",
	"name":"Definitive RT [TETs]"
},
{
	"jumpto":"ENAS5268_2.3.3.0",
	"name":"Delayed emesis [N/V]"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Denosumab [PC]"
},
{
	"jumpto":"ENAS5285_6.2.2.8",
	"name":"Denosumab [RCC]"
},
{
	"jumpto":"ENAS5304_5.9.0.0",
	"name":"Depth of response [mCRC]"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Dexamethasone [N/V]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Dexamethasone [PC]"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Dexrazoxane [Extra]"
},
{
	"jumpto":"ENAS5410_3.2.3.0",
	"name":"Diabetes mellitus [irAEs]"
},
{
	"jumpto":"ENAS5283_2.0.0.0",
	"name":"Diagnosis (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_2.0.0.0",
	"name":"Diagnosis (Oes CA)"
},
{
	"jumpto":"ENAS5262_5.3.0.0",
	"name":"Diagnosis, catheter-induced thrombosis [CVC]"
},
{
	"jumpto":"ENAS5279_2.0.0.0",
	"name":"Diagnosis, CLL"
},
{
	"jumpto":"ENAS5262_4.2.0.0",
	"name":"Diagnosis, CVC infections"
},
{
	"jumpto":"ENAS5271_2.0.0.0",
	"name":"Diagnosis, DLBCL"
},
{
	"jumpto":"ENAS5278_2.1.0.0",
	"name":"Diagnosis, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5406_3.0.0.0",
	"name":"Diagnosis, early NSCLC"
},
{
	"jumpto":"ENAS5267_6.1.0.0",
	"name":"Diagnosis, extravasation [Extra]"
},
{
	"jumpto":"ENAS5273_2.0.0.0",
	"name":"Diagnosis, FL"
},
{
	"jumpto":"ENAS5280_2.1.0.0",
	"name":"Diagnosis, HCL"
},
{
	"jumpto":"ENAS5265_3.0.0.0",
	"name":"Diagnosis, occult cancer idiopathic VTE"
},
{
	"jumpto":"ENAS5643_2.1.0.0",
	"name":"Diagnosis, overview [mNSCLC]"
},
{
	"jumpto":"ENAS5278_2.5.0.0",
	"name":"Diagnosis, PBL"
},
{
	"jumpto":"ENAS5278_2.6.0.0",
	"name":"Diagnosis, PBoL"
},
{
	"jumpto":"ENAS5278_2.4.0.0",
	"name":"Diagnosis, PCNSL"
},
{
	"jumpto":"ENAS5278_2.2.0.0",
	"name":"Diagnosis, PMBCL"
},
{
	"jumpto":"ENAS5277_2.0.0.0",
	"name":"Diagnosis, PTCL"
},
{
	"jumpto":"ENAS5278_2.3.0.0",
	"name":"Diagnosis, PTL"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Diagnosis, rectal cancer"
},
{
	"jumpto":"ENAS5071_2.0.0.0",
	"name":"Diagnosis, SCLC"
},
{
	"jumpto":"ENAS5271_5.2.1.0",
	"name":"Diagnosis, staging and risk assessment (DLBCL)"
},
{
	"jumpto":"ENAS5271_7.4.2.1",
	"name":"Diagnosis, staging and risk assessment in DLBCL, summary"
},
{
	"jumpto":"ENAS5282_7.1.0.0",
	"name":"Diagnosis, summary (Oes CA)"
},
{
	"jumpto":"ENAS5284_7.1.0.0",
	"name":"Diagnosis, summary [Bil]"
},
{
	"jumpto":"ENAS6340_6.2.0.0",
	"name":"Diagnosis, summary [CRF]"
},
{
	"jumpto":"ENAS6370_8.2.0.0",
	"name":"Diagnosis, summary [Endometrial CA]"
},
{
	"jumpto":"ENAS6366_2020112721",
	"name":"Diagnosis, summary [EOC]"
},
{
	"jumpto":"ENAS5267_12.5.1.0",
	"name":"Diagnosis, summary [Extra]"
},
{
	"jumpto":"ENAS6371_7.1.0.0",
	"name":"Diagnosis, summary [GTD]"
},
{
	"jumpto":"ENAS5645_11.1.0.0",
	"name":"Diagnosis, summary [HL]"
},
{
	"jumpto":"ENAS5304_8.1.0.0",
	"name":"Diagnosis, summary [mCRC]"
},
{
	"jumpto":"ENAS5263_14.7.0.0",
	"name":"Diagnosis, summary [Mucosa]"
},
{
	"jumpto":"ENAS5285_9.1.0.0",
	"name":"Diagnosis, summary [RCC]"
},
{
	"jumpto":"ENAS5649_10.1.0.0",
	"name":"Diagnosis, summary [WM]"
},
{
	"jumpto":"ENAS6365_8.3.0.0",
	"name":"Diagnosis and monitoring, summary [Bone health]"
},
{
	"jumpto":"ENAS6365_4.1.0.0",
	"name":"Diagnosis and monitoring [Bone health]"
},
{
	"jumpto":"ENAS5283_8.1.0.0",
	"name":"Diagnosis and pathology (Gastric cancer)"
},
{
	"jumpto":"ENAS5646_2.1.0.0",
	"name":"Diagnosis and pathology, overniew [PCLs]"
},
{
	"jumpto":"ENAS6344_8.2.1.0",
	"name":"Diagnosis and pathology, summary [ACC]"
},
{
	"jumpto":"ENAS6369_8.1.0.0",
	"name":"Diagnosis and pathology, summary [Cervical CA]"
},
{
	"jumpto":"ENAS6343_8.1.0.0",
	"name":"Diagnosis and pathology, summary [GEP-NENs]"
},
{
	"jumpto":"ENAS5640_12.1.0.0",
	"name":"Diagnosis and pathology, summary [MM]"
},
{
	"jumpto":"ENAS6367_7.1.0.0",
	"name":"Diagnosis and pathology, summary [NEOC]"
},
{
	"jumpto":"ENAS5646_7.1.0.0",
	"name":"Diagnosis and pathology, summary [PCLs]"
},
{
	"jumpto":"ENAS6235_7.1.0.0",
	"name":"Diagnosis and pathology, summmary [EBC]"
},
{
	"jumpto":"ENAS6342_2.3.0.0",
	"name":"Diagnosis and pathology/molecular biology, EMZL [MZLs]"
},
{
	"jumpto":"ENAS6342_2.5.0.0",
	"name":"Diagnosis and pathology/molecular biology, NMZL [MZLs]"
},
{
	"jumpto":"ENAS6342_2.4.0.0",
	"name":"Diagnosis and pathology/molecular biology, SMZL [MZLs]"
},
{
	"jumpto":"ENAS5644_8.1.1.0",
	"name":"Diagnosis and pathology/molecular biology, summary [HCC]"
},
{
	"jumpto":"ENAS6342_7.1.0.0",
	"name":"Diagnosis and pathology/molecular biology, summary [MZLs]"
},
{
	"jumpto":"ENAS6342_2.1.0.0",
	"name":"Diagnosis and pathology/molecular biology [MZLs]"
},
{
	"jumpto":"ENAS5407_9.1.0.0",
	"name":"Diagnosis and pathology of rectal cancer, summary"
},
{
	"jumpto":"ENAS6369_2.1.0.0",
	"name":"Diagnosis and pathology [Cervical CA]"
},
{
	"jumpto":"ENAS6235_2.0.0.0",
	"name":"Diagnosis and pathology [EBC]"
},
{
	"jumpto":"ENAS5644_2.1.0.0",
	"name":"Diagnosis and pathology [HCC]"
},
{
	"jumpto":"ENAS6367_2.0.0.0",
	"name":"Diagnosis and pathology [NEOC]"
},
{
	"jumpto":"ENAS5633_2.2.0.0",
	"name":"Diagnosis and work-up [ALL]"
},
{
	"jumpto":"ENAS5644_8.1.1.0",
	"name":"Diagnosis by imaging, summary [HCC]"
},
{
	"jumpto":"ENAS5644_2.2.0.0",
	"name":"Diagnosis by imaging [HCC]"
},
{
	"jumpto":"ENAS5644_8.1.2.0",
	"name":"Diagnosis by pathology, summary [HCC]"
},
{
	"jumpto":"ENAS5644_2.3.0.0",
	"name":"Diagnosis by pathology [HCC]"
},
{
	"jumpto":"ENAS5262_6.4.3.0",
	"name":"Diagnosis of catheter-induced thrombosis, summary [CVC]"
},
{
	"jumpto":"ENAS5279_7.1.0.0",
	"name":"Diagnosis of CLL, summary"
},
{
	"jumpto":"ENAS5262_6.3.2.0",
	"name":"Diagnosis of CVC infections, summary"
},
{
	"jumpto":"ENAS5271_7.1.0.0",
	"name":"Diagnosis of DLBCL, summary"
},
{
	"jumpto":"ENAS5278_7.1.1.0",
	"name":"Diagnosis of DLBCL-PMBCL, summary"
},
{
	"jumpto":"ENAS5273_8.1.0.0",
	"name":"Diagnosis of FL, summary"
},
{
	"jumpto":"ENAS5280_7.1.0.0",
	"name":"Diagnosis of HCL, summary"
},
{
	"jumpto":"ENAS5408_7.1.0.0",
	"name":"Diagnosis of MCL, summary"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Diagnosis of MPM"
},
{
	"jumpto":"ENAS5265_8.2.0.0",
	"name":"Diagnosis of occult cancer idiopathic VTE, summary"
},
{
	"jumpto":"ENAS5278_7.1.5.0",
	"name":"Diagnosis of PBL, summary"
},
{
	"jumpto":"ENAS5278_7.1.6.0",
	"name":"Diagnosis of PBoL, summary"
},
{
	"jumpto":"ENAS5092_7.1.0.0",
	"name":"Diagnosis of PC, summary"
},
{
	"jumpto":"ENAS5278_7.1.4.0",
	"name":"Diagnosis of PCNSL, summary"
},
{
	"jumpto":"ENAS5096_7.1.0.0",
	"name":"Diagnosis of PenCa, summary"
},
{
	"jumpto":"ENAS5278_7.1.2.0",
	"name":"Diagnosis of PMBCL, summary"
},
{
	"jumpto":"ENAS5277_7.1.0.0",
	"name":"Diagnosis of PTCL, summary"
},
{
	"jumpto":"ENAS5278_7.1.3.0",
	"name":"Diagnosis of PTL, summary"
},
{
	"jumpto":"ENAS5071_6.1.0.0",
	"name":"Diagnosis of SCLC, summary"
},
{
	"jumpto":"ENAS5098_8.1.0.0",
	"name":"Diagnosis of TETs, summary"
},
{
	"jumpto":"ENAS6338_9.2.2.0",
	"name":"Diagnosis of the primary tumour, summary [LCC]"
},
{
	"jumpto":"ENAS6338_3.2.0.0",
	"name":"Diagnosis of the primary tumour [LCC]"
},
{
	"jumpto":"ENAS5633_2.1.0.0",
	"name":"Diagnosis [ALL]"
},
{
	"jumpto":"ENAS5284_2.0.0.0",
	"name":"Diagnosis [Bil]"
},
{
	"jumpto":"ENAS6340_3.0.0.0",
	"name":"Diagnosis [CRF]"
},
{
	"jumpto":"ENAS6370_3.0.0.0",
	"name":"Diagnosis [Endometrial CA]"
},
{
	"jumpto":"ENAS6366_202011272",
	"name":"Diagnosis [EOC]"
},
{
	"jumpto":"ENAS6371_2.0.0.0",
	"name":"Diagnosis [GTD]"
},
{
	"jumpto":"interactive_0002497",
	"name":"Diagnosis [Hereditary GC]"
},
{
	"jumpto":"ENAS6232_2.1.0.0",
	"name":"Diagnosis [Hereditary GC]"
},
{
	"jumpto":"ENAS5645_2.0.0.0",
	"name":"Diagnosis [HL]"
},
{
	"jumpto":"ENAS5408_2.0.0.0",
	"name":"Diagnosis [MCL]"
},
{
	"jumpto":"ENAS5304_2.0.0.0",
	"name":"Diagnosis [mCRC]"
},
{
	"jumpto":"ENAS5643_6.1.1.0",
	"name":"Diagnosis [mNSCLC]"
},
{
	"jumpto":"ENAS5263_8.0.0.0",
	"name":"Diagnosis [Mucosa]"
},
{
	"jumpto":"ENAS5285_2.0.0.0",
	"name":"Diagnosis [RCC]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Diagnosis [TETs]"
},
{
	"jumpto":"ENAS5649_2.0.0.0",
	"name":"Diagnosis [WM]"
},
{
	"jumpto":"interactive_0002836",
	"name":"Diagnostic algorithm for localised colon cancer, interactive tool [LCC]"
},
{
	"jumpto":"ENAS6338_4.1.2.0",
	"name":"Diagnostic algorithm for localised colon cancer [LCC]"
},
{
	"jumpto":"ENAS5279_3.1.0.0",
	"name":"Diagnostic and staging work-up, CLL"
},
{
	"jumpto":"ENAS5278_3.2.0.0",
	"name":"Diagnostic work-up, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5273_4.3.0.0",
	"name":"Diagnostic work-up, FL"
},
{
	"jumpto":"ENAS5280_2.2.0.0",
	"name":"Diagnostic work-up, HCL"
},
{
	"jumpto":"ENAS6235_2.0.0.0",
	"name":"Diagnostic work-up for EBC [EBC]"
},
{
	"jumpto":"ENAS5407_3.3.0.0",
	"name":"Diagnostic work-up in primary rectal cancer"
},
{
	"jumpto":"ENAS6344_3.2.2.0",
	"name":"Diagnostic work-up of adrenal- or paraganglioma-related malignancies [ACC]"
},
{
	"jumpto":"ENAS5635_2.0.0.0",
	"name":"Diagnostic work-up [AML]"
},
{
	"jumpto":"ENAS5644_2.1.0.0",
	"name":"Diagnostic work-up [HCC]"
},
{
	"jumpto":"ENAS5645_4.0.0.0",
	"name":"Diagnostic work-up [HL]"
},
{
	"jumpto":"ENAS5649_4.0.0.0",
	"name":"Diagnostic work-up [WM]"
},
{
	"jumpto":"ENAS5647_3.1.0.0",
	"name":"Diarrhoea, assessment"
},
{
	"jumpto":"ENAS5647_2.0.0.0",
	"name":"Diarrhoea, definition"
},
{
	"jumpto":"ENAS5647_8.0.0.0",
	"name":"Diarrhoea, immunotherapy-induced"
},
{
	"jumpto":"ENAS5647_3.3.0.0",
	"name":"Diarrhoea, medical history and warning signs"
},
{
	"jumpto":"ENAS5647_10.1.0.0",
	"name":"Diarrhoea, radiotherapy-induced"
},
{
	"jumpto":"ENAS5269_6.4.6.9",
	"name":"Diarrhoea, summary [FN]"
},
{
	"jumpto":"ENAS5263_14.8.4.0",
	"name":"Diarrhoea, summary [Mucosa]"
},
{
	"jumpto":"ENAS5647_7.0.0.0",
	"name":"Diarrhoea, targeted therapy-induced"
},
{
	"jumpto":"ENAS5410_3.4.1.3",
	"name":"Diarrhoea and colitis management, interactive tool [irAEs]"
},
{
	"jumpto":"interactive_0001767",
	"name":"Diarrhoea and colitis management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5647_20.3.0.0",
	"name":"Diarrhoea as a cancer-related symptom, summary [Diarrh.]"
},
{
	"jumpto":"ENAS5647_5.0.0.0",
	"name":"Diarrhoea as a cancer-related symptom [Diarrh.]"
},
{
	"jumpto":"ENAS5647_9.0.0.0",
	"name":"Diarrhoea associated with hormonal therapy"
},
{
	"jumpto":"ENAS5647_20.7.0.0",
	"name":"Diarrhoea associated with hormonal therapy, summary"
},
{
	"jumpto":"interactive_0002210",
	"name":"Diarrhoea diagnostic exams, interactive tool"
},
{
	"jumpto":"ENAS5647_3.2.0.0",
	"name":"Diarrhoea diagnostic exams, interactive tool"
},
{
	"jumpto":"ENAS5647_11.4.0.0",
	"name":"Diarrhoea due to surgical procedures"
},
{
	"jumpto":"ENAS5647_15.0.0.0",
	"name":"Diarrhoea in advanced care patients not receiving oncological treatments: practical management"
},
{
	"jumpto":"ENAS5647_20.13.0.0",
	"name":"Diarrhoea in advanced care pts. not receiving oncological Tx, summary"
},
{
	"jumpto":"ENAS5647_20.11.0.0",
	"name":"Diarrhoea in elderly cancer patients, summary"
},
{
	"jumpto":"ENAS5269_5.9.9.0",
	"name":"Diarrhoea [FN]"
},
{
	"jumpto":"ENAS5263_9.4.0.0",
	"name":"Diarrhoea [Mucosa]"
},
{
	"jumpto":"ENAS5283_7.0.0.0",
	"name":"Dietary support for vit. and mineral deficiencies (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.6.0.0",
	"name":"Dietary support for vit. and mineral deficiencies (Gastric cancer)"
},
{
	"jumpto":"ENAS5647_20.14.0.0",
	"name":"Diet in acute and chronic diarrhoea, summary"
},
{
	"jumpto":"ENAS5268_2.2.4.0",
	"name":"Differences, NK1 RAs [N/V]"
},
{
	"jumpto":"ENAS5267_6.2.0.0",
	"name":"Differential diagnosis, extravasation"
},
{
	"jumpto":"ENAS5267_12.5.2.0",
	"name":"Differential diagnosis, summary [Extra]"
},
{
	"jumpto":"ENAS6228_2.1.0.0",
	"name":"Differentiated & poorly differentiated TC [TC]"
},
{
	"jumpto":"ENAS5278_2.1.0.0",
	"name":"Diffuse large B-cell lymphoma (DLBCL)"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"Digital rectal examination"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Digital rectal examination, risk assessment"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"Digital rectal examination [PC]"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Digital rectal examination [Rectal CA]"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"Dihydropyrimidine dehydrogenase (DPD) testing [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.9.0",
	"name":"Discontinuation of treatment, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.7.0",
	"name":"Disease control (control of progression) [mCRC]"
},
{
	"jumpto":"ENAS5285_4.0.0.0",
	"name":"Diseases of chromosome 3p [RCC]"
},
{
	"jumpto":"ENAS5284_3.2.1.3",
	"name":"distal, cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5284_7.3.1.4",
	"name":"Distal cholangiocarcinoma, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.4.0",
	"name":"Distal cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5271_7.3.1.0",
	"name":"DLBCL treatment stratified according to age, summary"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"DNA-binding compounds [Extra]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Docetaxel, side effects, [PC]"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"Docetaxel [PC]"
},
{
	"jumpto":"ENAS5267_12.9.0.0",
	"name":"Documentation, summary [Extra]"
},
{
	"jumpto":"ENAS5267_10.0.0.0",
	"name":"Documentation [Extra]"
},
{
	"jumpto":"ENAS5268_2.3.2.0",
	"name":"Dolasetron [N/V]"
},
{
	"jumpto":"ENAS5648_3.3.1.0",
	"name":"Dosage, darbepoetin alpha [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.3.1.0",
	"name":"Dosage, epoetin alpha [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.3.1.0",
	"name":"Dosage, epoetin beta [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.3.1.0",
	"name":"Dosage, epoetin theta [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.3.1.0",
	"name":"Dosage, epoetin zeta [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.3.1.0",
	"name":"Dosage, ferric carboxymaltose [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.3.1.0",
	"name":"Dosage, ferric gluconate [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.3.1.0",
	"name":"Dosage, iron dextran [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.3.1.0",
	"name":"Dosage, iron isomaltoside [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.3.1.0",
	"name":"Dosage, iron sucrose [Anaemia]"
},
{
	"jumpto":"ENAS5268_6.1.3.1",
	"name":"Dose of antiemetics, summary [N/V]"
},
{
	"jumpto":"ENAS5269_6.3.2.0",
	"name":"Dose of G-CSF, summary [FN]"
},
{
	"jumpto":"ENAS5269_6.3.2.0",
	"name":"Dose of pegfilgrastim, summary [FN]"
},
{
	"jumpto":"ENAS5268_2.3.2.0",
	"name":"Doses, (5-HT)3 receptor antagonists [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.3.0",
	"name":"Doses, corticosteroids [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.4.0",
	"name":"Doses, NK1 receptor antagonists[N/V]"
},
{
	"jumpto":"ENAS5086_5.4.3.0",
	"name":"Dosimetric constraints, EPP"
},
{
	"jumpto":"ENAS6365_5.5.7.0",
	"name":"Dosing frequency of BTAs [Bone health]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Doxepin mouthwash [Mucosa]"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Doxorubicin, second-line treatment [SCLC]"
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Doxorubicin [Anal cancer]"
},
{
	"jumpto":"ENAS5092_6.0.0.0",
	"name":"DRE, PC follow-up [PC]"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"DRE [PC]"
},
{
	"jumpto":"ENAS6228_2.1.0.0",
	"name":"DTCs, diagnosis and pathology [TC]"
},
{
	"jumpto":"ENAS6228_2.4.7.0",
	"name":"DTCs, follow-up strategies [TC]"
},
{
	"jumpto":"ENAS6228_2.4.6.0",
	"name":"DTCs, imaging studies [TC]"
},
{
	"jumpto":"ENAS6228_2.5.2.0",
	"name":"DTCs, locoregional therapy [TC]"
},
{
	"jumpto":"ENAS6228_2.5.1.0",
	"name":"DTCs, management of advanced/met. Disease [TC]"
},
{
	"jumpto":"ENAS6228_2.4.5.0",
	"name":"DTCs, neck ultrasound [TC]"
},
{
	"jumpto":"ENAS6228_5.2.4.2",
	"name":"DTCs, Neck US, summary [TC]"
},
{
	"jumpto":"ENAS6228_2.4.2.0",
	"name":"DTCs, postoperative management [TC]"
},
{
	"jumpto":"ENAS6228_2.3.1.1",
	"name":"DTCs, primary tumour management [TC]"
},
{
	"jumpto":"ENAS6228_2.5.1.0",
	"name":"DTCs, RAI therapy [TC]"
},
{
	"jumpto":"ENAS6228_2.4.3.0",
	"name":"DTCs, response to treatment categories [TC]"
},
{
	"jumpto":"ENAS6228_2.2.3.0",
	"name":"DTCs, risk stratification system [TC]"
},
{
	"jumpto":"ENAS6228_2.3.1.1",
	"name":"DTCs, surgery [TC]"
},
{
	"jumpto":"ENAS6228_2.3.1.1",
	"name":"DTCs, surgical management overview [TC]"
},
{
	"jumpto":"ENAS6228_2.3.1.2",
	"name":"DTCs, surgical management recommendations [TC]"
},
{
	"jumpto":"ENAS6228_2.5.7.1",
	"name":"DTCs, systemic therapy & personalised medicine [TC]"
},
{
	"jumpto":"ENAS6228_2.1.0.0",
	"name":"DTCs, WHO classification [TC]"
},
{
	"jumpto":"ENAS6228_5.2.1.0",
	"name":"DTCs diagnosis and pathology, summary [TC]"
},
{
	"jumpto":"ENAS6228_5.2.4.1",
	"name":"DTCs follow-up, long-term implications, summary [TC]"
},
{
	"jumpto":"ENAS6228_5.2.4.1",
	"name":"DTCs follow-up, summary [TC]"
},
{
	"jumpto":"ENAS6228_5.2.5.2",
	"name":"DTCs locoregional therapy, summary [TC]"
},
{
	"jumpto":"ENAS6228_5.2.3.2",
	"name":"DTCs RAI therapy, summary [TC]"
},
{
	"jumpto":"ENAS6228_5.2.2.0",
	"name":"DTCs staging and risk assessment, summary [TC]"
},
{
	"jumpto":"ENAS6228_5.2.5.3",
	"name":"DTCs systemic therapy and personalised medicine [TC]"
},
{
	"jumpto":"ENAS6228_2.5.3.0",
	"name":"DTCs with bone metastases [TC]"
},
{
	"jumpto":"ENAS6228_2.5.6.0",
	"name":"DTCs with invasion of upper aerodigestive tract [TC]"
},
{
	"jumpto":"ENAS6228_2.5.5.0",
	"name":"DTCs with liver metastases [TC]"
},
{
	"jumpto":"ENAS6228_2.5.4.0",
	"name":"DTCs with lung metastases [TC]"
},
{
	"jumpto":"ENAS5269_6.4.8.0",
	"name":"Duration of therapy, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.11.0.0",
	"name":"Duration of therapy [FN]"
},
{
	"jumpto":"ENAS5265_8.4.3.0",
	"name":"Duration of Tx to prevent VTE recurr., summary"
},
{
	"jumpto":"ENAS5265_5.3.0.0",
	"name":"Duration of Tx to prevent VTE recurrence"
},
{
	"jumpto":"ENAS6339_11.4.1.0",
	"name":"During cancer treatment: cardiac safety surveillance [CVD]"
},
{
	"jumpto":"ENAS6339_5.1.0.0",
	"name":"During cancer treatment: cardiac safety surveillance [CVD]"
},
{
	"jumpto":"ENAS5280_2.3.0.0",
	"name":"Dx criteria for HCL and HCL-V"
},
{
	"jumpto":"ENAS5637_2.0.0.0",
	"name":"Dysplasia signs in MDS"
},
{
	"jumpto":"interactive_0002490",
	"name":"Early breast cancer treatment algorithm, tool [EBC]"
},
{
	"jumpto":"ENAS6235_4.2.0.0",
	"name":"Early breast cancer treatment algorithm [EBC]"
},
{
	"jumpto":"ENAS5406_3.0.0.0",
	"name":"Early NSCLC, diagnosis"
},
{
	"jumpto":"ENAS5406_2.0.0.0",
	"name":"Early NSCLC, screening"
},
{
	"jumpto":"ENAS6366_202011276",
	"name":"Early primary ovarian cancer [EOC]"
},
{
	"jumpto":"ENAS5304_5.9.0.0",
	"name":"Early tumour shrinkage [mCRC]"
},
{
	"jumpto":"ENAS5277_7.3.2.0",
	"name":"EATL in PTCL, summary"
},
{
	"jumpto":"ENAS5304_4.2.2.0",
	"name":"EGFR antibody therapy [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"EGFR ligands [mCRC]"
},
{
	"jumpto":"ENAS6340_6.4.7.0",
	"name":"Elderly cancer patients and CRF, summary [CRF]"
},
{
	"jumpto":"ENAS6340_5.6.0.0",
	"name":"Elderly cancer patients and CRF [CRF]"
},
{
	"jumpto":"ENAS5283_8.3.3.0",
	"name":"Elderly patients, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5304_8.6.12.3",
	"name":"Elderly patients, summary [mCRC]"
},
{
	"jumpto":"ENAS5643_6.3.9.0",
	"name":"Elderly patients, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5283_4.5.0.0",
	"name":"Elderly patients with gastric cancer"
},
{
	"jumpto":"ENAS5643_4.9.0.0",
	"name":"Elderly patients [mNSCLC]"
},
{
	"jumpto":"ENAS5263_11.3.0.0",
	"name":"Emergent data, systematic enteral nutrition [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.10.3.0",
	"name":"Emergent data of systematic enteral nutrition, summary [Mucosa]"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"Emerging biomarkers [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"Emerging technologies [mCRC]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Emetogenicity, levels [N/V]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Emetogenic potential [N/V]"
},
{
	"jumpto":"ENAS5269_6.4.6.6",
	"name":"Encephalitis, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.6.0",
	"name":"Encephalitis [FN]"
},
{
	"jumpto":"ENAS6341_4.2.2.0",
	"name":"Encephalopathy, summary [PCN]"
},
{
	"jumpto":"ENAS6341_3.2.0.0",
	"name":"Encephalopathy [PCN]"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Endo-anal ultrasound (EAUS)"
},
{
	"jumpto":"ENAS5407_3.3.0.0",
	"name":"Endorectal ultrasound [Rectal CA]"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Endoscopic mucosal resection, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Endoscopic mucosal resection, management (Oes CA)"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Endoscopic resection, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Endoscopic resection, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Endoscopic resection criteria, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5284_2.0.0.0",
	"name":"Endoscopic retrograde cholangiopancreatography [Bil]"
},
{
	"jumpto":"ENAS5282_4.1.1.0",
	"name":"Endoscopic stenting, treatment (Oes CA)"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Endoscopic sub-mucosal dissection, management (Oes CA)"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Endoscopic submucosal dissection, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Endoscopic ultrasound (EUS)"
},
{
	"jumpto":"ENAS5283_3.1.0.0",
	"name":"Endoscopic ultrasound (Gastric cancer)"
},
{
	"jumpto":"ENAS5277_7.3.3.0",
	"name":"ENKTCL in PTCL, summary"
},
{
	"jumpto":"ENAS5262_5.5.1.0",
	"name":"Enoxaparin [CVC]"
},
{
	"jumpto":"ENAS5647_11.2.0.0",
	"name":"Enteral feeding [Diarrh.]"
},
{
	"jumpto":"ENAS5262_6.3.3.7",
	"name":"Enterococcus, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.9.0",
	"name":"Enterococcus [CVC]"
},
{
	"jumpto":"ENAS5277_4.4.0.0",
	"name":"Enteropathy-associated T-cell lymphoma (EATL)"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Enzalutamide, palliative care [PC]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Enzalutamide, side effects [PC]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Enzalutamide, treatment of CRPC [PC]"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"Enzalutamide [PC]"
},
{
	"jumpto":"ENAS6365_2.0.0.0",
	"name":"Epidemiology [Bone health]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Epidermal growth factor receptor (EGFR) [Pancr]"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"Epiregulin [mCRC]"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"Epithelioid angiomyolipoma [RCC]"
},
{
	"jumpto":"ENAS5648_9.1.1.3",
	"name":"EPO receptor and tumour growth, summary [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.3.3.0",
	"name":"EPO receptor and tumour growth [Anaemia]"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"EP [TS/T-NS]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Erlotinib [Pancr]"
},
{
	"jumpto":"ENAS5096_2.1.0.0",
	"name":"Erythroplasia of Queyrat [PenCa]"
},
{
	"jumpto":"ENAS5648_3.3.1.0",
	"name":"Erythropoiesis-stimulating agents [Anaemia]"
},
{
	"jumpto":"ENAS6235_4.4.3.0",
	"name":"ER [EBC]"
},
{
	"jumpto":"ENAS5648_9.1.1.4",
	"name":"ESA and VTE risk, summary [Anaemia]"
},
{
	"jumpto":"ENAS5648_9.1.1.2",
	"name":"ESA effects on mortality and tumour progression, summary [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.3.2.0",
	"name":"ESA effects on mortality and tumour progresssion [Anaemia]"
},
{
	"jumpto":"ENAS5648_5.2.0.0",
	"name":"ESA in MDS [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.3.1.0",
	"name":"ESAs and IV iron compunds [Anaemia]"
},
{
	"jumpto":"ENAS5648_9.3.1.0",
	"name":"ESAs in MDS, summary [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.3.1.0",
	"name":"ESA therapy [Anaemia]"
},
{
	"jumpto":"ENAS5268_3.2.0.0",
	"name":"ESMO antiemetic guidelines [N/V]"
},
{
	"jumpto":"ENAS5639_3.3.1.0",
	"name":"Essential thrombocythaemia, treatment [MPNs]"
},
{
	"jumpto":"ENAS5639_7.2.2.0",
	"name":"Essential thrombocythaemia treatment, summary [MPNs]"
},
{
	"jumpto":"ENAS6235_7.3.3.0",
	"name":"ET, summary [EBC]"
},
{
	"jumpto":"ENAS5071_4.2.0.0",
	"name":"Etoposide, localised SCLC"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Etoposide/ifosfamide/cisplatin (VIP/PEI) [TS/T-NS]"
},
{
	"jumpto":"ENAS5639_3.3.2.0",
	"name":"ET treatment, interactive tool"
},
{
	"jumpto":"interactive_0002111",
	"name":"ET treatment algorithm, interactive tool"
},
{
	"jumpto":"ENAS6235_4.4.5.1",
	"name":"ET [EBC]"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"European Society of Gastrointestinal Endoscopy"
},
{
	"jumpto":"ENAS6365_4.5.0.0",
	"name":"Evaluation [Bone health]"
},
{
	"jumpto":"ENAS6343_5.3.3.4",
	"name":"Everolimus [GEP-NENs]"
},
{
	"jumpto":"ENAS5285_6.2.2.5",
	"name":"Everolimus [RCC]"
},
{
	"jumpto":"ENAS5647_20.2.1.0",
	"name":"Examinations and investigations, summary [Diarrh.]"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Examination under anaesthesia (EUA)"
},
{
	"jumpto":"ENAS5263_10.2.2.0",
	"name":"Example, basic oral care protocol [Mucosa]"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"Excision repair cross-complementation group 1 (ERCC1) [mCRC]"
},
{
	"jumpto":"ENAS5062_4.4.2.0",
	"name":"Exophytic tumors"
},
{
	"jumpto":"ENAS5304_5.1.0.0",
	"name":"Expert multidisciplinary team (MDT) [mCRC]"
},
{
	"jumpto":"ENAS5304_5.1.0.0",
	"name":"Expert multidisciplinary team (MDT) [mCRC]"
},
{
	"jumpto":"ENAS5086_5.5.3.0",
	"name":"Extended decortification, surgery in MPM"
},
{
	"jumpto":"ENAS5086_5.5.3.0",
	"name":"Extended pleurectomy, surgery in MPM"
},
{
	"jumpto":"ENAS5096_4.2.0.0",
	"name":"External beam radiotherapy (EBRT) [PenCa]"
},
{
	"jumpto":"ENAS6233_3.1.2.6",
	"name":"Extraintestinal surveillance [LS]"
},
{
	"jumpto":"ENAS5277_4.5.0.0",
	"name":"Extranodal natural killer/T-cell lymphoma (ENKTCL)"
},
{
	"jumpto":"ENAS5646_4.6.0.0",
	"name":"Extranodal NK/T cell lymphoma, nasal type [PCLs]"
},
{
	"jumpto":"ENAS5646_7.3.6.0",
	"name":"Extranodal NK/T cell lymphoma nasal type, summary [PCLs]"
},
{
	"jumpto":"ENAS5086_5.4.2.0",
	"name":"Extrapleural pneumonectomy (EPP)"
},
{
	"jumpto":"ENAS5086_5.4.3.0",
	"name":"Extrapleural pneumonectomy, choice of radiation"
},
{
	"jumpto":"ENAS5267_6.1.0.0",
	"name":"Extravasation, common initial symptoms"
},
{
	"jumpto":"ENAS5267_2.0.0.0",
	"name":"Extravasation, definition"
},
{
	"jumpto":"ENAS5267_6.1.0.0",
	"name":"Extravasation, diagnosis [Extra]"
},
{
	"jumpto":"ENAS5267_6.1.0.0",
	"name":"Extravasation, Later symptoms"
},
{
	"jumpto":"ENAS5267_5.0.0.0",
	"name":"Extravasation, prevention [Extra]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Extravasation, risk factors [Extra]"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"FA/5-FU/irinotecan/oxaliplatin"
},
{
	"jumpto":"ENAS5062_2.1.0.0",
	"name":"Faecal incontinence"
},
{
	"jumpto":"ENAS6233_3.1.1.0",
	"name":"Familial adenomatous polyposis [LS]"
},
{
	"jumpto":"ENAS5283_2.0.0.0",
	"name":"Familial cancer syndrome (Gastric cancer)"
},
{
	"jumpto":"ENAS6232_2.4.1.0",
	"name":"Familial intestinal gastric cancer [Hereditary GC]"
},
{
	"jumpto":"ENAS6233_4.2.1.1",
	"name":"FAP, summary [LS]"
},
{
	"jumpto":"ENAS5096_2.1.0.0",
	"name":"FDG-PET/CT [PenCa]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"FDG-PET scan in TS"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"FDG-PET [TS/T-NS]"
},
{
	"jumpto":"ENAS5269_2.0.0.0",
	"name":"Febrile neutropaenia"
},
{
	"jumpto":"ENAS6370_8.4.1.0",
	"name":"Fertility-preserving management, summary [Endometrial CA]"
},
{
	"jumpto":"ENAS6370_5.1.0.0",
	"name":"Fertility-preserving management [Endometrial CA]"
},
{
	"jumpto":"ENAS6367_6.1.3.0",
	"name":"Fertility preservation [NEOC]"
},
{
	"jumpto":"ENAS6369_8.4.3.0",
	"name":"Fertility sparing, summary [Cervical CA]"
},
{
	"jumpto":"ENAS6369_5.3.0.0",
	"name":"Fertility sparing [Cervical CA]"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Fibrinous pleurisy"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Fibulin-3 [MPM]"
},
{
	"jumpto":"ENAS6232_4.1.3.0",
	"name":"FIGC, summary [Hereditary GC]"
},
{
	"jumpto":"ENAS6366_2020112711",
	"name":"FIGO stage II–IV [EOC]"
},
{
	"jumpto":"ENAS5273_8.3.1.0",
	"name":"First-line of Rx in FL, summary"
},
{
	"jumpto":"ENAS5280_7.3.2.0",
	"name":"First-line of Rx in HCL, summary"
},
{
	"jumpto":"ENAS5408_4.1.0.0",
	"name":"First-line of Rx stage I-II [MCL]"
},
{
	"jumpto":"ENAS5408_4.2.0.0",
	"name":"First-line of Rx stage III-IV [MCL]"
},
{
	"jumpto":"ENAS5273_5.1.2.0",
	"name":"First-line of Rx stage III–IV, FL"
},
{
	"jumpto":"ENAS5273_5.1.1.0",
	"name":"First-line of Rx stage I–II, FL"
},
{
	"jumpto":"ENAS5408_7.3.1.0",
	"name":"First-line Rx of MCL stage I-II, summary"
},
{
	"jumpto":"ENAS5408_7.3.2.0",
	"name":"First-line Rx of MCL stage III-IV, summary"
},
{
	"jumpto":"ENAS5649_6.2.1.0",
	"name":"First-line therapy, overview [WM]"
},
{
	"jumpto":"ENAS5285_6.2.2.4",
	"name":"First-line treat., poor prognosis [RCC]"
},
{
	"jumpto":"ENAS5637_10.5.3.0",
	"name":"First-line treat. of anaemia, summary [MDS]"
},
{
	"jumpto":"ENAS5643_6.3.11.1",
	"name":"First-line treatment, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5643_6.3.12.1",
	"name":"First-line treatment, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5285_9.4.2.2",
	"name":"First-line treatment, summary [RCC]"
},
{
	"jumpto":"ENAS5643_6.3.2.0",
	"name":"First-line treatment of EGFR- and ALK-negative NSCLC, PD-L1 ≥ 50%, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5643_6.3.3.0",
	"name":"First-line treatment of EGFR- and ALK-negative NSCLC disease, regardless of PD-L1 status, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5643_6.3.6.0",
	"name":"First-line treatment of NSCC, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5643_4.6.1.0",
	"name":"First-line treatment of NSCC [mNSCLC]"
},
{
	"jumpto":"ENAS5643_6.3.4.0",
	"name":"First-line treatment of NSCLC without actionable oncogenic driver, with contraindications to use of immunotherapy, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5643_6.3.5.0",
	"name":"First-line treatment of SCC, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5643_4.5.0.0",
	"name":"First-line treatment of SCC [mNSCLC]"
},
{
	"jumpto":"ENAS5278_4.1.0.0",
	"name":"First-line treatment strategies, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5643_4.11.1.1",
	"name":"First-line treatment [mNSCLC]"
},
{
	"jumpto":"ENAS5643_4.12.1.1",
	"name":"First-line treatment [mNSCLC]"
},
{
	"jumpto":"ENAS5062_2.1.0.0",
	"name":"Fistulae"
},
{
	"jumpto":"ENAS5062_4.9.0.0",
	"name":"Flap reconstruction"
},
{
	"jumpto":"ENAS5273_4.4.0.0",
	"name":"FLIPI risk factors"
},
{
	"jumpto":"ENAS5269_5.9.10.0",
	"name":"Fluconazole [FN]"
},
{
	"jumpto":"ENAS5647_14.3.1.0",
	"name":"Fluids and electrolytes [Diarrh.]"
},
{
	"jumpto":"ENAS5282_4.1.6.0",
	"name":"Fluoropyrimidine, treatment (Oes CA)"
},
{
	"jumpto":"ENAS5269_5.1.0.0",
	"name":"FN, management"
},
{
	"jumpto":"ENAS5269_6.1.0.0",
	"name":"FN, summary"
},
{
	"jumpto":"ENAS5096_6.3.0.0",
	"name":"FNAC biopsy [PenCa]"
},
{
	"jumpto":"ENAS5269_5.8.0.0",
	"name":"FN management, key recommendations"
},
{
	"jumpto":"ENAS5269_5.4.0.0",
	"name":"FN mgmt., algo."
},
{
	"jumpto":"ENAS5643_6.3.21.0",
	"name":"Focus on bone metastases, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5643_4.21.0.0",
	"name":"Focus on bone metastases [mNSCLC]"
},
{
	"jumpto":"ENAS5643_6.3.17.0",
	"name":"Focus on brain metastases, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5643_4.17.0.0",
	"name":"Focus on brain metastases [mNSCLC]"
},
{
	"jumpto":"ENAS5643_6.3.18.0",
	"name":"Focus on LM carcinomatosis, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5643_4.18.0.0",
	"name":"Focus on LM carcinomatosis [mNSCLC]"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"FOLFIRINOX (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"FOLFIRINOX, 5-FU/cisplatin"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"FOLFIRINOX, metastatic pancreatic cancer"
},
{
	"jumpto":"ENAS5304_5.7.0.0",
	"name":"FOLFOX [mCRC]"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"Follicle-stimulating hormone (FSH) [TS/T-NS]"
},
{
	"jumpto":"ENAS5283_7.0.0.0",
	"name":"Follow-up & long term implications (Gastric cancer)"
},
{
	"jumpto":"ENAS5645_11.7.0.0",
	"name":"Follow-up & survivorship, summary"
},
{
	"jumpto":"ENAS5644_8.6.0.0",
	"name":"Follow-up & survivorship, summary [HCC]"
},
{
	"jumpto":"ENAS5649_10.6.0.0",
	"name":"Follow-up & survivorship, summary [WM]"
},
{
	"jumpto":"ENAS5644_7.0.0.0",
	"name":"Follow-up & survivorship [HCC]"
},
{
	"jumpto":"ENAS5643_5.0.0.0",
	"name":"Follow-up & survivorship [mNSCLC]"
},
{
	"jumpto":"ENAS5271_5.1.0.0",
	"name":"Follow-up, DLBCL"
},
{
	"jumpto":"ENAS5278_6.0.0.0",
	"name":"Follow-up, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5640_12.10.0.0",
	"name":"Follow-up, log term implications, summary [MM]"
},
{
	"jumpto":"ENAS6343_8.6.0.0",
	"name":"Follow-up, long-term implication and survivorship, summary [GEP-NENs]"
},
{
	"jumpto":"ENAS6344_8.6.0.0",
	"name":"Follow-up, long-term implications, summary [ACC]"
},
{
	"jumpto":"ENAS5633_7.5.0.0",
	"name":"Follow-up, long-term implications, summary [ALL]"
},
{
	"jumpto":"ENAS5648_9.6.0.0",
	"name":"Follow-up, long-term implications, summary [Anaemia]"
},
{
	"jumpto":"ENAS6235_7.5.0.0",
	"name":"Follow-up, long-term implications, summary [EBC]"
},
{
	"jumpto":"ENAS6369_8.6.0.0",
	"name":"Follow-up, long-term implications and survivorship, summary [Cervical CA]"
},
{
	"jumpto":"ENAS5643_6.4.0.0",
	"name":"Follow-up, long-term implications and survivorship, summary [mNSCLC]"
},
{
	"jumpto":"ENAS6367_7.5.0.0",
	"name":"Follow-up, long-term implications and survivorship, summary [NEOC]"
},
{
	"jumpto":"ENAS5646_7.5.0.0",
	"name":"Follow-up, long-term implications and survivorship, summary [PCLs]"
},
{
	"jumpto":"ENAS6228_5.4.4.0",
	"name":"Follow-up, long-term implications and survivorship in MTC, summary [TC]"
},
{
	"jumpto":"ENAS6369_7.0.0.0",
	"name":"Follow-up, long-term implications and survivorship [Cervical CA]"
},
{
	"jumpto":"ENAS5645_10.0.0.0",
	"name":"Follow-up, long-term implications and survivorship [HL]"
},
{
	"jumpto":"ENAS5646_6.0.0.0",
	"name":"Follow-up, long-term implications and survivorship [PCLs]"
},
{
	"jumpto":"ENAS5649_9.0.0.0",
	"name":"Follow-up, long-term implications and survivorship [WM]"
},
{
	"jumpto":"ENAS6344_7.0.0.0",
	"name":"Follow-up, long-term implications [ACC]"
},
{
	"jumpto":"ENAS5633_6.0.0.0",
	"name":"Follow-up, long-term implications [ALL]"
},
{
	"jumpto":"ENAS5635_6.0.0.0",
	"name":"Follow-up, long-term implications [AML]"
},
{
	"jumpto":"ENAS5648_8.0.0.0",
	"name":"Follow-up, long-term implications [Anaemia]"
},
{
	"jumpto":"ENAS6235_6.0.0.0",
	"name":"Follow-up, long-term implications [EBC]"
},
{
	"jumpto":"ENAS6343_7.0.0.0",
	"name":"Follow-up, long-term implications [GEP-NENs]"
},
{
	"jumpto":"ENAS5645_10.0.0.0",
	"name":"Follow-up, long-term implications [HL]"
},
{
	"jumpto":"ENAS5640_11.0.0.0",
	"name":"Follow-up, long-term implications [MM]"
},
{
	"jumpto":"ENAS6367_6.1.1.0",
	"name":"Follow-up, long-term implications [NEOC]"
},
{
	"jumpto":"ENAS6228_2.4.1.0",
	"name":"Follow-up, long-term implications [TC]"
},
{
	"jumpto":"ENAS5283_8.6.0.0",
	"name":"Follow-up, long term implications, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_7.6.0.0",
	"name":"Follow-up, long term implications, summary (Oes CA)"
},
{
	"jumpto":"ENAS5071_5.0.0.0",
	"name":"Follow-up, SCLC"
},
{
	"jumpto":"ENAS5284_7.5.0.0",
	"name":"Follow-up, summary [Bil]"
},
{
	"jumpto":"ENAS6370_8.6.0.0",
	"name":"Follow-up, summary [Endometrial CA]"
},
{
	"jumpto":"ENAS6366_2020112732",
	"name":"Follow-up, summary [EOC]"
},
{
	"jumpto":"ENAS5267_12.10.0.0",
	"name":"Follow-up, summary [Extra]"
},
{
	"jumpto":"ENAS6371_7.5.0.0",
	"name":"Follow-up, summary [GTD]"
},
{
	"jumpto":"ENAS6338_9.7.1.0",
	"name":"Follow-up, summary [LCC]"
},
{
	"jumpto":"ENAS5637_10.8.0.0",
	"name":"Follow-up, summary [MDS]"
},
{
	"jumpto":"ENAS5285_9.6.0.0",
	"name":"Follow-up, summary [RCC]"
},
{
	"jumpto":"ENAS5098_7.0.0.0",
	"name":"Follow-up, TETs"
},
{
	"jumpto":"ENAS5407_9.7.0.0",
	"name":"Follow-up. Long term implications and survivorship, summary [Rectal CA]"
},
{
	"jumpto":"ENAS6338_8.1.2.0",
	"name":"Follow-up after curative resection [LCC]"
},
{
	"jumpto":"ENAS5273_7.2.0.0",
	"name":"Follow-up after end of therapy, FL"
},
{
	"jumpto":"ENAS5279_6.0.0.0",
	"name":"Follow-up and long-term implications, CLL"
},
{
	"jumpto":"ENAS5273_7.1.0.0",
	"name":"Follow-up and long-term implications, FL"
},
{
	"jumpto":"ENAS5280_6.0.0.0",
	"name":"Follow-up and long-term implications, HCL"
},
{
	"jumpto":"ENAS5279_7.5.0.0",
	"name":"Follow-up and long-term implications in CLL, summary"
},
{
	"jumpto":"ENAS5273_8.5.0.0",
	"name":"Follow-up and long-term implications in FL, summary"
},
{
	"jumpto":"ENAS5408_7.5.0.0",
	"name":"Follow-up and long-term implications in MCL, summary"
},
{
	"jumpto":"ENAS5094_9.6.0.0",
	"name":"Follow-up and long term implications in BC, summary"
},
{
	"jumpto":"ENAS5280_7.5.0.0",
	"name":"Follow-up and long term implications in HCL, summary"
},
{
	"jumpto":"ENAS5092_7.5.0.0",
	"name":"Follow-up and long term implications in PC, summary"
},
{
	"jumpto":"ENAS5062_8.6.0.0",
	"name":"Follow-up in anal cancer, summary"
},
{
	"jumpto":"ENAS5271_7.4.1.0",
	"name":"Follow-up in DLBCL, summary"
},
{
	"jumpto":"ENAS5278_7.5.0.0",
	"name":"Follow-up in DLBCL-PMBCL, summary"
},
{
	"jumpto":"ENAS5096_7.5.0.0",
	"name":"Follow-up in PenCa, summary"
},
{
	"jumpto":"ENAS5097_7.4.0.0",
	"name":"Follow-up in TS/T-NS, summary"
},
{
	"jumpto":"ENAS5282_6.0.0.0",
	"name":"Follow-up long term implications (Oes CA)"
},
{
	"jumpto":"ENAS6229_5.0.0.0",
	"name":"Follow-up of bronchial and thymic NETs [NETs] Follow-up [NETs]"
},
{
	"jumpto":"ENAS5068_8.5.0.0",
	"name":"Follow-up of pancreatic cancer, summary"
},
{
	"jumpto":"ENAS6228_5.2.4.4",
	"name":"Follow-up strategies, summary [TC]"
},
{
	"jumpto":"ENAS5284_6.0.0.0",
	"name":"Follow-up [Bil]"
},
{
	"jumpto":"ENAS6370_7.0.0.0",
	"name":"Follow-up [Endometrial CA]"
},
{
	"jumpto":"ENAS6366_2020112718",
	"name":"Follow-up [EOC]"
},
{
	"jumpto":"ENAS5267_11.0.0.0",
	"name":"Follow-up [Extra]"
},
{
	"jumpto":"ENAS6371_6.0.0.0",
	"name":"Follow-up [GTD]"
},
{
	"jumpto":"ENAS6338_8.1.1.0",
	"name":"Follow-up [LCC]"
},
{
	"jumpto":"ENAS5408_6.0.0.0",
	"name":"Follow-up [MCL]"
},
{
	"jumpto":"ENAS5637_9.0.0.0",
	"name":"Follow-up [MDS]"
},
{
	"jumpto":"ENAS5263_13.0.0.0",
	"name":"Follow-up [Mucosa]"
},
{
	"jumpto":"ENAS5285_8.0.0.0",
	"name":"Follow-up [RCC]"
},
{
	"jumpto":"ENAS5407_8.1.0.0",
	"name":"Follow-up [Rectal CA]"
},
{
	"jumpto":"ENAS5283_4.3.3.4",
	"name":"Following preoperative chemotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5262_5.5.1.0",
	"name":"Fondaparinux [CVC]"
},
{
	"jumpto":"ENAS5304_5.2.2.0",
	"name":"FONG score [mCRC]"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Foseprepitant [N/V]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"FP monotherapy [mCRC]"
},
{
	"jumpto":"ENAS5640_12.4.1.0",
	"name":"Front-line treatment, summary [MM]"
},
{
	"jumpto":"ENAS5279_4.2.2.2",
	"name":"Front-line treatment algo., interactive tool"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Fuhrman’s grade, management of metastatic disease [RCC]"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"Fusion biopsy [PC]"
},
{
	"jumpto":"ENAS6339_11.9.0.0",
	"name":"Future directions and conclusion [CVD]"
},
{
	"jumpto":"ENAS6339_10.0.0.0",
	"name":"Future directions and conclusion [CVD]"
},
{
	"jumpto":"ENAS5269_4.3.0.0",
	"name":"G-CSF, dose [FN]"
},
{
	"jumpto":"ENAS5269_4.3.0.0",
	"name":"G-CSF, route of application [FN]"
},
{
	"jumpto":"ENAS5269_4.3.0.0",
	"name":"G-CSF, schedule [FN]"
},
{
	"jumpto":"ENAS5284_3.2.2.0",
	"name":"Gallbladder cancer, AJCC/UICC staging [Bil]"
},
{
	"jumpto":"ENAS5284_7.3.1.5",
	"name":"Gallbladder cancer, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.5.0",
	"name":"Gallbladder cancer [Bil]"
},
{
	"jumpto":"ENAS5269_5.9.5.0",
	"name":"Ganciclovir [FN]"
},
{
	"jumpto":"ENAS6232_4.1.4.0",
	"name":"GAPPS, summary [Hereditary GC]"
},
{
	"jumpto":"ENAS6232_2.5.1.0",
	"name":"GAPPS [Hereditary GC]"
},
{
	"jumpto":"ENAS6232_2.5.1.0",
	"name":"Gastric adenocarcinoma and proximal polyposis of the stomach [Hereditary GC]"
},
{
	"jumpto":"ENAS6233_3.1.2.5",
	"name":"Gastric and small bowel surveillance [LS]"
},
{
	"jumpto":"ENAS5283_4.2.0.0",
	"name":"Gastric CA treatment algo., interactive tool"
},
{
	"jumpto":"ENAS6342_5.2.0.0",
	"name":"Gastric MZL [MZLs]"
},
{
	"jumpto":"ENAS5263_14.8.3.0",
	"name":"Gastrointestinal mucositis grading, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_9.3.0.0",
	"name":"Gastrointestinal mucositis grading [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Gastrointestinal mucositis guideline [Mucosa]"
},
{
	"jumpto":"ENAS5283_2.0.0.0",
	"name":"Gastrointestinal stromal tumours (Gastric cancer)"
},
{
	"jumpto":"ENAS5410_4.2.4.1",
	"name":"Gastrointestinal toxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5284_7.3.1.5",
	"name":"GBC, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.5.0",
	"name":"GBC [Bil]"
},
{
	"jumpto":"ENAS6367_5.1.0.0",
	"name":"GCTs, management of advanced disease [NEOC]"
},
{
	"jumpto":"ENAS6367_4.1.1.0",
	"name":"GCTs, management of early stages [NEOC]"
},
{
	"jumpto":"ENAS6367_6.1.1.0",
	"name":"GCTs, response evaluation and follow-up [NEOC]"
},
{
	"jumpto":"ENAS6367_3.2.2.0",
	"name":"GCTs, staging [NEOC]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"GC [BC]"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"Gemcitabine(Pancreatic cancer)"
},
{
	"jumpto":"ENAS5068_5.5.0.0",
	"name":"Gemcitabine, gemicitabine [Pancr]"
},
{
	"jumpto":"ENAS5068_5.6.2.0",
	"name":"Gemcitabine, locally advanced pancreatic cancer"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Gemcitabine, metastatic pancreatic cancer"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Gemcitabine-refractory [Pancr]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Gemcitabine/cisplatin (GC) [BC]"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"Gemcitabine [PenCa]"
},
{
	"jumpto":"ENAS5267_12.6.2.0",
	"name":"General measures, summary [Extra]"
},
{
	"jumpto":"ENAS5267_7.2.0.0",
	"name":"General measures [Extra]"
},
{
	"jumpto":"ENAS6340_6.1.0.0",
	"name":"General principles of care, summary [CRF]"
},
{
	"jumpto":"ENAS5647_20.12.1.0",
	"name":"General principles of mgmt. of diarrhoea, summary"
},
{
	"jumpto":"ENAS6339_11.1.0.0",
	"name":"General principles [CVD]"
},
{
	"jumpto":"ENAS6339_2.0.0.0",
	"name":"General principles [CVD]"
},
{
	"jumpto":"ENAS5304_4.2.3.0",
	"name":"Genetic counselling [mCRC]"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"Gentamicin [CVC]"
},
{
	"jumpto":"ENAS6343_2.0.0.0",
	"name":"GEP-NENs, diagnosis and pathology [GEP-NENs]"
},
{
	"jumpto":"ENAS6343_4.1.0.0",
	"name":"GEP-NENs, management of local/locoregional disease [GEP-NENs]"
},
{
	"jumpto":"ENAS6343_3.0.0.0",
	"name":"GEP-NENs, staging and risk assessment [GEP-NENs]"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"Germ cell tumour (GCT) [TS/T-NS]"
},
{
	"jumpto":"ENAS5268_2.5.0.0",
	"name":"Germ cell tumours [N/V]"
},
{
	"jumpto":"ENAS5263_14.6.0.0",
	"name":"GI mucositis in targeted therapy, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_7.0.0.0",
	"name":"GI mucositis in targeted therapy [Mucosa]"
},
{
	"jumpto":"ENAS5410_3.4.1.4",
	"name":"GI toxicity, follow-up and long term implications [irAEs]"
},
{
	"jumpto":"ENAS5410_3.4.1.1",
	"name":"GI toxicity, immune related [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.4.1",
	"name":"GI toxicity of anti-CTLA4 antibodies, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.4.2",
	"name":"GI toxicity of anti-PD-1 antibodies, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.4.2.0",
	"name":"GI toxicity of anti-PD-1 antibodies [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.4.3",
	"name":"GI toxicity of combined anti-CTLA4 and anti-PD-1 antibodies, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.4.3.0",
	"name":"GI toxicity of combined anti-CTLA4 and anti-PD-1 antibodies [irAEs]"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"Gleason grades [PC]"
},
{
	"jumpto":"ENAS5273_9.0.0.0",
	"name":"Glossary"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Glutamine [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"GM-CSF [Mucosa]"
},
{
	"jumpto":"ENAS5285_6.2.2.3",
	"name":"Good/intermed. Px, 1st-line treat. [RCC]"
},
{
	"jumpto":"ENAS5273_3.0.0.0",
	"name":"Grading of follicular lymphoma"
},
{
	"jumpto":"ENAS5647_3.4.0.0",
	"name":"Grading [Diarrh.]"
},
{
	"jumpto":"ENAS5262_6.3.3.8",
	"name":"Gram-negative bacillus, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.10.0",
	"name":"Gram-negative bacillus [CVC]"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Granisetron [N/V]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Granulocyte-colony stimulating factor [BC]"
},
{
	"jumpto":"ENAS5406_4.1.0.0",
	"name":"Ground glass opacity areas [Early NSCLC]"
},
{
	"jumpto":"ENAS5273_5.2.0.0",
	"name":"Groupe d'Etude des lymphomes folliculaires"
},
{
	"jumpto":"ENAS5410_3.1.1.0",
	"name":"Grover’s dis­ease [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.6.6",
	"name":"Haematological toxicities, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.6.0",
	"name":"Haematological toxicities [irAEs]"
},
{
	"jumpto":"ENAS5263_4.0.0.0",
	"name":"Haematopoietic stem cell transplantation [Mucosa]"
},
{
	"jumpto":"ENAS5262_6.2.2.0",
	"name":"Haemothorax, summary [CVC]"
},
{
	"jumpto":"ENAS5262_3.2.0.0",
	"name":"Haemothorax [CVC]"
},
{
	"jumpto":"ENAS5407_3.6.3.0",
	"name":"Haggitt's sub-classification [Rectal CA]"
},
{
	"jumpto":"ENAS5268_3.3.0.0",
	"name":"Half body irradiation [N/V]"
},
{
	"jumpto":"ENAS5644_4.2.0.0",
	"name":"HCC treatment options depending on BCLC stage, interactive tool"
},
{
	"jumpto":"interactive_0002180",
	"name":"HCC treatment options depending on BCLC stage, interactive tool"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"HCG [TS/T-NS]"
},
{
	"jumpto":"ENAS6232_4.1.1.0",
	"name":"HDGC, summary [Hereditary GC]"
},
{
	"jumpto":"ENAS5263_10.2.1.0",
	"name":"Head & neck radiation, mucositis [Mucosa]"
},
{
	"jumpto":"ENAS5086_5.4.2.0",
	"name":"Hemi-thoracic radiotherapy (MPM)"
},
{
	"jumpto":"ENAS5304_5.5.0.0",
	"name":"Hepatic resection [mCRC]"
},
{
	"jumpto":"interactive_0001762",
	"name":"Hepatitis management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.3.2.2",
	"name":"Hepatitis management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Hepatojejunostomy [Pancr]"
},
{
	"jumpto":"ENAS5277_4.6.0.0",
	"name":"Hepatosplenic T-cell lymphoma (HSTCL)"
},
{
	"jumpto":"ENAS6235_4.4.3.0",
	"name":"HER2 [EBC]"
},
{
	"jumpto":"ENAS5283_4.2.0.0",
	"name":"HER2, human epidermal growth factor receptor 2 (Gastric cancer)"
},
{
	"jumpto":"interactive_0002492",
	"name":"HER2-positive breast cancer treatment, tool [EBC]"
},
{
	"jumpto":"ENAS6235_4.4.7.2",
	"name":"HER2-positive breast cancer treatment [EBC]"
},
{
	"jumpto":"ENAS6346_8.0.0.0",
	"name":"Hereditary ABC"
},
{
	"jumpto":"ENAS5283_2.0.0.0",
	"name":"Hereditary diffuse gastric cancer (Gastric cancer)"
},
{
	"jumpto":"ENAS6232_2.2.1.0",
	"name":"Hereditary diffuse gastric cancer [Hereditary GC]"
},
{
	"jumpto":"ENAS6232_4.1.1.0",
	"name":"Hereditary GC, summary [Hereditary GC]"
},
{
	"jumpto":"ENAS6233_4.1.1.0",
	"name":"Hereditary non-polyposis CRC syndrome, summary [LS]"
},
{
	"jumpto":"ENAS6233_2.1.0.0",
	"name":"Hereditary non-polyposis CRC syndrome [LS]"
},
{
	"jumpto":"ENAS6232_3.1.0.0",
	"name":"Hereditary pancreatic cancer [Hereditary GC]"
},
{
	"jumpto":"ENAS6232_4.2.1.0",
	"name":"Hereditary PC, summary [Hereditary GC]"
},
{
	"jumpto":"ENAS6233_4.2.1.1",
	"name":"Hereditary polyposis CRC syndromes, summary [LS]"
},
{
	"jumpto":"ENAS6233_3.1.1.0",
	"name":"Hereditary polyposis CRC syndromes [LS]"
},
{
	"jumpto":"ENAS5268_2.9.0.0",
	"name":"High-dose chemotherapy, prevention [N/V]"
},
{
	"jumpto":"ENAS5636_8.3.2.0",
	"name":"High-dose imatinib and combination with IFNα, summary [CML]"
},
{
	"jumpto":"ENAS5636_4.3.0.0",
	"name":"High-dose imatinib and combination with IFNα [CML]"
},
{
	"jumpto":"ENAS6369_4.3.3.0",
	"name":"High-risk disease [Cervical CA]"
},
{
	"jumpto":"ENAS5637_10.4.1.0",
	"name":"High-risk MDS treatment, summary"
},
{
	"jumpto":"ENAS5269_5.7.1.0",
	"name":"High-risk patients, overview [FN]"
},
{
	"jumpto":"ENAS5269_6.4.5.1",
	"name":"High-risk patients, summary [FN]"
},
{
	"jumpto":"ENAS5644_8.3.5.0",
	"name":"High conformal, high dose rate radioablation, summary [HCC]"
},
{
	"jumpto":"ENAS5644_4.7.0.0",
	"name":"High conformal, high dose rate radioablation [HCC]"
},
{
	"jumpto":"ENAS5304_5.12.0.0",
	"name":"High conformal radiation techniques [mCRC]"
},
{
	"jumpto":"ENAS5268_6.1.1.0",
	"name":"Highly emetogenic agents, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Highly emetogenic agents [N/V]"
},
{
	"jumpto":"ENAS5637_5.1.0.0",
	"name":"High risk MDS, treatment"
},
{
	"jumpto":"ENAS5273_5.2.0.0",
	"name":"High tumour burden criteria, FL"
},
{
	"jumpto":"ENAS5304_8.6.6.0",
	"name":"HIPEC, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.13.0.0",
	"name":"HIPEC [mCRC]"
},
{
	"jumpto":"ENAS5643_6.1.2.1",
	"name":"Histological diagnosis, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5643_2.2.1.0",
	"name":"Histological diagnosis [mNSCLC]"
},
{
	"jumpto":"ENAS5407_3.6.3.0",
	"name":"Histopathology, rectal cancer"
},
{
	"jumpto":"ENAS5407_9.2.2.0",
	"name":"Histopathology of rectal cancer, summary"
},
{
	"jumpto":"ENAS5637_5.2.0.0",
	"name":"HMAs [MDS]"
},
{
	"jumpto":"ENAS6344_8.2.2.0",
	"name":"Hormonal evaluation, summary [ACC]"
},
{
	"jumpto":"ENAS6344_3.2.1.0",
	"name":"Hormonal evaluation [ACC]"
},
{
	"jumpto":"ENAS5639_7.5.5.0",
	"name":"Hormonal therapy, summary [MPNs]"
},
{
	"jumpto":"ENAS5639_6.5.0.0",
	"name":"Hormonal therapy [MPNs]"
},
{
	"jumpto":"ENAS6367_6.2.0.0",
	"name":"Hormone replacement therapy and contraception [NEOC]"
},
{
	"jumpto":"ENAS5092_7.3.1.2",
	"name":"Hormone treatment of PC, summary"
},
{
	"jumpto":"ENAS5263_4.0.0.0",
	"name":"HSCT [Mucosa]"
},
{
	"jumpto":"ENAS5277_7.3.4.0",
	"name":"HSTCL in PTCL, summary"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"Human chorionic gonadotropin [TS/T-NS]"
},
{
	"jumpto":"ENAS5282_5.0.0.0",
	"name":"Human epidermal growth factor receptor 2 (HER2)-positive AC (Oes CA)"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Hyaluronidase [Extra]"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Hyperbaric oxygen [Mucosa]"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Hyperthermic intraperitoneal chemotherapy (HIPEC) [mCRC]"
},
{
	"jumpto":"ENAS5097_4.7.0.0",
	"name":"Hypogonadism [TS/T-NS]"
},
{
	"jumpto":"ENAS5637_10.4.2.0",
	"name":"Hypomethylating agents in MDS, summary"
},
{
	"jumpto":"ENAS5637_5.2.0.0",
	"name":"Hypomethylating agents [MDS]"
},
{
	"jumpto":"ENAS5410_4.2.2.2",
	"name":"Hypophysitis, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.2.2.2",
	"name":"Hypophysitis management, interactive tool [irAEs]"
},
{
	"jumpto":"interactive_0001761",
	"name":"Hypophysitis management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.2.2.1",
	"name":"Hypophysitis [irAEs]"
},
{
	"jumpto":"ENAS5406_4.1.0.0",
	"name":"IASLC [Early NSCLC]"
},
{
	"jumpto":"ENAS5284_7.3.1.2",
	"name":"iCCA, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.2.0",
	"name":"iCCA [Bil]"
},
{
	"jumpto":"ENAS6339_11.8.0.0",
	"name":"ICI-associated CV toxicity [CVD]"
},
{
	"jumpto":"interactive_0001758",
	"name":"ICPI-related toxicity: management of suspected central neurological toxicity [tool]"
},
{
	"jumpto":"ENAS5278_3.8.2.0",
	"name":"IELSG score, interactive tool"
},
{
	"jumpto":"ENAS5278_3.11.0.0",
	"name":"IELSG staging"
},
{
	"jumpto":"ENAS6343_5.3.3.3",
	"name":"IFN-α [GEP-NENs]"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"Ifosfamide [PenCa]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"IHC [TETs]"
},
{
	"jumpto":"ENAS6344_8.2.3.0",
	"name":"Imaging, summary [ACC]"
},
{
	"jumpto":"ENAS5304_8.6.2.3",
	"name":"Imaging identification of resectable/unresectable disease, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.6.0.0",
	"name":"Imaging identification [mCRC]"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"Imaging in TS"
},
{
	"jumpto":"ENAS6371_3.2.2.0",
	"name":"Imaging investigations for patients with GTN, interactive tool"
},
{
	"jumpto":"interactive_0002879",
	"name":"Imaging investigations for patients with GTN, interactive tool"
},
{
	"jumpto":"ENAS5647_20.2.4.0",
	"name":"Imaging studies and radiology, summary [Diarrh.]"
},
{
	"jumpto":"ENAS5647_4.2.3.0",
	"name":"Imaging studies and radiology [Diarrh.]"
},
{
	"jumpto":"ENAS6228_5.2.4.3",
	"name":"Imaging studies in DTCs, summary [TC]"
},
{
	"jumpto":"ENAS6344_3.3.0.0",
	"name":"Imaging [ACC]"
},
{
	"jumpto":"ENAS5285_5.2.2.1",
	"name":"IMDC risk groups"
},
{
	"jumpto":"ENAS5285_5.2.2.2",
	"name":"IMDC score [RCC]"
},
{
	"jumpto":"ENAS5262_6.2.2.0",
	"name":"Immediate complications, summary [CVC]"
},
{
	"jumpto":"ENAS5262_3.2.0.0",
	"name":"Immediate complications [CVC]"
},
{
	"jumpto":"ENAS5410_4.2.2.1",
	"name":"Immune-related endocrinopathies, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.2.1.1",
	"name":"Immune-related endocrinopathies [irAEs]"
},
{
	"jumpto":"ENAS5410_3.4.1.1",
	"name":"Immune-related gastrointestinal toxicity [irAEs]"
},
{
	"jumpto":"ENAS5410_3.3.2.1",
	"name":"Immune-related hepatotoxicity, management [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.3.1",
	"name":"Immune-related hepatotoxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.3.1.0",
	"name":"Immune-related hepatotoxicity [irAEs]"
},
{
	"jumpto":"ENAS5410_3.5.2.1",
	"name":"Immune-related pneumonitis, management [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.5.1",
	"name":"Immune-related pneumonitis, summary [irAEs]"
},
{
	"jumpto":"interactive_0001768",
	"name":"Immune-related pneumonitis mgmt., interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.5.2.2",
	"name":"Immune-related pneumonitis mgmt., interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.5.1.0",
	"name":"Immune-related pneumonitis [irAEs]"
},
{
	"jumpto":"ENAS5410_3.1.2.0",
	"name":"Immune-related skin toxicities, diagnosis & pathology [irAEs]"
},
{
	"jumpto":"ENAS5410_3.1.3.1",
	"name":"Immune-related skin toxicities, grades [irAEs]"
},
{
	"jumpto":"ENAS5410_3.1.3.1",
	"name":"Immune-related skin toxicities, management of rash [irAEs]"
},
{
	"jumpto":"interactive_0001760",
	"name":"Immune-related skin toxicities mgmt. of rash, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.1.3.3",
	"name":"Immune-related skin toxicities mgmt. of rash, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.1.1.0",
	"name":"Immune-related skin toxicities [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.1.1",
	"name":"Immune-related skin toxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.1.1.0",
	"name":"Immune-related toxicities [irAEs]"
},
{
	"jumpto":"ENAS6339_9.0.0.0",
	"name":"Immune checkpoint inhibitor-associated CV toxicity [CVD]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Immunohistochemistry [TETs]"
},
{
	"jumpto":"ENAS5647_20.6.0.0",
	"name":"Immunotherapy-induced diarrhoea, summary"
},
{
	"jumpto":"ENAS5409_11.2.5.0",
	"name":"Immunotherapy [IRs]"
},
{
	"jumpto":"ENAS6365_8.1.0.0",
	"name":"Incidence, epidem. & clinical consequences, summary [Bone health]"
},
{
	"jumpto":"ENAS6344_8.1.0.0",
	"name":"Incidence and epidemiology, summary [ACC]"
},
{
	"jumpto":"ENAS5096_2.1.0.0",
	"name":"Incisional or excisional biopsy [PenCa]"
},
{
	"jumpto":"ENAS5262_4.3.4.0",
	"name":"Indications, CVC removal"
},
{
	"jumpto":"ENAS5262_6.3.3.2",
	"name":"Indications for CVC removal, summary"
},
{
	"jumpto":"ENAS5647_20.2.5.0",
	"name":"Indications for endoscopy, summary [Diarrh.]"
},
{
	"jumpto":"ENAS5647_4.2.4.0",
	"name":"Indications for endoscopy [Diarrh.]"
},
{
	"jumpto":"ENAS5649_6.1.2.0",
	"name":"Indications for initiation of therapy [WM]"
},
{
	"jumpto":"ENAS5407_4.8.1.0",
	"name":"Indications for postoperative chemoradiotherapy [Rectal CA]"
},
{
	"jumpto":"ENAS5269_4.1.0.0",
	"name":"Indications for primary prophylaxis with G-CSF, overview [FN]"
},
{
	"jumpto":"ENAS5269_6.3.1.0",
	"name":"Indications for primary prophylaxis with G-CSF, summary [FN]"
},
{
	"jumpto":"ENAS6371_7.2.1.0",
	"name":"Indications for treatment, summary [GTD]"
},
{
	"jumpto":"ENAS6371_3.1.0.0",
	"name":"Indications for treatment [GTD]"
},
{
	"jumpto":"ENAS5094_8.0.0.0",
	"name":"Induction chemoradiation therapy [BC]"
},
{
	"jumpto":"ENAS5633_4.1.2.0",
	"name":"Induction of complete remission [ALL]"
},
{
	"jumpto":"ENAS5408_4.2.0.0",
	"name":"Induction therapy in stage III non-indolent MCL"
},
{
	"jumpto":"ENAS5640_9.2.0.0",
	"name":"Infections, supportive care [MM]"
},
{
	"jumpto":"ENAS5304_5.4.0.0",
	"name":"Infusional 5-FU/leucovorin/oxaliplatin (FOLFOX) [mCRC]"
},
{
	"jumpto":"ENAS5409_11.1.1.0",
	"name":"Infusion reactions, causative drugs [IRs]"
},
{
	"jumpto":"ENAS5409_7.0.0.0",
	"name":"Infusion reactions, diagnosis [IRs]"
},
{
	"jumpto":"ENAS5409_9.0.0.0",
	"name":"Infusion reactions, documentation [IRs]"
},
{
	"jumpto":"ENAS5409_12.0.0.0",
	"name":"Infusion reactions, follow-up [IRs]"
},
{
	"jumpto":"ENAS5409_8.1.0.0",
	"name":"Infusion reactions, management [IRs]"
},
{
	"jumpto":"ENAS5409_5.0.0.0",
	"name":"Infusion reactions, risk assessment [IRs]"
},
{
	"jumpto":"ENAS5409_6.0.0.0",
	"name":"Infusion reactions, signs and symptoms [IRs]"
},
{
	"jumpto":"ENAS5409_13.1.0.0",
	"name":"Infusion reactions, summary [IRs]"
},
{
	"jumpto":"ENAS5409_4.0.0.0",
	"name":"Infusion reactions, terminology criteria for adverse events [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.1.1",
	"name":"Infusion reactions and anthracyclines, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.1.1",
	"name":"Infusion reactions and chemotherapy, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.2.2",
	"name":"Infusion reactions and cituximab, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.2.1",
	"name":"Infusion reactions and monoclonal antibodies, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.1.2",
	"name":"Infusion reactions and platinum derivatives, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.2.3",
	"name":"Infusion reactions and rituximab, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.2.5",
	"name":"Infusion reactions and taxanes, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.1.3",
	"name":"Infusion reactions and taxanes, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.2.4",
	"name":"Infusion reactions and trastuzumab, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.8.1.1",
	"name":"Infusion reactions causative drugs, summary [IRs]"
},
{
	"jumpto":"ENAS5409_11.1.1.0",
	"name":"Infusion reactions charact. & mgmt., asso. with chemo drugs [IRs]"
},
{
	"jumpto":"ENAS5409_13.1.0.0",
	"name":"Infusion reactions definitions, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.4.0.0",
	"name":"Infusion reactions diagnosis, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.6.0.0",
	"name":"Infusion reactions documentation, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.9.0.0",
	"name":"Infusion reactions follow-up, summary [IRs]"
},
{
	"jumpto":"ENAS5409_8.3.2.0",
	"name":"Infusion reactions management, interactive tool [IRs]"
},
{
	"jumpto":"ENAS5409_13.5.1.0",
	"name":"Infusion reactions management, summary [IRs]"
},
{
	"jumpto":"interactive_0001748",
	"name":"Infusion reactions mgmt., interactive tool [IRs]"
},
{
	"jumpto":"ENAS5409_13.2.0.0",
	"name":"Infusion reactions risk assessment, summary [IRs]"
},
{
	"jumpto":"ENAS5409_13.3.0.0",
	"name":"Infusion reactions sign & symptoms, summary [IRs]"
},
{
	"jumpto":"ENAS5269_6.4.2.0",
	"name":"Initial assessment and investigations, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.2.0.0",
	"name":"Initial assessment and investigations [FN]"
},
{
	"jumpto":"ENAS6342_4.1.1.1",
	"name":"Initial therapy with antibiotics in gastric MZL [MZLs]"
},
{
	"jumpto":"ENAS6342_3.1.2.0",
	"name":"Initial work-up, EMZL [MZLs]"
},
{
	"jumpto":"ENAS6342_3.1.4.0",
	"name":"Initial work-up, NMZL [MZLs]"
},
{
	"jumpto":"ENAS6342_3.1.3.0",
	"name":"Initial work-up, SMZL [MZLs]"
},
{
	"jumpto":"ENAS6342_3.1.1.0",
	"name":"Initial work-up [MZLs]"
},
{
	"jumpto":"ENAS5269_6.4.4.1",
	"name":"Inpatient oral antibacterial therapy, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.6.1.0",
	"name":"Inpatient oral antibacterial therapy [FN]"
},
{
	"jumpto":"ENAS5262_6.2.1.0",
	"name":"Insertion, summary [CVC]"
},
{
	"jumpto":"ENAS5262_3.1.0.0",
	"name":"Insertion [CVC]"
},
{
	"jumpto":"ENAS6346_14.0.0.0",
	"name":"Integrative medicine [ABC]"
},
{
	"jumpto":"ENAS5062_4.4.2.0",
	"name":"Intensity-modulated radiotherapy (IMRT) [Anal]"
},
{
	"jumpto":"ENAS5086_5.4.2.0",
	"name":"Intensity-modulated radiotherapy (IMRT) [MPM]"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"Intensity modulated RT [TETs]"
},
{
	"jumpto":"ENAS5635_7.3.2.0",
	"name":"Intensive treatment of non-APL AML, summary [AML]"
},
{
	"jumpto":"ENAS5280_4.2.4.0",
	"name":"Interferon-α"
},
{
	"jumpto":"ENAS5271_4.6.2.0",
	"name":"Interim evaluation, DLBCL"
},
{
	"jumpto":"ENAS6369_4.3.2.0",
	"name":"Intermediate-risk disease [Cervical CA]"
},
{
	"jumpto":"ENAS5645_6.2.1.0",
	"name":"Intermediate-stage disease, overview [HL]"
},
{
	"jumpto":"ENAS5645_11.3.2.0",
	"name":"Intermediate-stage disease, summary"
},
{
	"jumpto":"ENAS5645_6.2.1.0",
	"name":"Intermediate-stage disease, treatment of cHL"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"International consortium-developed molecular classification system [mCRC]"
},
{
	"jumpto":"ENAS5278_3.5.1.0",
	"name":"International prognostic index, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5271_3.3.0.0",
	"name":"International prognostic index, interactive tool"
},
{
	"jumpto":"ENAS5407_4.7.2.6",
	"name":"Interval to surgery [Rectal CA]"
},
{
	"jumpto":"ENAS5269_6.4.6.8",
	"name":"Intra-abdominal or pelvic sepsis, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.8.0",
	"name":"Intra-abdominal or pelvic sepsis [FN]"
},
{
	"jumpto":"ENAS5284_3.2.1.1",
	"name":"Intra-hepatic, cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5407_3.6.4.0",
	"name":"Intra-mesorectal plane [Rectal CA]"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Intraductal papillary mucinous neoplasm"
},
{
	"jumpto":"ENAS5284_7.3.1.2",
	"name":"Intrahepatic cholangiocarcinoma, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.2.0",
	"name":"Intrahepatic cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5263_11.4.0.0",
	"name":"Intralesional injection [Mucosa]"
},
{
	"jumpto":"ENAS5262_6.1.0.0",
	"name":"Introduction, summary [CVC]"
},
{
	"jumpto":"ENAS5269_6.1.0.0",
	"name":"Introduction, summary [FN]"
},
{
	"jumpto":"ENAS5284_4.1.0.0",
	"name":"Introduction, treatment [Bil]"
},
{
	"jumpto":"ENAS5262_2.0.0.0",
	"name":"Introduction [CVC]"
},
{
	"jumpto":"ENAS5269_2.0.0.0",
	"name":"Introduction [FN]"
},
{
	"jumpto":"ENAS5647_20.2.2.0",
	"name":"Investigations, summary [Diarrh.]"
},
{
	"jumpto":"ENAS5647_4.2.1.0",
	"name":"Investigations [Diarrh.]"
},
{
	"jumpto":"ENAS5278_3.5.2.0",
	"name":"IPI & aaIPI, interactive tool"
},
{
	"jumpto":"ENAS5649_5.0.0.0",
	"name":"IPSSWM [WM]"
},
{
	"jumpto":"ENAS5410_2.5.0.0",
	"name":"irAEs, baseline assessment"
},
{
	"jumpto":"ENAS5410_2.1.0.0",
	"name":"irAEs, epidemiology"
},
{
	"jumpto":"ENAS5410_2.4.0.0",
	"name":"irAEs, general aspects"
},
{
	"jumpto":"ENAS5410_2.1.0.0",
	"name":"irAEs, overview"
},
{
	"jumpto":"ENAS5410_2.5.0.0",
	"name":"irAEs, patient selection and baseline assessment"
},
{
	"jumpto":"ENAS5410_4.1.1.0",
	"name":"irAEs epidemiology, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_4.1.1.0",
	"name":"irAEs general aspects, summary [irAEs]"
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Irinotecan [Anal cancer]"
},
{
	"jumpto":"ENAS5647_6.1.3.0",
	"name":"Irinotecan [Diarrh.]"
},
{
	"jumpto":"ENAS5263_5.0.0.0",
	"name":"Irinotecan [Mucosa]"
},
{
	"jumpto":"ENAS5648_3.4.3.0",
	"name":"Iron deficiency, management [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.4.1.0",
	"name":"Iron deficiency in solid or haemat. malignancies [Anaemia]"
},
{
	"jumpto":"ENAS5648_9.1.2.4",
	"name":"Iron effects on tumour progression, summary [Anaemia]"
},
{
	"jumpto":"ENAS5648_9.1.2.1",
	"name":"Iron status assessment, summary [Anaemia]"
},
{
	"jumpto":"ENAS5648_3.4.1.0",
	"name":"Iron status assessment [Anaemia]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Irritants [Extra]"
},
{
	"jumpto":"ENAS5647_12.2.0.0",
	"name":"Ischaemic colitis [Diarrh.]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Iseganan antimicrobial mouthwash [Mucosa]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"IV chemotherapy [N/V]"
},
{
	"jumpto":"ENAS5648_3.4.4.0",
	"name":"IV iron treatment, effect on tumour progression [Anaemia]"
},
{
	"jumpto":"ENAS5648_9.1.2.2",
	"name":"IV iron treatment, summary [Anaemia]"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Ivor-Lewis procedure, management (Oes CA)"
},
{
	"jumpto":"ENAS5282_7.3.1.2",
	"name":"Ivor-Lewis procedure, summary (Oes CA)"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Jaundice in introduction(Pancreatic cancer)"
},
{
	"jumpto":"ENAS5269_5.8.0.0",
	"name":"Key recommendations, FN management"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"KGF-1/palifermin [Mucosa]"
},
{
	"jumpto":"ENAS6235_4.4.3.0",
	"name":"Ki67 [EBC]"
},
{
	"jumpto":"ENAS5098_6.0.0.0",
	"name":"KIT sequencing [TETs]"
},
{
	"jumpto":"ENAS5284_7.3.1.3",
	"name":"Klatskin tumour, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.3.0",
	"name":"Klatskin tumour [Bil]"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"KRAS exons [mCRC]"
},
{
	"jumpto":"ENAS5407_3.6.3.0",
	"name":"Kudo/Kikuchi (sm)-system [Rectal CA]"
},
{
	"jumpto":"ENAS6346_12.0.0.0",
	"name":"LABC [ABC]"
},
{
	"jumpto":"ENAS5647_20.2.3.0",
	"name":"Laboratory and microbiological tests, summary [Diarrh.]"
},
{
	"jumpto":"ENAS5647_4.2.2.0",
	"name":"Laboratory and microbiological tests [Diarrh.]"
},
{
	"jumpto":"ENAS5643_3.2.0.0",
	"name":"Laboratory [mNSCLC]"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Laparoscopic gastric mobilisation (Oes CA)"
},
{
	"jumpto":"ENAS5285_6.1.2.0",
	"name":"Laparoscopic RN [RCC]"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Laparoscopic surgery, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Laparoscopic surgery recommended option for early gastric cancer, summary"
},
{
	"jumpto":"ENAS5283_8.2.0.0",
	"name":"Laparoscopy ± peritoneal washings, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_3.1.0.0",
	"name":"Laparoscopy ± peritoneal washings for malignant cells (Gastric cancer)"
},
{
	"jumpto":"ENAS5097_7.3.5.0",
	"name":"Late relapse and toxicity treatment, summary"
},
{
	"jumpto":"ENAS5267_6.1.0.0",
	"name":"Later symptoms, extravasation"
},
{
	"jumpto":"ENAS5267_12.5.1.0",
	"name":"Later symptoms, summary [Extra]"
},
{
	"jumpto":"ENAS5283_2.0.0.0",
	"name":"Lauren classification (Gastric cancer)"
},
{
	"jumpto":"ENAS5406_2.0.0.0",
	"name":"LDCT [Early NSCLC]"
},
{
	"jumpto":"ENAS5285_6.2.2.5",
	"name":"Lenvatinib [RCC]"
},
{
	"jumpto":"ENAS5408_3.5.0.0",
	"name":"Leukaemic non-nodal subtype of MCL"
},
{
	"jumpto":"ENAS5408_7.2.2.0",
	"name":"Leukaemic non-nodal subtype of MCL, summary"
},
{
	"jumpto":"ENAS5639_7.5.3.0",
	"name":"Leukaemic transformation, summary [MPNs]"
},
{
	"jumpto":"ENAS5639_6.3.0.0",
	"name":"Leukaemic transformation [MPNs]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Levels, emetogenicity [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.1.0",
	"name":"Levels of emetogenicity, summary [N/V]"
},
{
	"jumpto":"ENAS5268_5.1.0.0",
	"name":"Levomepromazine [N/V]"
},
{
	"jumpto":"ENAS5647_18.0.0.0",
	"name":"Limitations [Diarrh.]"
},
{
	"jumpto":"ENAS5645_11.3.1.0",
	"name":"Limited-stage disease, summary"
},
{
	"jumpto":"ENAS5645_6.1.1.0",
	"name":"Limited-stage disease, treatment of cHL"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Limited disease, management (Oes CA)"
},
{
	"jumpto":"ENAS5282_7.3.1.2",
	"name":"Limited disease, summary (Oes CA)"
},
{
	"jumpto":"ENAS5262_6.3.3.7",
	"name":"Linezolid, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.9.0",
	"name":"Linezolid [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.7.0",
	"name":"Linezolid [FN]"
},
{
	"jumpto":"ENAS5269_5.9.4.0",
	"name":"Liposomal amphotericin B [FN]"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"Liquid circulating tumour (ct)DNA biopsies [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.2.4",
	"name":"Liver metastases, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.2.2",
	"name":"Liver metastases, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.7.0.0",
	"name":"Liver metastases [mCRC]"
},
{
	"jumpto":"ENAS5304_5.2.2.0",
	"name":"Liver metastases [mCRC]"
},
{
	"jumpto":"ENAS5644_8.3.1.0",
	"name":"Liver resection, summary [HCC]"
},
{
	"jumpto":"ENAS5644_4.3.0.0",
	"name":"Liver resection [HCC]"
},
{
	"jumpto":"ENAS5265_5.1.1.0",
	"name":"LMWH and UFH, acute treatment [VTE]"
},
{
	"jumpto":"ENAS5265_4.1.0.0",
	"name":"LMWHs enoxaparin [VTE]"
},
{
	"jumpto":"ENAS5407_9.3.1.1",
	"name":"Local.locoregional disease mgmt., summary [Rectal CA]"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Local ablative treatments (LAT) [mCRC]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Local damage [Extra]"
},
{
	"jumpto":"ENAS5062_4.3.0.0",
	"name":"Local excision, anal cancer"
},
{
	"jumpto":"ENAS6338_4.1.1.0",
	"name":"Localised colonic tumours, management [LCC]"
},
{
	"jumpto":"ENAS5285_5.2.1.1",
	"name":"Localised disease, overview [RCC]"
},
{
	"jumpto":"ENAS5285_9.3.0.0",
	"name":"Localised disease, summary [RCC]"
},
{
	"jumpto":"ENAS5282_7.3.1.3",
	"name":"Locally advanced disease, summary (Oes CA)"
},
{
	"jumpto":"ENAS5285_6.1.3.0",
	"name":"Locally advanced RCC"
},
{
	"jumpto":"ENAS5285_9.4.1.3",
	"name":"Locally advanced RCC, summary [RCC]"
},
{
	"jumpto":"ENAS5062_4.1.0.0",
	"name":"Local or locoregional disease [Anal cancer]"
},
{
	"jumpto":"ENAS5269_6.4.1.0",
	"name":"Local policies, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.1.0.0",
	"name":"Local policies [FN]"
},
{
	"jumpto":"ENAS6369_8.4.2.0",
	"name":"Local recurrence of cervical cancer following radical surgery, summary [Cervical CA]"
},
{
	"jumpto":"ENAS6369_5.2.0.0",
	"name":"Local recurrence of cervical cancer following radical surgery [Cervical CA]"
},
{
	"jumpto":"ENAS5267_6.3.0.0",
	"name":"Local skin reactions [Extra]"
},
{
	"jumpto":"ENAS5304_5.12.0.0",
	"name":"Local thermal ablation [mCRC]"
},
{
	"jumpto":"ENAS5304_5.3.0.0",
	"name":"Local treatments [mCRC]"
},
{
	"jumpto":"ENAS6235_4.3.1.1",
	"name":"Local treatment [EBC]"
},
{
	"jumpto":"ENAS5406_4.2.0.0",
	"name":"Locoregional LN staging, interactive tool [Early NSCLC]"
},
{
	"jumpto":"interactive_0001743",
	"name":"Locoregional LN staging, interactive tool [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_4.3.0.0",
	"name":"Locoregional NSCLC treatment, interactive tool [Early NSCLC]"
},
{
	"jumpto":"ENAS6228_5.4.5.2",
	"name":"Locoregional therapy of advanced/metastatic MTC, summary [TC]"
},
{
	"jumpto":"ENAS5304_5.3.0.0",
	"name":"Locoregional treatments [mCRC]"
},
{
	"jumpto":"ENAS6339_8.5.0.0",
	"name":"Long-term cancer survivors and dietary habits [CVD]"
},
{
	"jumpto":"ENAS6339_8.4.0.0",
	"name":"Long-term cancer survivors and exercise [CVD]"
},
{
	"jumpto":"ENAS5639_7.4.0.0",
	"name":"Long-term follow-up and response evaluation, summary [MPNs]"
},
{
	"jumpto":"ENAS5639_5.0.0.0",
	"name":"Long-term follow-up and response evaluation [MPNs]"
},
{
	"jumpto":"ENAS5284_7.5.0.0",
	"name":"Long-term implications, summary [Bil]"
},
{
	"jumpto":"ENAS6338_9.7.2.0",
	"name":"Long-term implications/survivorship care plans, summary [LCC]"
},
{
	"jumpto":"ENAS6338_8.2.0.0",
	"name":"Long-term implications/ survivorship care plans [LCC]"
},
{
	"jumpto":"ENAS5284_6.0.0.0",
	"name":"Long-term implications [Bil]"
},
{
	"jumpto":"ENAS5263_13.0.0.0",
	"name":"Long-term implications [Mucosa]"
},
{
	"jumpto":"ENAS5265_5.2.0.0",
	"name":"Long-term treatment, solid tumours [VTE]"
},
{
	"jumpto":"ENAS5265_8.4.2.0",
	"name":"Long-term treatment in solid tumours, summary [VTE]"
},
{
	"jumpto":"ENAS5285_9.6.0.0",
	"name":"Long term implications, summary [RCC]"
},
{
	"jumpto":"ENAS5098_7.0.0.0",
	"name":"Long term implications, TETs"
},
{
	"jumpto":"ENAS5285_8.0.0.0",
	"name":"Long term implications [RCC]"
},
{
	"jumpto":"ENAS5637_10.4.4.0",
	"name":"Low-dose chemotherapy, summary [MDS]"
},
{
	"jumpto":"ENAS5637_5.4.0.0",
	"name":"Low-dose chemotherapy [MDS]"
},
{
	"jumpto":"ENAS5406_2.0.0.0",
	"name":"Low-dose computed tomography [Early NSCLC]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Low-level laser therapy [Mucosa]"
},
{
	"jumpto":"ENAS5269_5.6.1.0",
	"name":"Low-risk patients, oral therapy [FN]"
},
{
	"jumpto":"ENAS5269_6.4.4.1",
	"name":"Low-risk patients, summary [FN]"
},
{
	"jumpto":"ENAS5637_10.5.1.0",
	"name":"Low-risk treatment, summary [MDS]"
},
{
	"jumpto":"ENAS5268_6.1.1.0",
	"name":"Low emetogenic potential, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Low emetogenic potential [N/V]"
},
{
	"jumpto":"ENAS5637_6.1.0.0",
	"name":"Low risk MDS, treatment"
},
{
	"jumpto":"ENAS5408_3.2.0.0",
	"name":"Lugano classification [MCL]"
},
{
	"jumpto":"ENAS5406_4.6.0.0",
	"name":"Lung function test [Early NSCLC]"
},
{
	"jumpto":"ENAS5269_6.4.6.4",
	"name":"Lung infiltrates, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.4.0",
	"name":"Lung infiltrates [FN]"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"Luteinising hormone (LH) [TS/T-NS]"
},
{
	"jumpto":"ENAS5068_5.4.0.0",
	"name":"Lymphadenectomy, extended [Pancr]"
},
{
	"jumpto":"ENAS5068_5.4.0.0",
	"name":"Lymphadenectomy, standard [Pancr]"
},
{
	"jumpto":"ENAS5068_8.3.3.0",
	"name":"Lymphadenectomy in pancreatic cancer, summary"
},
{
	"jumpto":"ENAS6370_5.2.2.0",
	"name":"Lymphadenectomy in surgical management [Endometrial CA]"
},
{
	"jumpto":"ENAS5284_4.3.3.0",
	"name":"Lymphadenectomy [Bil]"
},
{
	"jumpto":"ENAS5068_5.4.0.0",
	"name":"Lymph nodes, infrapyloric [Pancr]"
},
{
	"jumpto":"ENAS5068_5.4.0.0",
	"name":"Lymph nodes, suprpyloric [Pancr]"
},
{
	"jumpto":"ENAS6369_4.2.7.0",
	"name":"Lymph node staging and RT [Cervical CA]"
},
{
	"jumpto":"ENAS6233_4.1.1.0",
	"name":"Lynch syndrome, summary [LS]"
},
{
	"jumpto":"ENAS6233_2.1.0.0",
	"name":"Lynch syndrome [LS]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"M-CAVI [BC]"
},
{
	"jumpto":"ENAS5086_5.5.3.0",
	"name":"Macroscopic resection, MPM surgery"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Magnetic resonance cholangiopancreatography (MRCP)"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"Magnetic resonance imaging (MRI) [BC]"
},
{
	"jumpto":"ENAS5086_4.1.0.0",
	"name":"Magnetic resonance imaging (MRI) [MP]"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Magnetic resonance imaging (MRI) [PC]"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"Magnetic resonance imaging (MRI) [TS/T-NS]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Magnetic resonance imaging [TETs]"
},
{
	"jumpto":"ENAS6342_3.2.1.0",
	"name":"Main prognostic factors & prognostic indices, EMZL [MZLs]"
},
{
	"jumpto":"ENAS6342_3.2.3.0",
	"name":"Main prognostic factors & prognostic indices, EMZL [MZLs]"
},
{
	"jumpto":"ENAS6342_3.2.2.0",
	"name":"Main prognostic factors & prognostic indices, SMZL [MZLs]"
},
{
	"jumpto":"ENAS5643_6.3.7.0",
	"name":"Maintenance, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5304_5.14.10.1",
	"name":"Maintenance and second-line treatment options [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.9.0",
	"name":"Maintenance therapy, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.3.0",
	"name":"Maintenance therapy [mCRC]"
},
{
	"jumpto":"ENAS5643_4.7.0.0",
	"name":"Maintenance [mNSCLC]"
},
{
	"jumpto":"ENAS5268_6.4.2.0",
	"name":"Malignant bowel obstruction, summary [N/V]"
},
{
	"jumpto":"ENAS5268_5.2.0.0",
	"name":"Malignant bowel obstruction [N/V]"
},
{
	"jumpto":"ENAS5283_3.1.0.0",
	"name":"Malignant lymph nodes (Gastric cancer)"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Malignant pleural meothelioma, definition (MPM)"
},
{
	"jumpto":"ENAS5086_6.0.0.0",
	"name":"Malignant pleural mesothelioma, follow-up"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Malignant pleural mesothelioma, pathology"
},
{
	"jumpto":"ENAS5086_5.4.2.0",
	"name":"Malignant pleural mesothelioma, post-op radiotherapy"
},
{
	"jumpto":"ENAS5086_5.4.2.0",
	"name":"Malignant pleural mesothelioma, pre-op radiotherapy"
},
{
	"jumpto":"ENAS5086_5.4.1.0",
	"name":"Malignant pleural mesothelioma, radiotherapy"
},
{
	"jumpto":"ENAS5086_4.1.0.0",
	"name":"Malignant pleural mesothelioma, staging"
},
{
	"jumpto":"ENAS5086_4.2.0.0",
	"name":"Malignant pleural mesothelioma, TNM staging"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"Malignant pleural mesothelioma, treatment"
},
{
	"jumpto":"ENAS5649_6.1.1.0",
	"name":"Management, asymptomatic patients [WM]"
},
{
	"jumpto":"ENAS5262_4.3.2.0",
	"name":"Management, CVC infections"
},
{
	"jumpto":"ENAS5269_5.1.0.0",
	"name":"Management, FN"
},
{
	"jumpto":"ENAS5263_11.1.0.0",
	"name":"Management, overview [Mucosa]"
},
{
	"jumpto":"ENAS6340_6.4.1.0",
	"name":"Management, summary [CRF]"
},
{
	"jumpto":"ENAS5649_10.3.1.0",
	"name":"Management, summary [WM]"
},
{
	"jumpto":"ENAS6344_6.1.1.0",
	"name":"Management of advanced/metastatic ACC [ACC]"
},
{
	"jumpto":"ENAS5282_7.4.0.0",
	"name":"Management of advanced/metastatic disease (M1), summary (Oes CA)"
},
{
	"jumpto":"ENAS6344_8.5.1.0",
	"name":"Management of advanced/metastatic disease, summary [ACC]"
},
{
	"jumpto":"ENAS6369_8.4.1.0",
	"name":"Management of advanced/metastatic disease, summary [Cervical CA]"
},
{
	"jumpto":"ENAS6343_8.4.1.0",
	"name":"Management of advanced/metastatic disease, summary [GEP-NENs]"
},
{
	"jumpto":"ENAS6344_6.1.1.0",
	"name":"Management of advanced/metastatic disease [ACC]"
},
{
	"jumpto":"ENAS6369_5.1.0.0",
	"name":"Management of advanced/metastatic disease [Cervical CA]"
},
{
	"jumpto":"ENAS6343_5.1.0.0",
	"name":"Management of advanced/metastatic disease [GEP-NENs]"
},
{
	"jumpto":"ENAS5407_6.1.0.0",
	"name":"Management of advanced/metastatic disease [Rectal CA]"
},
{
	"jumpto":"ENAS5643_6.3.1.0",
	"name":"Management of advanced/metastatic NSCLC, summary"
},
{
	"jumpto":"ENAS5644_8.4.1.1",
	"name":"Management of advanced disease, summary [HCC]"
},
{
	"jumpto":"ENAS6367_7.4.0.0",
	"name":"Management of advanced disease, summary [NEOC]"
},
{
	"jumpto":"ENAS5644_5.1.1.0",
	"name":"Management of advanced disease [HCC]"
},
{
	"jumpto":"ENAS5092_7.3.2.1",
	"name":"Management of advanced PC, summary"
},
{
	"jumpto":"ENAS5648_5.4.0.0",
	"name":"Management of anaemia in MDS, interactive tool"
},
{
	"jumpto":"interactive_0002202",
	"name":"Management of anaemia in MDS, interactive tool"
},
{
	"jumpto":"ENAS6339_1.0.0.0",
	"name":"Management of cardiac disease in cancer patients throughout oncological treatment [CVD]"
},
{
	"jumpto":"interactive_0002203",
	"name":"Management of chemo-induced anaemia, interactive tool"
},
{
	"jumpto":"ENAS5648_3.2.0.0",
	"name":"Management of chemo-induced anaemia, interactive tool"
},
{
	"jumpto":"ENAS5647_14.1.0.0",
	"name":"Management of diarrhoea"
},
{
	"jumpto":"interactive_0002211",
	"name":"Management of diarrhoea, interactive tool"
},
{
	"jumpto":"ENAS5647_20.12.1.0",
	"name":"Management of diarrhoea, summary"
},
{
	"jumpto":"ENAS6371_7.3.3.0",
	"name":"Management of drug-resistant disease, summary [GTD]"
},
{
	"jumpto":"ENAS6371_4.3.0.0",
	"name":"Management of drug-resistant disease [GTD]"
},
{
	"jumpto":"ENAS6367_4.1.2.0",
	"name":"Management of dysgerminoma, interactive tool"
},
{
	"jumpto":"interactive_0002872",
	"name":"Management of dysgerminoma, interactive tool"
},
{
	"jumpto":"ENAS5644_4.1.0.0",
	"name":"Management of early and intermediate HCC"
},
{
	"jumpto":"ENAS5644_8.3.1.0",
	"name":"Management of early and intermediate HCC, summary"
},
{
	"jumpto":"ENAS6367_7.3.0.0",
	"name":"Management of early stages, summary [NEOC]"
},
{
	"jumpto":"ENAS6367_4.1.1.0",
	"name":"Management of early stages [NEOC]"
},
{
	"jumpto":"ENAS5267_7.1.0.0",
	"name":"Management of extravasation, overview"
},
{
	"jumpto":"ENAS5267_12.6.1.0",
	"name":"Management of extravasation, summary [Extra]"
},
{
	"jumpto":"ENAS5269_6.4.1.0",
	"name":"Management of FN, summary [FN]"
},
{
	"jumpto":"interactive_0002875",
	"name":"Management of granulosa cell tumour, interactive tool"
},
{
	"jumpto":"ENAS6367_4.2.2.0",
	"name":"Management of granulosa cell tumour, interactive tool"
},
{
	"jumpto":"ENAS6371_7.3.2.0",
	"name":"Management of high-risk gestational trophoblastic neoplasia, summary [GTD]"
},
{
	"jumpto":"ENAS6371_4.2.0.0",
	"name":"Management of high-risk gestational trophoblastic neoplasia [GTD]"
},
{
	"jumpto":"ENAS6344_6.1.7.0",
	"name":"Management of hormone excess [ACC]"
},
{
	"jumpto":"interactive_0002873",
	"name":"Management of immature teratoma, interactive tool"
},
{
	"jumpto":"ENAS6367_4.1.3.0",
	"name":"Management of immature teratoma, interactive tool"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Management of local/locoregional disease (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_7.3.1.1",
	"name":"Management of local/locoregional disease (M0), summary (Oes CA)"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Management of local/locoregional disease, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5094_9.3.1.0",
	"name":"Management of local/locoregional disease, summary [BC]"
},
{
	"jumpto":"ENAS6369_8.3.1.0",
	"name":"Management of local/locoregional disease, summary [Cervical CA]"
},
{
	"jumpto":"ENAS6343_8.3.1.0",
	"name":"Management of local/locoregional disease, summary [GEP-NENs]"
},
{
	"jumpto":"ENAS5285_9.4.1.1",
	"name":"Management of local / locoregional disease, summary [RCC]"
},
{
	"jumpto":"ENAS6369_4.1.0.0",
	"name":"Management of local/locoregional disease [Cervical CA]"
},
{
	"jumpto":"ENAS5407_4.1.0.0",
	"name":"Management of local/locoregional disease [Rectal CA]"
},
{
	"jumpto":"ENAS5407_9.3.1.1",
	"name":"Management of local/locoregional rectal cancer, summary"
},
{
	"jumpto":"ENAS6338_9.3.1.0",
	"name":"Management of localised colonic tumours, summary [LCC]"
},
{
	"jumpto":"ENAS6338_9.3.2.0",
	"name":"Management of locally infiltrative colon cancers, summary [LCC]"
},
{
	"jumpto":"ENAS6338_4.2.0.0",
	"name":"Management of locally infiltrative colon cancers [LCC]"
},
{
	"jumpto":"ENAS5092_7.3.1.1",
	"name":"Management of local PC, summary"
},
{
	"jumpto":"ENAS5092_4.2.1.0",
	"name":"Management of local PC [PC]"
},
{
	"jumpto":"ENAS5407_9.4.0.0",
	"name":"Management of local recurrence of rectal cancer, summary"
},
{
	"jumpto":"ENAS5407_5.1.0.0",
	"name":"Management of local recurrence [Rectal CA]"
},
{
	"jumpto":"ENAS6344_8.4.1.0",
	"name":"Management of locoregional disease, summary [ACC]"
},
{
	"jumpto":"ENAS6344_5.1.1.0",
	"name":"Management of locoregional disease [ACC]"
},
{
	"jumpto":"ENAS6371_7.3.1.0",
	"name":"Management of low-risk disease, summary [GTD]"
},
{
	"jumpto":"ENAS6371_4.1.0.0",
	"name":"Management of low-risk disease [GTD]"
},
{
	"jumpto":"ENAS5648_5.1.0.0",
	"name":"Management of MDS associated anaemia, overview [Anaemia]"
},
{
	"jumpto":"ENAS5648_5.3.0.0",
	"name":"Management of MDS associated anaemia [Anaemia]"
},
{
	"jumpto":"ENAS5285_9.4.2.1",
	"name":"Management of metastatic disease, summary [RCC]"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Management of metastatic disease, treatment [RCC]"
},
{
	"jumpto":"ENAS5092_4.3.1.0",
	"name":"Management of metastatic PC, overview"
},
{
	"jumpto":"ENAS5647_14.2.3.0",
	"name":"Management of neutropaenic enterocolitis [Diarrh.]"
},
{
	"jumpto":"ENAS6235_4.3.1.5",
	"name":"Management of occult breast cancer [EBC]"
},
{
	"jumpto":"ENAS6343_4.2.1.0",
	"name":"Management of Pan-NETs [GEP-NENs]"
},
{
	"jumpto":"ENAS5640_12.7.3.0",
	"name":"Management of plasma cell leukaemia in MM, summary"
},
{
	"jumpto":"ENAS6371_7.3.4.0",
	"name":"Management of PSTT and ETT, summary [GTD]"
},
{
	"jumpto":"ENAS6371_4.4.0.0",
	"name":"Management of PSTT and ETT [GTD]"
},
{
	"jumpto":"ENAS5410_4.2.1.3",
	"name":"Management of rash, summary [irAEs]"
},
{
	"jumpto":"ENAS5636_5.1.0.0",
	"name":"Management of resistant and refractory CML"
},
{
	"jumpto":"ENAS5636_8.4.1.0",
	"name":"Management of resistant and refractory CML, summary"
},
{
	"jumpto":"ENAS6367_4.3.2.0",
	"name":"Management of SCCOHT, interactive tool"
},
{
	"jumpto":"interactive_0002877",
	"name":"Management of SCCOHT, interactive tool"
},
{
	"jumpto":"interactive_0002876",
	"name":"Management of SCSTS of the ovary SLCT, interactive tool"
},
{
	"jumpto":"ENAS5640_12.7.2.0",
	"name":"Management of solitary plasmacytoma in MM, summary"
},
{
	"jumpto":"interactive_0001759",
	"name":"Management of thyroid gland disorders [tool]"
},
{
	"jumpto":"ENAS6367_4.1.4.0",
	"name":"Management of YST, interactive tool"
},
{
	"jumpto":"interactive_0002874",
	"name":"Management of YST, interactive tool"
},
{
	"jumpto":"ENAS6340_5.1.0.0",
	"name":"Management [CRF]"
},
{
	"jumpto":"ENAS5648_9.3.2.0",
	"name":"Managing anaemia with MDS [Anaemia]"
},
{
	"jumpto":"ENAS5648_9.1.2.3",
	"name":"Managing iron deficiency, summary [Anaemia]"
},
{
	"jumpto":"ENAS6233_4.2.2.1",
	"name":"MAP, summary [LS]"
},
{
	"jumpto":"ENAS6235_4.4.4.0",
	"name":"Marker expression and intrinsic phenotype, tool [EBC]"
},
{
	"jumpto":"ENAS5098_4.2.0.0",
	"name":"Masaoka-Koga staging, TETs"
},
{
	"jumpto":"ENAS5098_8.2.0.0",
	"name":"Masaoka-Koga staging system, summary [TETs]"
},
{
	"jumpto":"ENAS5098_4.3.0.0",
	"name":"Masaoka-‍Koga stage"
},
{
	"jumpto":"ENAS5263_11.2.1.0",
	"name":"MASCC/ISOO guidelines, overview [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.10.2.0",
	"name":"MASCC/ISOO guidelines, summary [Mucosa]"
},
{
	"jumpto":"ENAS5268_3.2.0.0",
	"name":"MASCC antiemetic guidelines [N/V]"
},
{
	"jumpto":"ENAS5269_6.4.3.0",
	"name":"MASCC index, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.5.0.0",
	"name":"MASCC index [FN]"
},
{
	"jumpto":"ENAS6235_4.3.1.2",
	"name":"Mastectomy [EBC]"
},
{
	"jumpto":"ENAS5408_2.0.0.0",
	"name":"MCL, diagnosis"
},
{
	"jumpto":"ENAS5408_3.3.0.0",
	"name":"MCL, diagnostic work-up"
},
{
	"jumpto":"interactive_0001757",
	"name":"MCL therapeutic recom., interactive tool"
},
{
	"jumpto":"ENAS5408_4.3.0.0",
	"name":"MCL therapeutic recom., tool"
},
{
	"jumpto":"ENAS5637_2.0.0.0",
	"name":"MDS, diagnosis"
},
{
	"jumpto":"ENAS5637_2.0.0.0",
	"name":"MDS, dysplasia signs"
},
{
	"jumpto":"ENAS5637_3.0.0.0",
	"name":"MDS, prognosis and risk assessment"
},
{
	"jumpto":"ENAS5637_4.0.0.0",
	"name":"MDS, response criteria"
},
{
	"jumpto":"ENAS5637_7.0.0.0",
	"name":"MDS, supportive care and chelation therapy"
},
{
	"jumpto":"ENAS5637_5.1.0.0",
	"name":"MDS, treatment"
},
{
	"jumpto":"ENAS5637_10.1.0.0",
	"name":"MDS diagnosis, summary"
},
{
	"jumpto":"ENAS5637_10.2.0.0",
	"name":"MDS prognosis and risk assessment, summary"
},
{
	"jumpto":"ENAS5637_10.3.0.0",
	"name":"MDS response criteria, summary"
},
{
	"jumpto":"ENAS5637_5.3.0.0",
	"name":"MDS treatment, AML-like chemotherapy"
},
{
	"jumpto":"ENAS5268_2.4.1.0",
	"name":"MEC-induced acute nausea and vomiting, prophylaxis"
},
{
	"jumpto":"ENAS5268_6.1.4.1",
	"name":"MEC-induced acute nausea and vomiting prophylaxis, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.4.1.0",
	"name":"MEC-induced delayed nausea and vomiting, prophylaxis"
},
{
	"jumpto":"ENAS5268_6.1.4.1",
	"name":"MEC-induced delayed nausea and vomiting prophylaxis, summary [N/V]"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Mechlorethamine [Extra]"
},
{
	"jumpto":"ENAS5098_5.4.0.0",
	"name":"Median sternotomy [TETs]"
},
{
	"jumpto":"ENAS5265_4.2.0.0",
	"name":"Medical patients, prevention of VTE"
},
{
	"jumpto":"ENAS6343_8.4.3.1",
	"name":"Medical therapy, summary [GEP-NENs]"
},
{
	"jumpto":"ENAS6343_5.3.1.0",
	"name":"Medical therapy [GEP-NENs]"
},
{
	"jumpto":"ENAS6228_4.1.0.0",
	"name":"Medullary thyroid cancer [TC]"
},
{
	"jumpto":"ENAS5269_5.9.6.0",
	"name":"Meropenem [FN]"
},
{
	"jumpto":"ENAS5407_3.6.4.0",
	"name":"Mesorectal plane [Rectal CA]"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Mesothelial marker, calretinin"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Mesothelial marker, cytokeratin 5/6"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Mesothelial marker, podplanin (D240)"
},
{
	"jumpto":"ENAS5086_2.0.0.0",
	"name":"Mesothelin"
},
{
	"jumpto":"ENAS6365_4.3.0.0",
	"name":"Metabolic and molecular imaging [Bone health]"
},
{
	"jumpto":"ENAS5285_4.0.0.0",
	"name":"Metabolic RCCs"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Metallic stent [Pancr]"
},
{
	"jumpto":"ENAS5283_8.5.0.0",
	"name":"Metastasectomy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Metastasectomy [RCC]"
},
{
	"jumpto":"ENAS5304_8.6.4.0",
	"name":"Metastases at unfavourable/uncommon sites, summary [mCRC]"
},
{
	"jumpto":"ENAS6365_8.5.0.0",
	"name":"Metastasis prevention, summary [Bone health]"
},
{
	"jumpto":"ENAS6365_6.1.1.0",
	"name":"Metastasis prevention [Bone health]"
},
{
	"jumpto":"ENAS5304_5.14.1.0",
	"name":"Metastatic disease, first-line [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.4.0",
	"name":"Metastatic disease, second-line [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.5.0",
	"name":"Metastatic disease, third-line [mCRC]"
},
{
	"jumpto":"ENAS5285_9.4.2.2",
	"name":"Metastatic disease of non-clear cell histology, summary [RCC]"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Metastatic PC, palliative care [PC]"
},
{
	"jumpto":"ENAS5071_4.3.1.0",
	"name":"Metastatic SCLC, first-line treatment"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Metastatic SCLC, second-line treatment"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Metastatic TETs, treatment algorithm [TETs]"
},
{
	"jumpto":"ENAS5097_7.3.3.0",
	"name":"Metastatic TS/T-NS treatment, summary"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Methotrexate/carboplatin/vinblastine [BC]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Methotrexate/vinblastine/adriamycin/cisplatin [BC]"
},
{
	"jumpto":"ENAS5268_2.7.0.0",
	"name":"Metopimazine [N/V]"
},
{
	"jumpto":"ENAS5269_5.9.8.0",
	"name":"Metronidazole [FN]"
},
{
	"jumpto":"ENAS5639_3.4.2.0",
	"name":"MF treatment, interactive tool"
},
{
	"jumpto":"interactive_0002112",
	"name":"MF treatment algorithm, interactive tool"
},
{
	"jumpto":"ENAS6228_5.3.5.0",
	"name":"Mgmt. of advanced/metastatic ATC, summary [TC]"
},
{
	"jumpto":"ENAS5282_4.2.0.0",
	"name":"Mgmt. of advanced/ metastatic disease (Oes CA)"
},
{
	"jumpto":"ENAS6228_5.2.5.1",
	"name":"Mgmt. of advanced/metastatic DTCs, RAI therapy, summary [TC]"
},
{
	"jumpto":"ENAS6228_5.2.5.1",
	"name":"Mgmt. of advanced/metastatic DTCs, summary [TC]"
},
{
	"jumpto":"ENAS6228_5.4.5.1",
	"name":"Mgmt. of advanced/metastatic MTC, summary [TC]"
},
{
	"jumpto":"ENAS5643_4.1.0.0",
	"name":"Mgmt. of advanced/metastatic NSCLC, overview"
},
{
	"jumpto":"ENAS5407_9.5.0.0",
	"name":"Mgmt. of advanced/metastatic rectal cancer, summary"
},
{
	"jumpto":"ENAS5284_7.3.2.1",
	"name":"Mgmt. of advanced and/or mets. disease, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.4.1.0",
	"name":"Mgmt. of advanced and/or mets. disease [Bil]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Mgmt. of advanced and metastatic BC"
},
{
	"jumpto":"interactive_0002840",
	"name":"Mgmt. of cardiotoxic anticancer therapy, interactive tool [CVD]"
},
{
	"jumpto":"ENAS6228_5.3.3.0",
	"name":"Mgmt. of local/locoregional ATC, summary [TC]"
},
{
	"jumpto":"ENAS5282_4.1.1.0",
	"name":"Mgmt. of local/ locoregional disease (Oes CA)"
},
{
	"jumpto":"ENAS5284_4.3.1.0",
	"name":"Mgmt. of local/ locoregional disease, overview [Bil]"
},
{
	"jumpto":"ENAS5284_7.3.1.1",
	"name":"Mgmt. of local/ locoregional disease, summary [Bil]"
},
{
	"jumpto":"ENAS5285_6.1.1.0",
	"name":"Mgmt. of local/ locoregional disease, treatment [RCC]"
},
{
	"jumpto":"ENAS6228_5.4.3.0",
	"name":"Mgmt. of local/locoregional MTC, summary [TC]"
},
{
	"jumpto":"ENAS5062_8.3.1.0",
	"name":"Mgmt. of local and locoregional anal cancer, summary"
},
{
	"jumpto":"ENAS5094_6.0.0.0",
	"name":"Mgmt. of local disease, interactive tool [BC]"
},
{
	"jumpto":"ENAS5062_8.3.10.0",
	"name":"Mgmt. of metastatic anal cancer, summary"
},
{
	"jumpto":"ENAS5094_6.0.0.0",
	"name":"Mgmt. of metastatic disease, interactive tool [BC]"
},
{
	"jumpto":"ENAS5263_14.10.4.0",
	"name":"Mgmt. of mucosal injury caused by cancer Tx, summary [Mucosa]"
},
{
	"jumpto":"ENAS5646_4.4.2.0",
	"name":"Mgmt. of primary cutaneous CD30+ LPDS [PCLs]"
},
{
	"jumpto":"interactive_0002098",
	"name":"Mgmt. of primary cutaneous CD30+ LPDS [tool]"
},
{
	"jumpto":"interactive_0002478",
	"name":"Mgmt. of RAI-refractory, adv./met. DTC pts., tool"
},
{
	"jumpto":"ENAS6228_2.5.7.2",
	"name":"Mgmt. of RAI-refractory, adv./met. DTC pts., tool [TC]"
},
{
	"jumpto":"ENAS5646_4.8.3.0",
	"name":"Mgmt of PCLBCL-LT [PCLs]"
},
{
	"jumpto":"interactive_0002100",
	"name":"Mgmt of PCLBCL-LT [tool]"
},
{
	"jumpto":"ENAS5646_4.8.2.0",
	"name":"Mgmt of PCMZL and PCFCL [PCLs]"
},
{
	"jumpto":"interactive_0002099",
	"name":"Mgmt of PCMZL and PCFCL [tool]"
},
{
	"jumpto":"ENAS5263_14.9.2.2",
	"name":"mIAS, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_10.2.3.0",
	"name":"mIAS [Mucosa]"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"MIBC, extended lymphadenectomy"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"MIBC, external beam radiotherapy"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"MIBC, neoadjuvant chemotherapy"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"MIBC, radical cystectomy (RC)"
},
{
	"jumpto":"ENAS5304_4.2.3.0",
	"name":"Microsatellite instability (MSI)"
},
{
	"jumpto":"ENAS5304_8.5.3.0",
	"name":"Microsatellite instability, summary [mCRC]"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Microscopic pancreatic intraepithelial"
},
{
	"jumpto":"ENAS6340_6.4.6.0",
	"name":"Mind-body interventions, summary [CRF]"
},
{
	"jumpto":"ENAS6340_5.5.0.0",
	"name":"Mind-body interventions [CRF]"
},
{
	"jumpto":"ENAS5283_4.5.0.0",
	"name":"miniDOX regimen (Gastric cancer)"
},
{
	"jumpto":"ENAS5268_6.1.1.0",
	"name":"Minimally emetogenic, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Minimally emetogenic [N/V]"
},
{
	"jumpto":"ENAS5633_3.2.0.0",
	"name":"Minimal residual disease [ALL]"
},
{
	"jumpto":"ENAS5408_3.4.0.0",
	"name":"MIPI, interactive tool [MCL]"
},
{
	"jumpto":"ENAS5408_3.1.0.0",
	"name":"MIPI [MCL]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Misoprostol mouthwash [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Misoprostol suppositories [Mucosa]"
},
{
	"jumpto":"ENAS5062_4.1.0.0",
	"name":"Mitomycin C (MMC)"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Mitomycin C [Extra]"
},
{
	"jumpto":"ENAS6344_6.1.3.0",
	"name":"Mitotane monotherapy [ACC]"
},
{
	"jumpto":"ENAS5640_6.0.0.0",
	"name":"MM, consolidation"
},
{
	"jumpto":"ENAS5640_2.0.0.0",
	"name":"MM, diagnosis"
},
{
	"jumpto":"ENAS5640_5.1.0.0",
	"name":"MM, front-line treatment"
},
{
	"jumpto":"ENAS5640_5.2.1.0",
	"name":"MM, front-line treatment regimens"
},
{
	"jumpto":"ENAS5640_5.2.3.0",
	"name":"MM, in elderly"
},
{
	"jumpto":"ENAS5640_5.2.4.0",
	"name":"MM, in younger patients"
},
{
	"jumpto":"ENAS5640_7.0.0.0",
	"name":"MM, maintenance"
},
{
	"jumpto":"ENAS5640_8.4.0.0",
	"name":"MM, management of plasma cell leukaemia"
},
{
	"jumpto":"ENAS5640_8.3.0.0",
	"name":"MM, management of solitary plasmacytoma"
},
{
	"jumpto":"ENAS5640_4.0.0.0",
	"name":"MM, response evaluation"
},
{
	"jumpto":"ENAS5640_3.0.0.0",
	"name":"MM, staging and risk assessment"
},
{
	"jumpto":"ENAS5640_9.1.0.0",
	"name":"MM, supportive care"
},
{
	"jumpto":"ENAS5640_8.1.0.0",
	"name":"MM, treatment of relapsed/refractory disease"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"MM-398 [Pancr]"
},
{
	"jumpto":"ENAS5640_12.5.0.0",
	"name":"MM consolidation, summary"
},
{
	"jumpto":"ENAS5640_12.4.2.1",
	"name":"MM front-line treatment, summary"
},
{
	"jumpto":"ENAS5640_12.4.2.2",
	"name":"MM in elderly, summary"
},
{
	"jumpto":"ENAS5640_12.4.2.3",
	"name":"MM in young patients, summary"
},
{
	"jumpto":"ENAS5640_12.6.0.0",
	"name":"MM maintenance, summary"
},
{
	"jumpto":"ENAS5640_12.7.1.0",
	"name":"MM treatment of relapsed/refractory disease, summary"
},
{
	"jumpto":"ENAS6365_5.5.6.0",
	"name":"MM [Bone health]"
},
{
	"jumpto":"ENAS5268_6.1.1.0",
	"name":"Moderately emetogenic agents, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Moderately emetogenic agents [N/V]"
},
{
	"jumpto":"ENAS6344_6.1.6.0",
	"name":"Molecular-targeted therapies and immunotherapy [ACC]"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Molecular biology, rectal cancer"
},
{
	"jumpto":"ENAS6344_8.2.5.0",
	"name":"Molecular biology, summary [ACC]"
},
{
	"jumpto":"ENAS6344_3.5.0.0",
	"name":"Molecular biology [ACC]"
},
{
	"jumpto":"interactive_0002496",
	"name":"Molecular diagnosis of Lynch syndrome, tool [LS]"
},
{
	"jumpto":"ENAS6233_2.3.0.0",
	"name":"Molecular diagnosis of Lynch syndrome, tool [LS]"
},
{
	"jumpto":"ENAS5643_2.2.2.0",
	"name":"Molecular diagnostics"
},
{
	"jumpto":"ENAS5643_6.1.2.2",
	"name":"Molecular diagnostics, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5263_13.0.0.0",
	"name":"Molecular modelling [Mucosa]"
},
{
	"jumpto":"ENAS5636_8.3.5.0",
	"name":"Molecular monitoring, summary [CML]"
},
{
	"jumpto":"ENAS5636_4.6.0.0",
	"name":"Molecular monitoring [CML]"
},
{
	"jumpto":"ENAS5304_8.2.0.0",
	"name":"Molecular pathology and biomarkers, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.7.0",
	"name":"Molecular profile [mCRC]"
},
{
	"jumpto":"ENAS5285_9.3.0.0",
	"name":"Molecular prognostication, summary [RCC]"
},
{
	"jumpto":"ENAS5285_5.2.3.0",
	"name":"Molecular prognostication [RCC]"
},
{
	"jumpto":"ENAS5409_11.2.1.0",
	"name":"Monoclonal antibodies [IRs]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Morphine [Mucosa]"
},
{
	"jumpto":"ENAS5633_2.2.0.0",
	"name":"Morphology, immunophenotype, molecular screening [ALL]"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"MPM, first-line therapy"
},
{
	"jumpto":"ENAS5086_5.5.1.0",
	"name":"MPM, indications for surgery"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"MPM, maintenance therapy"
},
{
	"jumpto":"ENAS5086_5.5.2.0",
	"name":"MPM, palliative surgery"
},
{
	"jumpto":"ENAS5086_5.5.3.0",
	"name":"MPM, radical surgery"
},
{
	"jumpto":"ENAS5086_5.2.0.0",
	"name":"MPM, second-line therapy"
},
{
	"jumpto":"ENAS5086_5.5.2.0",
	"name":"MPM, surgery for staging"
},
{
	"jumpto":"ENAS5086_5.5.3.0",
	"name":"MPM, surgical procedures definition"
},
{
	"jumpto":"ENAS5086_7.1.0.0",
	"name":"MPM diagnosis, summary"
},
{
	"jumpto":"ENAS5086_7.5.0.0",
	"name":"MPM follow-up, summary"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"MPM subtype, biphasic"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"MPM subtype, epitheloid"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"MPM subtype, sarcomatoid"
},
{
	"jumpto":"ENAS5639_2.1.0.0",
	"name":"MPNs, diagnosis and pathology"
},
{
	"jumpto":"ENAS5639_2.3.0.0",
	"name":"MPNs, prognosis assessment"
},
{
	"jumpto":"ENAS5639_3.1.0.0",
	"name":"MPNs, treatment"
},
{
	"jumpto":"ENAS5639_7.1.0.0",
	"name":"MPNs diagnosis and pathology, summary"
},
{
	"jumpto":"ENAS5639_2.2.0.0",
	"name":"MPNs disgnostic algorithm, interactive tool"
},
{
	"jumpto":"ENAS5639_7.2.1.1",
	"name":"MPNs treatment, summary"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"MRI [PC]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"MRI [TETs]"
},
{
	"jumpto":"ENAS5304_4.2.3.0",
	"name":"MSI testing [mCRC]"
},
{
	"jumpto":"ENAS6228_5.4.2.0",
	"name":"MTC, staging and risk assessment, summary [TC]"
},
{
	"jumpto":"ENAS6228_5.4.1.0",
	"name":"MTC diagnosis and pathology, summary [TC]"
},
{
	"jumpto":"ENAS6228_4.1.0.0",
	"name":"MTCs, diagnosis and pathology [TC]"
},
{
	"jumpto":"ENAS6228_4.4.1.0",
	"name":"MTCs, follow-up, long-term implications, survivorship [TC]"
},
{
	"jumpto":"ENAS6228_4.5.2.0",
	"name":"MTCs, locoregional therapy [TC]"
},
{
	"jumpto":"ENAS6228_4.5.1.0",
	"name":"MTCs, management of advanced/metastatic disease [TC]"
},
{
	"jumpto":"ENAS6228_4.3.1.0",
	"name":"MTCs, management of local/locoregional disease [TC]"
},
{
	"jumpto":"ENAS6228_4.2.0.0",
	"name":"MTCs, staging and risk assessment [TC]"
},
{
	"jumpto":"ENAS6228_4.5.3.0",
	"name":"MTCs, systemic therapy and personalised medicine [TC]"
},
{
	"jumpto":"ENAS6228_4.4.2.0",
	"name":"MTCs postoperative management, tool [TC]"
},
{
	"jumpto":"interactive_0002475",
	"name":"MTCs surgical management recommendations, tool"
},
{
	"jumpto":"ENAS6228_4.3.2.0",
	"name":"MTCs surgical management recommendations, tool [TC]"
},
{
	"jumpto":"ENAS6228_4.1.0.0",
	"name":"MTC [TC]"
},
{
	"jumpto":"ENAS5263_2.0.0.0",
	"name":"mTOR inhibitor-associated stomatitis [Mucosa]"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Mucinous cystic neoplasm (Pancreatic Cancer)"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Mucinous lesions (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5263_10.2.1.0",
	"name":"Mucositis, chemotherapy [Mucosa]"
},
{
	"jumpto":"ENAS5263_10.2.1.0",
	"name":"Mucositis, head & neck radiation [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.1.0.0",
	"name":"Mucositis, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.9.2.1",
	"name":"Mucositis caused by chemotherapy, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.9.2.1",
	"name":"Mucositis caused by head & neck radiation, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_2.0.0.0",
	"name":"Mucositis [Mucosa]"
},
{
	"jumpto":"ENAS5263_5.0.0.0",
	"name":"Multi-cycle chemotherapy [Mucosa]"
},
{
	"jumpto":"ENAS6365_5.1.0.0",
	"name":"Multidisciplinary management [Bone health]"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Multidisciplinary treatment planning, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"Multiparametric MRI [PC]"
},
{
	"jumpto":"ENAS5268_2.5.0.0",
	"name":"Multiple-day cisplatin ChT, prev. [N/V]"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"Muscle-invasive BC, treatment"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"Muscle-invasive bladder cancer (MIBC)"
},
{
	"jumpto":"ENAS5407_3.6.4.0",
	"name":"Muscularis propria plane [Rectal CA]"
},
{
	"jumpto":"ENAS5615_9.2.0.0",
	"name":"Mutation detection, summary [BRCA]"
},
{
	"jumpto":"ENAS5615_4.0.0.0",
	"name":"Mutation detection [BRCA]"
},
{
	"jumpto":"ENAS6233_3.2.1.0",
	"name":"MUTYH-associated polyposis [LS]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"MVAC [BC]"
},
{
	"jumpto":"ENAS5098_7.0.0.0",
	"name":"Myasthenic crisis [TETs]"
},
{
	"jumpto":"ENAS5646_4.2.1.0",
	"name":"Mycosis fungoides and variants, overview [PCLs]"
},
{
	"jumpto":"ENAS5646_7.3.2.0",
	"name":"Mycosis fungoides and variants, summary [PCLs]"
},
{
	"jumpto":"ENAS5639_7.2.3.1",
	"name":"Myelofibrosis, summary [MPNs]"
},
{
	"jumpto":"ENAS5639_3.4.1.0",
	"name":"Myelofibrosis, treatment [MPNs]"
},
{
	"jumpto":"ENAS5639_2.1.0.0",
	"name":"Myelofibrosis grading [MPNs]"
},
{
	"jumpto":"ENAS6341_4.2.5.0",
	"name":"Myelopathy, summary [PCN]"
},
{
	"jumpto":"ENAS6341_3.5.0.0",
	"name":"Myelopathy [PCN]"
},
{
	"jumpto":"ENAS6342_7.3.4.0",
	"name":"MZL patients with recurrent disease, summary [MZLs]"
},
{
	"jumpto":"ENAS6342_4.4.0.0",
	"name":"MZL patients with recurrent disease [MZLs]"
},
{
	"jumpto":"ENAS6369_4.2.6.0",
	"name":"NACT and RT [Cervical CA]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Nanoliposomal irinotecan [Pancr]"
},
{
	"jumpto":"ENAS5268_5.3.0.0",
	"name":"Nausea and vomiting, opioid-induced"
},
{
	"jumpto":"ENAS5268_6.4.2.0",
	"name":"Nausea and vomiting in malignant bowel obstruction, summary [N/V]"
},
{
	"jumpto":"ENAS5263_14.8.2.0",
	"name":"NCI-CTCAE, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_9.2.0.0",
	"name":"NCI-CTCAE scale [Mucosa]"
},
{
	"jumpto":"ENAS6228_5.2.4.2",
	"name":"Neck US in DTCs [TC]"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Needle aspiration biopsy"
},
{
	"jumpto":"ENAS5062_4.4.1.0",
	"name":"Neo-adjuvant chemotherapy, anal cancer"
},
{
	"jumpto":"ENAS5092_4.2.2.0",
	"name":"Neoadjuvant ADT [PC]"
},
{
	"jumpto":"ENAS5094_9.3.3.0",
	"name":"Neoadjuvant and adjuvant therapy in BC, summary"
},
{
	"jumpto":"ENAS6369_4.2.4.0",
	"name":"Neoadjuvant chemotherapy to surgery [Cervical CA]"
},
{
	"jumpto":"ENAS5094_4.3.0.0",
	"name":"Neoadjuvant chemotherapy [BC]"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"Neoadjuvant chemotherapy [PenCa]"
},
{
	"jumpto":"ENAS5282_5.0.0.0",
	"name":"Neoadjuvant treatment (Oes CA)"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"Neoadjuvant treatment [Pancr]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Neoadjuvant [TS/T-NS]"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Neoplasia [Pancr]"
},
{
	"jumpto":"interactive_0001764",
	"name":"Nephritis management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.4.2",
	"name":"Nephritis management, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS6229_2.1.0.0",
	"name":"NETs diagnosis [NETs]"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Netupitant [N/V]"
},
{
	"jumpto":"ENAS6341_4.1.4.10",
	"name":"Neurofeedback, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.4.10.0",
	"name":"Neurofeedback [PCN]"
},
{
	"jumpto":"ENAS5410_4.2.6.1",
	"name":"Neurological toxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.1.1",
	"name":"Neurological toxicity [irAEs]"
},
{
	"jumpto":"ENAS6341_4.1.2.3",
	"name":"Neurophysiological examination, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.2.3.0",
	"name":"Neurophysiological examination [PCN]"
},
{
	"jumpto":"ENAS5097_4.7.0.0",
	"name":"Neurotoxicity [TS/T-NS]"
},
{
	"jumpto":"ENAS5647_14.2.3.0",
	"name":"Neutropaenic enterocolitis, management [Diarrh.]"
},
{
	"jumpto":"ENAS5647_12.1.0.0",
	"name":"Neutropaenic enterocolitis [Diarrh.]"
},
{
	"jumpto":"ENAS5633_2.4.0.0",
	"name":"New genetics/genomics [ALL]"
},
{
	"jumpto":"ENAS5633_4.1.3.0",
	"name":"Newly diagnosed ALL, maintenance therapy"
},
{
	"jumpto":"ENAS5633_4.1.1.0",
	"name":"Newly diagnosed ALL, pre-phase Tx & supportive measure [ALL]"
},
{
	"jumpto":"ENAS5633_4.1.2.0",
	"name":"Newly diagnosed ALL, remission induction Tx & consolidation [ALL]"
},
{
	"jumpto":"ENAS5633_4.1.1.0",
	"name":"Newly diagnosed ALL, treatment [ALL]"
},
{
	"jumpto":"ENAS5633_7.3.1.1",
	"name":"Newly diagnosed ALL treatment, summary"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"New onset diabetes (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5285_6.2.2.6",
	"name":"Nivolumab [RCC]"
},
{
	"jumpto":"ENAS5268_2.2.4.0",
	"name":"NK1 RAs, differences [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.4.0",
	"name":"NK1 receptor antagonists, doses [N/V]"
},
{
	"jumpto":"ENAS5277_2.0.0.0",
	"name":"Nodal and extranodal PTCL subtypes"
},
{
	"jumpto":"ENAS5071_4.2.0.0",
	"name":"Nodal dissection"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Nodal dissection [mCRC]"
},
{
	"jumpto":"ENAS5277_4.3.0.0",
	"name":"Nodal PTCL"
},
{
	"jumpto":"ENAS5277_7.3.1.0",
	"name":"Nodal PTCLs in PTCL, summary"
},
{
	"jumpto":"ENAS5285_6.2.2.7",
	"name":"Non-clear cell histology, treatment [RCC]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Non-DNA-binding compounds [Extra]"
},
{
	"jumpto":"ENAS6370_5.2.6.0",
	"name":"Non-endometrioid endometrial cancer [Endometrial CA]"
},
{
	"jumpto":"ENAS5062_2.1.0.0",
	"name":"Non-healing ulcer"
},
{
	"jumpto":"ENAS6338_2.3.0.0",
	"name":"Non-invasive tests [LCC]"
},
{
	"jumpto":"ENAS6338_9.1.3.0",
	"name":"Non-invasive tests [LCC]"
},
{
	"jumpto":"ENAS6339_5.2.0.0",
	"name":"Non-irradiating imaging [CVD]"
},
{
	"jumpto":"ENAS6339_11.4.1.0",
	"name":"Non-irradiating imaging [CVD]"
},
{
	"jumpto":"ENAS5094_4.1.0.0",
	"name":"Non-muscle-invasive BC, treatment"
},
{
	"jumpto":"ENAS5094_4.1.0.0",
	"name":"Non-muscle-invasive bladder cancer (NIBC)"
},
{
	"jumpto":"ENAS6341_2.3.3.0",
	"name":"Non-pharmacological prevention [PCN]"
},
{
	"jumpto":"ENAS6341_4.1.4.4",
	"name":"Non-pharmacological treatment, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.4.4.0",
	"name":"Non-pharmacological treatment [PCN]"
},
{
	"jumpto":"ENAS5615_5.1.0.0",
	"name":"Non-surgical preventative options, surveillance [BRCA]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Non-vesicant [Extra]"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"NRAS exons [mCRC]"
},
{
	"jumpto":"ENAS5406_7.0.0.0",
	"name":"NSCLC, follow-up and long term implications [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_6.0.0.0",
	"name":"NSCLC, personalised medicine [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.3.4.0",
	"name":"NSCLC, pretreatment risk assessment [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_4.1.0.0",
	"name":"NSCLC, staging and risk assessment [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.1.0.0",
	"name":"NSCLC, summary of recommendations [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.2.0.0",
	"name":"NSCLC diagnosis and pathology, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_3.0.0.0",
	"name":"NSCLC early, diagnosis"
},
{
	"jumpto":"ENAS5406_8.7.0.0",
	"name":"NSCLC follow-up, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_4.5.0.0",
	"name":"NSCLC locally advanced (stage III), staging [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.2.1.0",
	"name":"NSCLC locally advanced (stage III), treatment [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.3.3.0",
	"name":"NSCLC locally advanced (stage III) staging, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.5.1.0",
	"name":"NSCLC locally advanced (stage III) systemic therapy, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.5.1.0",
	"name":"NSCLC locally advanced (stage III) treatment, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.3.2.0",
	"name":"NSCLC locoregional staging, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.6.0.0",
	"name":"NSCLC personalised medicine, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.5.2.0",
	"name":"NSCLC resectable locally advanced (stage III) treatment, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.2.2.0",
	"name":"NSCLC resectable locally advanced, treatment [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.1.5.0",
	"name":"NSCLC stages I and II, postoperative radiotherapy [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.1.4.0",
	"name":"NSCLC stages I and II, radiofrequency ablation [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.1.3.0",
	"name":"NSCLC stages I and II, radiotherapy treatment [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.1.1.0",
	"name":"NSCLC stages I and II, surgical treatment [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.1.2.0",
	"name":"NSCLC stages I and II, systemic therapy [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.4.5.0",
	"name":"NSCLC stages I and II postop radiotherapy, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.4.3.0",
	"name":"NSCLC stages I and II primary radiotherapy treatment, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.4.4.0",
	"name":"NSCLC stages I and II radiofrequency ablation, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.4.1.0",
	"name":"NSCLC stages I and II surgical treatment, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.4.2.0",
	"name":"NSCLC stages I and II systemic therapy, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.3.1.0",
	"name":"NSCLC staging and risk assessment, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_8.5.3.0",
	"name":"NSCLC unresectable locally advanced (stage III) treatment, summary [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.2.3.0",
	"name":"NSCLC unresectable locally advanced, treatment [Early NSCLC]"
},
{
	"jumpto":"ENAS6340_6.4.4.0",
	"name":"Nutraceutical treatments, summary [CRF]"
},
{
	"jumpto":"ENAS6340_5.3.0.0",
	"name":"Nutraceutical treatments [CRF]"
},
{
	"jumpto":"ENAS5282_3.1.0.0",
	"name":"Nutritional status (Oes CA)"
},
{
	"jumpto":"ENAS5647_20.14.0.0",
	"name":"Nutritional strategies during acute and chronic diarrhoea, summary"
},
{
	"jumpto":"ENAS5265_3.0.0.0",
	"name":"Occult cancer idiopathic VTE, diagnosis"
},
{
	"jumpto":"ENAS5265_8.2.0.0",
	"name":"Occult cancer idiopathic VTE diagnosis, summary"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Octreotide [Mucosa]"
},
{
	"jumpto":"ENAS5410_4.2.6.5",
	"name":"Ocular toxicities, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.5.0",
	"name":"Ocular toxicities [irAEs]"
},
{
	"jumpto":"ENAS5268_6.1.3.2",
	"name":"Olanzapine, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.3.5.0",
	"name":"Olanzapine [N/V]"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Oligometastatic disease (OMD) [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.2.1",
	"name":"Oligometastatic disease, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.4.0.0",
	"name":"Oncological criteria [mCRC]"
},
{
	"jumpto":"ENAS5268_2.3.2.0",
	"name":"Ondansetron [N/V]"
},
{
	"jumpto":"ENAS6365_5.5.10.0",
	"name":"ONJ [Bone health]"
},
{
	"jumpto":"ENAS5268_5.3.0.0",
	"name":"Opioid-induced, nausea and vomiting"
},
{
	"jumpto":"ENAS5268_6.4.3.0",
	"name":"Opioid-induced nausea and vomiting, summary [N/V]"
},
{
	"jumpto":"ENAS5268_5.3.0.0",
	"name":"Opioid rotation [N/V]"
},
{
	"jumpto":"ENAS5647_14.3.2.0",
	"name":"Opioids (loperamide) [Diarrh.]"
},
{
	"jumpto":"ENAS5263_14.3.0.0",
	"name":"Oral and GI mucositis in HSCT, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_4.0.0.0",
	"name":"Oral and GI mucositis in HSCT [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Oral cavity mucositis guideline [Mucosa]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Oral chemotherapy [N/V]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Oral cryotherapy [Mucosa]"
},
{
	"jumpto":"ENAS6341_4.1.4.2",
	"name":"Oral drugs, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.4.2.0",
	"name":"Oral drugs [PCN]"
},
{
	"jumpto":"ENAS5263_3.0.0.0",
	"name":"Oral mucositis, head and neck radiation [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.8.2.0",
	"name":"Oral mucositis grading, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_9.2.0.0",
	"name":"Oral mucositis grading [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.2.0.0",
	"name":"Oral mucositis in head and neck radiation, summary [Mucosa]"
},
{
	"jumpto":"ENAS5269_5.6.1.0",
	"name":"Oral quinolone therapy [FN]"
},
{
	"jumpto":"ENAS5269_5.6.1.0",
	"name":"Oral therapy, low-risk patients [FN]"
},
{
	"jumpto":"ENAS5269_6.4.4.1",
	"name":"Oral therapy, summary [FN]"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Organising fibrinous exudates"
},
{
	"jumpto":"ENAS5094_6.0.0.0",
	"name":"Organ preservation therapy, interactive tool [BC]"
},
{
	"jumpto":"ENAS5094_9.3.4.0",
	"name":"Organ preservation therapy in BC, summary"
},
{
	"jumpto":"ENAS6365_5.4.0.0",
	"name":"Orthopaedic surgery [Bone health]"
},
{
	"jumpto":"ENAS5644_8.3.2.0",
	"name":"Orthotopic liver transplantation, summary [HCC]"
},
{
	"jumpto":"ENAS5644_4.4.0.0",
	"name":"Orthotopic liver transplantation [HCC]"
},
{
	"jumpto":"ENAS6365_5.5.12.0",
	"name":"Osteolysis after denosumab [Bone health]"
},
{
	"jumpto":"ENAS5647_20.9.0.0",
	"name":"Other causes of diarrhoea in cancer patients, summary"
},
{
	"jumpto":"ENAS6369_2.4.0.0",
	"name":"Other cervical carcinoma [Cervical CA]"
},
{
	"jumpto":"ENAS6235_7.3.7.0",
	"name":"Other clinical scenarios, summary [EBC]"
},
{
	"jumpto":"ENAS6235_4.4.10.0",
	"name":"Other clinical scenarios [EBC]"
},
{
	"jumpto":"ENAS5268_6.1.2.4",
	"name":"Other highly emetogenic ChT, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.2.5.0",
	"name":"Other highly emetogenic ChT [N/V]"
},
{
	"jumpto":"ENAS6233_3.1.2.3",
	"name":"Other polyposis syndromes surveillance [LS]"
},
{
	"jumpto":"ENAS6365_5.5.5.0",
	"name":"Other solid tumours [Bone health]"
},
{
	"jumpto":"ENAS6365_6.3.0.0",
	"name":"Other solid tumours [Bone health]"
},
{
	"jumpto":"ENAS5645_11.4.2.0",
	"name":"Other stages, summary"
},
{
	"jumpto":"ENAS5645_7.2.0.0",
	"name":"Other stages, treatment of NLPHL"
},
{
	"jumpto":"ENAS6233_4.1.4.0",
	"name":"Other syndromes, summary [LS]"
},
{
	"jumpto":"ENAS6233_4.2.3.0",
	"name":"Other syndromes, summary [LS]"
},
{
	"jumpto":"ENAS6233_2.5.0.0",
	"name":"Other syndromes [LS]"
},
{
	"jumpto":"ENAS6233_3.3.0.0",
	"name":"Other syndromes [LS]"
},
{
	"jumpto":"ENAS6342_4.1.4.0",
	"name":"Other treatments for EMZL, [MZLs]"
},
{
	"jumpto":"ENAS6341_2.6.4.0",
	"name":"Ototoxicity, prevention [PCN]"
},
{
	"jumpto":"ENAS6341_4.1.6.0",
	"name":"Ototoxicity, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.6.5.0",
	"name":"Ototoxicity, treatment [PCN]"
},
{
	"jumpto":"ENAS6341_2.6.1.0",
	"name":"Ototoxicity [PCN]"
},
{
	"jumpto":"ENAS5097_4.7.0.0",
	"name":"Ototoxicity [TS/T-NS]"
},
{
	"jumpto":"ENAS5269_6.4.3.0",
	"name":"Outcome risk assessment, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.3.0.0",
	"name":"Outcome risk assessment [FN]"
},
{
	"jumpto":"ENAS5269_6.4.4.2",
	"name":"Outpatient and early discharge policies, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.6.2.0",
	"name":"Outpatient and early discharge policies [FN]"
},
{
	"jumpto":"ENAS5285_5.2.2.1",
	"name":"Overview, advanced disease [RCC]"
},
{
	"jumpto":"ENAS5268_5.1.0.0",
	"name":"Overview, antiemetics in advanced cancer [N/V]"
},
{
	"jumpto":"ENAS5262_5.1.0.0",
	"name":"Overview, catheter-induced thrombosis [CVC]"
},
{
	"jumpto":"ENAS5267_9.1.0.0",
	"name":"Overview, central venous access device extravasation"
},
{
	"jumpto":"ENAS5262_4.1.0.0",
	"name":"Overview, CVC-related infection"
},
{
	"jumpto":"ENAS5269_5.7.1.0",
	"name":"Overview, high-risk patients [FN]"
},
{
	"jumpto":"ENAS5269_4.1.0.0",
	"name":"Overview, indications for primary prophylaxis with G-CSF [FN]"
},
{
	"jumpto":"ENAS5285_5.2.1.1",
	"name":"Overview, localised disease [RCC]"
},
{
	"jumpto":"ENAS5267_7.1.0.0",
	"name":"Overview, management of extravasation"
},
{
	"jumpto":"ENAS5263_11.1.0.0",
	"name":"Overview, management [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.1.0",
	"name":"Overview, MASCC/ISOO guidelines [Mucosa]"
},
{
	"jumpto":"ENAS5284_4.3.1.0",
	"name":"Overview, mgmt. of local/ locoregional disease [Bil]"
},
{
	"jumpto":"ENAS5268_2.2.1.0",
	"name":"Overview, prevention by emetogenic ChT [N/V]"
},
{
	"jumpto":"ENAS5268_2.4.1.0",
	"name":"Overview, prevention by MEC [N/V]"
},
{
	"jumpto":"ENAS5268_3.1.0.0",
	"name":"Overview, prevention of RINV [N/V]"
},
{
	"jumpto":"ENAS5263_10.1.0.0",
	"name":"Overview, preventive measures [Mucosa]"
},
{
	"jumpto":"ENAS5285_6.2.2.1",
	"name":"Overview, systemic treatment [RCC]"
},
{
	"jumpto":"ENAS5262_6.4.1.0",
	"name":"Overview of catheter-induced thrombosis, summary [CVC]"
},
{
	"jumpto":"ENAS5262_6.3.1.0",
	"name":"Overview of CVC-related infection, summary"
},
{
	"jumpto":"ENAS5263_14.10.1.0",
	"name":"Overview of management, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.9.1.0",
	"name":"Overview of preventive measures, summary [Mucosa]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Oxaliplatin, metastatic pancreatic cancer"
},
{
	"jumpto":"ENAS5268_6.1.4.3",
	"name":"Oxaliplatin, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.4.3.0",
	"name":"Oxaliplatin [N/V]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Oxaliplatin [Pancr]"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"Paclitaxel (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Paclitaxel, metastatic pancreatic cancer"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"Paclitaxel/carboplatin [PenCa]"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"Paclitaxel/cisplatin/5-fluorouracil [PenCa]"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"Paclitaxel/cisplatin/ifosfamide [PenCa]"
},
{
	"jumpto":"ENAS5094_5.1.0.0",
	"name":"Paclitaxel plus [BC]"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"Paclitaxel [PenCa]"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Paclitaxel [TETs]"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Pain management [Pancr]"
},
{
	"jumpto":"ENAS5062_8.3.11.0",
	"name":"Palliative care in anal cancer, summary"
},
{
	"jumpto":"ENAS5092_7.3.3.0",
	"name":"Palliative care in metastatic PC, summary"
},
{
	"jumpto":"ENAS5282_4.2.0.0",
	"name":"Palliative chemotherapy (Oes CA)"
},
{
	"jumpto":"ENAS5304_7.0.0.0",
	"name":"Palliative chemotherapy [mCRC]"
},
{
	"jumpto":"ENAS6228_3.3.4.0",
	"name":"Palliative EBRT [TC]"
},
{
	"jumpto":"ENAS6365_5.2.0.0",
	"name":"Palliative RT [Bone health]"
},
{
	"jumpto":"ENAS5282_4.2.0.0",
	"name":"Palliative treatment (Oes CA)"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Palonosetron [N/V]"
},
{
	"jumpto":"ENAS6343_8.3.2.0",
	"name":"Pan-NET, summary [GEP-NENs]"
},
{
	"jumpto":"ENAS5068_5.5.0.0",
	"name":"Pancreatic cancer, adjuvant treatment"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Pancreatic cancer, advanced"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Pancreatic cancer, biology"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"Pancreatic cancer, Borderline resectable"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Pancreatic cancer, diagnosis"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Pancreatic cancer, diagnostic work-up"
},
{
	"jumpto":"ENAS5068_7.0.0.0",
	"name":"Pancreatic cancer, follow-up"
},
{
	"jumpto":"ENAS5068_5.6.2.0",
	"name":"Pancreatic cancer, locally advanced"
},
{
	"jumpto":"ENAS5068_7.0.0.0",
	"name":"Pancreatic cancer, long-term implications"
},
{
	"jumpto":"ENAS5068_5.4.0.0",
	"name":"Pancreatic cancer, lymphadenectomy"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"Pancreatic cancer, metastatic"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Pancreatic cancer, metastatic disease"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Pancreatic cancer, oncological treatment"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Pancreatic cancer, palliative care"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Pancreatic cancer, pathology"
},
{
	"jumpto":"ENAS5068_6.0.0.0",
	"name":"Pancreatic cancer, personalised medicine"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"Pancreatic cancer, resectable"
},
{
	"jumpto":"ENAS5068_3.0.0.0",
	"name":"Pancreatic cancer, staging and assessment"
},
{
	"jumpto":"ENAS5068_8.1.0.0",
	"name":"Pancreatic cancer, summary of recommendations"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Pancreatic cancer, supportive care"
},
{
	"jumpto":"ENAS5068_4.2.0.0",
	"name":"Pancreatic cancer, TNM classification"
},
{
	"jumpto":"ENAS5068_5.1.0.0",
	"name":"Pancreatic cancer, treatment strategy"
},
{
	"jumpto":"ENAS5068_5.2.0.0",
	"name":"Pancreatic cancer, treatment summary"
},
{
	"jumpto":"ENAS5068_8.3.1.0",
	"name":"Pancreatic cancer, treatment summary recommendations"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Pancreatic cancers, adenocarcinoma"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Pancreatic cancers, ductal adenocarcinoma"
},
{
	"jumpto":"ENAS5068_5.4.0.0",
	"name":"Pancreatoduodenectomy"
},
{
	"jumpto":"ENAS5086_3.0.0.0",
	"name":"Pancytokeratin markers"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"Panitumumab [mCRC]"
},
{
	"jumpto":"ENAS5285_2.0.0.0",
	"name":"Paraneoplastic syndromes [RCC]"
},
{
	"jumpto":"ENAS5285_6.1.1.0",
	"name":"Partial nephrectomy [RCC]"
},
{
	"jumpto":"ENAS6369_2.5.0.0",
	"name":"Pathogenesis — molecular biology [Cervical CA]"
},
{
	"jumpto":"ENAS5407_4.7.2.5",
	"name":"Pathological assessment of response [Rectal CA]"
},
{
	"jumpto":"ENAS6338_9.4.0.0",
	"name":"Pathological report, summary [LCC]"
},
{
	"jumpto":"ENAS6338_5.0.0.0",
	"name":"Pathological report [LCC]"
},
{
	"jumpto":"ENAS5283_2.0.0.0",
	"name":"Pathology (Gastric cancer)"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Pathology, rectal cancer"
},
{
	"jumpto":"ENAS6344_8.2.4.0",
	"name":"Pathology, summary [ACC]"
},
{
	"jumpto":"ENAS5284_7.1.0.0",
	"name":"Pathology, summary [Bil]"
},
{
	"jumpto":"ENAS5282_2.0.0.0",
	"name":"Pathology/molecular biology (Oes CA)"
},
{
	"jumpto":"ENAS5406_3.0.0.0",
	"name":"Pathology/molecular biology, early NSCLC"
},
{
	"jumpto":"ENAS5273_2.0.0.0",
	"name":"Pathology/molecular biology, FL"
},
{
	"jumpto":"ENAS5280_2.1.0.0",
	"name":"Pathology/molecular biology, HCL"
},
{
	"jumpto":"ENAS5282_7.1.0.0",
	"name":"Pathology/molecular biology, summary (Oes CA)"
},
{
	"jumpto":"ENAS5643_6.1.2.1",
	"name":"Pathology/molecular biology, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5263_14.7.0.0",
	"name":"Pathology/ molecular biology, summary [Mucosa]"
},
{
	"jumpto":"ENAS5273_8.1.0.0",
	"name":"Pathology/molecular biology of FL, summary"
},
{
	"jumpto":"ENAS5280_7.1.0.0",
	"name":"Pathology/molecular biology of HCL, summary"
},
{
	"jumpto":"ENAS5408_7.1.0.0",
	"name":"Pathology/molecular biology of MCL, summary"
},
{
	"jumpto":"ENAS5408_2.0.0.0",
	"name":"Pathology/molecular biology [MCL]"
},
{
	"jumpto":"ENAS5643_2.2.1.0",
	"name":"Pathology/molecular biology [mNSCLC]"
},
{
	"jumpto":"ENAS5263_8.0.0.0",
	"name":"Pathology/ molecular biology [Mucosa]"
},
{
	"jumpto":"ENAS5285_9.2.0.0",
	"name":"Pathology assessment, summary [RCC]"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"Pathology assessment [RCC]"
},
{
	"jumpto":"ENAS5086_7.2.0.0",
	"name":"Pathology of MPM, summary"
},
{
	"jumpto":"ENAS5092_7.1.0.0",
	"name":"Pathology of PC, summary"
},
{
	"jumpto":"ENAS6344_3.4.0.0",
	"name":"Pathology [ACC]"
},
{
	"jumpto":"ENAS5284_2.0.0.0",
	"name":"Pathology [Bil]"
},
{
	"jumpto":"ENAS6365_8.2.0.0",
	"name":"Pathophysiology, summary [Bone health]"
},
{
	"jumpto":"ENAS6365_3.0.0.0",
	"name":"Pathophysiology [Bone health]"
},
{
	"jumpto":"ENAS5267_12.3.0.0",
	"name":"Patient-related risk factors, summary [Extra]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Patient-related risk factors [Extra]"
},
{
	"jumpto":"ENAS5269_6.4.1.0",
	"name":"Patient education, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.1.0.0",
	"name":"Patient education [FN]"
},
{
	"jumpto":"ENAS5410_4.1.2.0",
	"name":"Patient selection and baseline assessment, summary [irAEs]"
},
{
	"jumpto":"ENAS6339_7.7.0.0",
	"name":"Patients for whom HER2-targeted molecular therapy has been interrupted with no resolved symptoms [CVD]"
},
{
	"jumpto":"ENAS6339_7.6.0.0",
	"name":"Patients for whom HER2-targeted molecular therapy has been interrupted with resolved symptoms [CVD]"
},
{
	"jumpto":"ENAS6339_8.2.0.0",
	"name":"Patients who developed LVD or HF [CVD]"
},
{
	"jumpto":"ENAS6339_7.3.0.0",
	"name":"Patients with abnormal LVEF [CVD]"
},
{
	"jumpto":"ENAS6339_7.2.0.0",
	"name":"Patients with abnormal LVEF [CVD]"
},
{
	"jumpto":"ENAS6339_8.3.0.0",
	"name":"Patients with a history of mediastinal chest radiation [CVD]"
},
{
	"jumpto":"ENAS6339_7.8.0.0",
	"name":"Patients with anti-VEGF-based therapy with signs and symptoms of HF [CVD]"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Patients with sensitive disease [SCLC]"
},
{
	"jumpto":"ENAS6339_7.5.0.0",
	"name":"Patients with signs and symptoms of HF, or an asymptomatic patient with an LVEF treated with HER2-targeted molecular therapy [CVD]"
},
{
	"jumpto":"ENAS6339_7.4.0.0",
	"name":"Patients with unexplained signs and symptoms [CVD]"
},
{
	"jumpto":"ENAS5285_6.2.2.3",
	"name":"Pazopanib [RCC]"
},
{
	"jumpto":"ENAS5092_4.2.1.0",
	"name":"PC, advantages and disadvantages of treatment"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"PC, androgen-deprivation therapy (ADT)"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"PC, classification"
},
{
	"jumpto":"ENAS5092_4.2.4.0",
	"name":"PC, continuous ADT"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"PC, diagnosis"
},
{
	"jumpto":"ENAS5092_6.0.0.0",
	"name":"PC, follow-up and long term implications"
},
{
	"jumpto":"ENAS5092_4.2.2.0",
	"name":"PC, hormone treatment in local disease"
},
{
	"jumpto":"ENAS5092_4.2.4.0",
	"name":"PC, intermittent ADT"
},
{
	"jumpto":"ENAS5092_4.2.1.0",
	"name":"PC, management of local disease"
},
{
	"jumpto":"ENAS5092_4.3.1.0",
	"name":"PC, management of metastatic disease"
},
{
	"jumpto":"ENAS5092_5.0.0.0",
	"name":"PC, personalised medicine"
},
{
	"jumpto":"ENAS5092_4.2.3.0",
	"name":"PC, post-operative RT in local disease"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"PC, risk assessment"
},
{
	"jumpto":"ENAS5092_3.3.0.0",
	"name":"PC, risk groups"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"PC, staging"
},
{
	"jumpto":"ENAS5092_7.1.0.0",
	"name":"PC, summary recommendations"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"PC, therapeutic strategies"
},
{
	"jumpto":"ENAS5092_3.2.0.0",
	"name":"PC, TNM staging"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"PC, treatment of CRPC"
},
{
	"jumpto":"ENAS5092_4.2.4.0",
	"name":"PC, treatment of relapse"
},
{
	"jumpto":"ENAS5284_7.3.1.3",
	"name":"pCCA, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.3.0",
	"name":"pCCA [Bil]"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"PC metastatic, palliative care"
},
{
	"jumpto":"ENAS5269_4.3.0.0",
	"name":"Pegfilgrastim, dose [FN]"
},
{
	"jumpto":"ENAS5269_4.3.0.0",
	"name":"Pegfilgrastim, route of application [FN]"
},
{
	"jumpto":"ENAS5269_4.3.0.0",
	"name":"Pegfilgrastim, schedule [FN]"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"Pelvic MRI [Anal cancer]"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"Pemetrexed, MPM therapy"
},
{
	"jumpto":"ENAS5096_4.2.0.0",
	"name":"PenCa, brachytherapy"
},
{
	"jumpto":"ENAS5096_4.3.0.0",
	"name":"PenCa, chemoradiotherapy"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"PenCa, chemotherapy"
},
{
	"jumpto":"ENAS5096_4.5.0.0",
	"name":"PenCa, chemotherapy for advanced disease"
},
{
	"jumpto":"ENAS5096_4.4.0.0",
	"name":"PenCa, combination chemotherapy"
},
{
	"jumpto":"ENAS5096_2.1.0.0",
	"name":"PenCa, diagnosis"
},
{
	"jumpto":"ENAS5096_2.2.0.0",
	"name":"PenCa, diagnosis guidelines"
},
{
	"jumpto":"ENAS5096_6.1.0.0",
	"name":"PenCa, follow-up"
},
{
	"jumpto":"ENAS5096_6.2.0.0",
	"name":"PenCa, follow-up of local recurrence"
},
{
	"jumpto":"ENAS5096_6.3.0.0",
	"name":"PenCa, follow-up of regional recurrence"
},
{
	"jumpto":"ENAS5096_5.0.0.0",
	"name":"PenCa, personalised medicine"
},
{
	"jumpto":"ENAS5096_4.2.0.0",
	"name":"PenCa, radiotherapy"
},
{
	"jumpto":"ENAS5096_4.6.1.0",
	"name":"PenCa, recommendations for treatment"
},
{
	"jumpto":"ENAS5096_3.1.0.0",
	"name":"PenCa, risk factors"
},
{
	"jumpto":"ENAS5096_3.1.0.0",
	"name":"PenCa, risk groups"
},
{
	"jumpto":"ENAS5096_3.1.0.0",
	"name":"PenCa, staging and risk assessment"
},
{
	"jumpto":"ENAS5096_4.1.0.0",
	"name":"PenCa, surgical treatment"
},
{
	"jumpto":"ENAS5096_3.2.0.0",
	"name":"PenCa, TNM staging"
},
{
	"jumpto":"ENAS5096_4.6.5.0",
	"name":"PenCa, treat. algo. for regional lymph node [Interactive tool]"
},
{
	"jumpto":"ENAS5096_4.6.3.0",
	"name":"PenCa, treat. algorithm of primary tumour"
},
{
	"jumpto":"ENAS5096_4.6.4.0",
	"name":"PenCa, treatment for regional lymph nodes"
},
{
	"jumpto":"ENAS5096_4.6.7.0",
	"name":"PenCa, treatment of metastatic disease"
},
{
	"jumpto":"ENAS5096_4.6.2.0",
	"name":"PenCa, treatment of primary tumour"
},
{
	"jumpto":"ENAS5096_4.6.6.0",
	"name":"PenCa, treatment strategies for recurrence"
},
{
	"jumpto":"ENAS5096_4.1.0.0",
	"name":"Penectomy, effects on QoL [PenCa]"
},
{
	"jumpto":"ENAS5096_6.2.0.0",
	"name":"Penectomy, in local recurrence [PenCa]"
},
{
	"jumpto":"ENAS5096_6.2.0.0",
	"name":"Penile-preserving treatment [PenCa]"
},
{
	"jumpto":"ENAS5280_4.2.3.0",
	"name":"Pentostatin"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Pentoxifylline [Mucosa]"
},
{
	"jumpto":"ENAS5284_3.2.1.2",
	"name":"Peri-hilar, cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5284_3.1.0.0",
	"name":"Peri-hilar cholangiocarcinoma, Bismuth-Corlette classification [Bil]"
},
{
	"jumpto":"ENAS5284_7.3.1.3",
	"name":"Perihilar cholangiocarcinoma, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.3.3.0",
	"name":"Perihilar cholangiocarcinoma [Bil]"
},
{
	"jumpto":"ENAS5062_4.9.0.0",
	"name":"Perineal reconstruction"
},
{
	"jumpto":"ENAS5283_4.3.2.0",
	"name":"Perioperative chemotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.1.2",
	"name":"Perioperative chemotherapy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5304_5.14.6.0",
	"name":"Perioperative chemotherapy [mCRC]"
},
{
	"jumpto":"ENAS5283_4.3.2.0",
	"name":"Perioperative trastuzumab therapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5267_7.4.0.0",
	"name":"Peripheral line extravasation, steps"
},
{
	"jumpto":"ENAS5262_6.2.1.0",
	"name":"Peripherally inserted central catheters, summary[CVC]"
},
{
	"jumpto":"ENAS5262_3.1.0.0",
	"name":"Peripherally inserted central catheters [CVC]"
},
{
	"jumpto":"ENAS5410_3.6.1.2",
	"name":"Peripheral neurological symptoms, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.1.3",
	"name":"Peripheral neurological syndromes, interactive tool [irAEs]"
},
{
	"jumpto":"interactive_0001769",
	"name":"Peripheral neurological toxicity mgmt-2., interactive tool [irAEs]"
},
{
	"jumpto":"interactive_0001766",
	"name":"Peripheral neurological toxicity mgmt., interactive tool [irAEs]"
},
{
	"jumpto":"ENAS6341_4.1.1.0",
	"name":"Peripheral neurotoxicity, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.1.0.0",
	"name":"Peripheral neurotoxicity [PCN]"
},
{
	"jumpto":"ENAS5646_7.3.7.0",
	"name":"Peripheral T cell lymph.-not otherwise specified, summary [PCLs]"
},
{
	"jumpto":"ENAS5283_8.5.0.0",
	"name":"Peritoneal metastases, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5304_8.6.6.0",
	"name":"Peritoneal metastases, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.13.0.0",
	"name":"Peritoneal metastases [mCRC]"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Peritonectomy [mCRC]"
},
{
	"jumpto":"ENAS5282_5.0.0.0",
	"name":"Personalised medicine (Oes CA)"
},
{
	"jumpto":"ENAS5062_4.10.0.0",
	"name":"Personalised medicine, anal cancer"
},
{
	"jumpto":"ENAS5279_5.0.0.0",
	"name":"Personalised medicine, CLL"
},
{
	"jumpto":"ENAS5271_6.0.0.0",
	"name":"Personalised medicine, DLBCL"
},
{
	"jumpto":"ENAS5278_5.0.0.0",
	"name":"Personalised medicine, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5273_6.0.0.0",
	"name":"Personalised medicine, FL"
},
{
	"jumpto":"ENAS5280_5.0.0.0",
	"name":"Personalised medicine, HCL"
},
{
	"jumpto":"ENAS5277_5.0.0.0",
	"name":"Personalised medicine, PTCL"
},
{
	"jumpto":"ENAS5071_4.4.0.0",
	"name":"Personalised medicine, SCLC"
},
{
	"jumpto":"ENAS5282_7.5.0.0",
	"name":"Personalised medicine, summary (Oes CA)"
},
{
	"jumpto":"ENAS5633_7.4.0.0",
	"name":"Personalised medicine, summary [ALL]"
},
{
	"jumpto":"ENAS5648_9.5.0.0",
	"name":"Personalised medicine, summary [Anaemia]"
},
{
	"jumpto":"ENAS5284_7.4.0.0",
	"name":"Personalised medicine, summary [Bil]"
},
{
	"jumpto":"ENAS6365_8.6.0.0",
	"name":"Personalised medicine, summary [Bone health]"
},
{
	"jumpto":"ENAS6369_8.5.0.0",
	"name":"Personalised medicine, summary [Cervical CA]"
},
{
	"jumpto":"ENAS5647_20.15.0.0",
	"name":"Personalised medicine, summary [Diarrh.]"
},
{
	"jumpto":"ENAS6235_7.4.0.0",
	"name":"Personalised medicine, summary [EBC]"
},
{
	"jumpto":"ENAS6370_8.5.0.0",
	"name":"Personalised medicine, summary [Endometrial CA]"
},
{
	"jumpto":"ENAS6366_2020112730",
	"name":"Personalised medicine, summary [EOC]"
},
{
	"jumpto":"ENAS6343_8.5.0.0",
	"name":"Personalised medicine, summary [GEP-NENs]"
},
{
	"jumpto":"ENAS6371_7.4.0.0",
	"name":"Personalised medicine, summary [GTD]"
},
{
	"jumpto":"ENAS5304_8.7.0.0",
	"name":"Personalised medicine, summary [mCRC]"
},
{
	"jumpto":"ENAS5637_10.7.0.0",
	"name":"Personalised medicine, summary [MDS]"
},
{
	"jumpto":"ENAS5640_12.9.0.0",
	"name":"Personalised medicine, summary [MM]"
},
{
	"jumpto":"ENAS5639_7.3.0.0",
	"name":"Personalised medicine, summary [MPNs]"
},
{
	"jumpto":"ENAS5263_14.11.0.0",
	"name":"Personalised medicine, summary [Mucosa]"
},
{
	"jumpto":"ENAS6342_7.5.0.0",
	"name":"Personalised medicine, summary [MZLs]"
},
{
	"jumpto":"ENAS5646_7.4.0.0",
	"name":"Personalised medicine, summary [PCLs]"
},
{
	"jumpto":"ENAS5285_9.5.0.0",
	"name":"Personalised medicine, summary [RCC]"
},
{
	"jumpto":"ENAS5407_9.6.0.0",
	"name":"Personalised medicine, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5649_10.5.0.0",
	"name":"Personalised medicine, summary [WM]"
},
{
	"jumpto":"ENAS5098_6.0.0.0",
	"name":"Personalised medicine, TETs"
},
{
	"jumpto":"ENAS5283_5.0.0.0",
	"name":"Personalised medicine and targeted therapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.4.0.0",
	"name":"Personalised medicine and targeted therapy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5062_8.3.9.0",
	"name":"Personalised medicine in anal cancer, summary"
},
{
	"jumpto":"ENAS5094_9.5.0.0",
	"name":"Personalised medicine in BC, summary"
},
{
	"jumpto":"ENAS5279_7.4.0.0",
	"name":"Personalised medicine in CLL, summary"
},
{
	"jumpto":"ENAS5271_7.5.0.0",
	"name":"Personalised medicine in DLBCL, summary"
},
{
	"jumpto":"ENAS5278_7.4.0.0",
	"name":"Personalised medicine in DLBCL-PMBCL, summary"
},
{
	"jumpto":"ENAS5273_8.4.0.0",
	"name":"Personalised medicine in FL, summary"
},
{
	"jumpto":"ENAS5280_7.4.0.0",
	"name":"Personalised medicine in HCL, summary"
},
{
	"jumpto":"ENAS5408_7.4.0.0",
	"name":"Personalised medicine in MCL, summary"
},
{
	"jumpto":"ENAS5068_8.4.0.0",
	"name":"Personalised medicine in pancreatic cancer, summary"
},
{
	"jumpto":"ENAS5092_7.4.0.0",
	"name":"Personalised medicine in PC, summary"
},
{
	"jumpto":"ENAS5096_7.4.0.0",
	"name":"Personalised medicine in PenCa, summary"
},
{
	"jumpto":"ENAS5277_7.4.0.0",
	"name":"Personalised medicine in PTCL, summary"
},
{
	"jumpto":"ENAS5098_8.4.0.0",
	"name":"Personalised medicine in TETs, summary"
},
{
	"jumpto":"ENAS5283_5.0.0.0",
	"name":"Personalised medicine synopsis table (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_5.0.0.0",
	"name":"Personalised medicine synopsis table (Oes CA)"
},
{
	"jumpto":"ENAS5633_5.0.0.0",
	"name":"Personalised medicine [ALL]"
},
{
	"jumpto":"ENAS5635_5.0.0.0",
	"name":"Personalised medicine [AML]"
},
{
	"jumpto":"ENAS5648_7.0.0.0",
	"name":"Personalised medicine [Anaemia]"
},
{
	"jumpto":"ENAS5094_7.0.0.0",
	"name":"Personalised medicine [BC]"
},
{
	"jumpto":"ENAS5284_5.0.0.0",
	"name":"Personalised medicine [Bil]"
},
{
	"jumpto":"ENAS6365_7.0.0.0",
	"name":"Personalised medicine [Bone health]"
},
{
	"jumpto":"ENAS6369_6.0.0.0",
	"name":"Personalised medicine [Cervical CA]"
},
{
	"jumpto":"ENAS5647_17.0.0.0",
	"name":"Personalised medicine [Diarrh.]"
},
{
	"jumpto":"ENAS6235_5.0.0.0",
	"name":"Personalised medicine [EBC]"
},
{
	"jumpto":"ENAS6370_6.0.0.0",
	"name":"Personalised medicine [Endometrial CA]"
},
{
	"jumpto":"ENAS6366_2020112716",
	"name":"Personalised medicine [EOC]"
},
{
	"jumpto":"ENAS6343_6.0.0.0",
	"name":"Personalised medicine [GEP-NENs]"
},
{
	"jumpto":"ENAS6371_5.0.0.0",
	"name":"Personalised medicine [GTD]"
},
{
	"jumpto":"ENAS5408_5.0.0.0",
	"name":"Personalised medicine [MCL]"
},
{
	"jumpto":"ENAS5304_6.0.0.0",
	"name":"Personalised medicine [mCRC]"
},
{
	"jumpto":"ENAS5637_8.1.0.0",
	"name":"Personalised medicine [MDS]"
},
{
	"jumpto":"ENAS5640_10.0.0.0",
	"name":"Personalised medicine [MM]"
},
{
	"jumpto":"ENAS5639_4.0.0.0",
	"name":"Personalised medicine [MPNs]"
},
{
	"jumpto":"ENAS5263_12.0.0.0",
	"name":"Personalised medicine [Mucosa]"
},
{
	"jumpto":"ENAS6342_6.0.0.0",
	"name":"Personalised medicine [MZLs]"
},
{
	"jumpto":"ENAS5646_5.0.0.0",
	"name":"Personalised medicine [PCLs]"
},
{
	"jumpto":"ENAS5285_7.0.0.0",
	"name":"Personalised medicine [RCC]"
},
{
	"jumpto":"ENAS5407_7.0.0.0",
	"name":"Personalised medicine [Rectal CA]"
},
{
	"jumpto":"ENAS5649_8.0.0.0",
	"name":"Personalised medicine [WM]"
},
{
	"jumpto":"ENAS5071_6.4.0.0",
	"name":"Personlised medicine in SCLC, summary"
},
{
	"jumpto":"ENAS5283_3.1.0.0",
	"name":"PET-CT imaging (Gastric cancer)"
},
{
	"jumpto":"ENAS5639_2.1.0.0",
	"name":"PET-MF diagnostic criteria [MPNs]"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"PET/CT [PC]"
},
{
	"jumpto":"ENAS5278_3.3.0.0",
	"name":"PET 5-point scale, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS6235_4.4.3.0",
	"name":"PgR [EBC]"
},
{
	"jumpto":"ENAS5633_7.3.2.4",
	"name":"Ph+ ALL, summary"
},
{
	"jumpto":"ENAS5096_4.1.0.0",
	"name":"Phalloplasty [PenCa]"
},
{
	"jumpto":"ENAS6341_2.3.2.0",
	"name":"Pharmacological prevention [PCN]"
},
{
	"jumpto":"ENAS6341_4.1.4.1",
	"name":"Pharmacological treatment, summary [PCN]"
},
{
	"jumpto":"ENAS6340_6.4.3.0",
	"name":"Pharmacological treatments, summary [CRF]"
},
{
	"jumpto":"ENAS6340_5.2.0.0",
	"name":"Pharmacological treatments [CRF]"
},
{
	"jumpto":"ENAS6341_2.4.1.0",
	"name":"Pharmacological treatment [PCN]"
},
{
	"jumpto":"ENAS6228_2.5.7.3",
	"name":"Phase II trials in RAI-refractory DTC [TC]"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"Phosphatase and tensin homologue (PTEN) [mCRC]"
},
{
	"jumpto":"ENAS5098_5.4.0.0",
	"name":"Phrenic nerve preservation [TETs]"
},
{
	"jumpto":"ENAS5647_20.2.1.0",
	"name":"Physical examination, summary [Diarrh.]"
},
{
	"jumpto":"ENAS5647_4.1.0.0",
	"name":"Physical examination [Diarrh.]"
},
{
	"jumpto":"ENAS6340_6.4.2.0",
	"name":"Physical exercise, summary [CRF]"
},
{
	"jumpto":"ENAS6341_4.1.4.5",
	"name":"Physical exercise, summary [PCN]"
},
{
	"jumpto":"ENAS6340_5.1.0.0",
	"name":"Physical exercise [CRF]"
},
{
	"jumpto":"ENAS6341_2.4.5.0",
	"name":"Physical exercise [PCN]"
},
{
	"jumpto":"ENAS5062_4.3.0.0",
	"name":"Piecemeal resection"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"PIK3CA exon [mCRC]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Pilocarpine [Mucosa]"
},
{
	"jumpto":"ENAS5640_2.0.0.0",
	"name":"Plasma cell disorders, diagnostic criteria [MM]"
},
{
	"jumpto":"ENAS5640_12.7.3.0",
	"name":"Plasma cell leukaemia management in MM, summary"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Platin salts [Extra]"
},
{
	"jumpto":"ENAS5282_4.1.6.0",
	"name":"Platinum, treatment (Oes CA)"
},
{
	"jumpto":"ENAS5094_4.3.0.0",
	"name":"Platinum-based combination chemotherapy [BC]"
},
{
	"jumpto":"ENAS5283_4.3.2.0",
	"name":"Platinum/fluoropyrimidine combination chemotherapy (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.1.2",
	"name":"Platinum/fluoropyrimidine combination chemotherapy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5409_11.1.3.0",
	"name":"Platinum derivatives [IRs]"
},
{
	"jumpto":"ENAS5086_5.3.0.0",
	"name":"Platinum doublet, unresectable mesothelioma"
},
{
	"jumpto":"ENAS5647_6.2.3.0",
	"name":"Platinum salts [Diarrh.]"
},
{
	"jumpto":"ENAS6341_4.2.6.0",
	"name":"PML, summary [PCN]"
},
{
	"jumpto":"ENAS5269_5.9.3.0",
	"name":"Pneumocystis jirovecii [FN]"
},
{
	"jumpto":"ENAS5269_6.4.6.3",
	"name":"Pneumonia, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.3.0",
	"name":"Pneumonia [FN]"
},
{
	"jumpto":"ENAS5410_3.5.1.0",
	"name":"Pneumonitis, immune related [irAEs]"
},
{
	"jumpto":"ENAS5410_3.5.2.2",
	"name":"Pneumonitis mgmt., interactive tool [irAEs]"
},
{
	"jumpto":"interactive_0001768",
	"name":"Pneumonitis mgmt., interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5262_6.2.2.0",
	"name":"Pneumothorax, summary [CVC]"
},
{
	"jumpto":"ENAS5262_3.2.0.0",
	"name":"Pneumothorax [CVC]"
},
{
	"jumpto":"ENAS5639_3.2.1.0",
	"name":"Polycythaemia vera [MPNs]"
},
{
	"jumpto":"ENAS5285_6.2.2.4",
	"name":"Poor prognosis, first-line treat. [RCC]"
},
{
	"jumpto":"ENAS5406_5.1.5.0",
	"name":"PORT [Early NSCLC]"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Positron-emission tomography (PET)/CT"
},
{
	"jumpto":"ENAS5639_2.1.0.0",
	"name":"Post-ET myelofibrosis diagnostic criteria [MPNs]"
},
{
	"jumpto":"ENAS5098_8.3.4.0",
	"name":"Post-op chemotherapy in TETs, summary"
},
{
	"jumpto":"ENAS5062_8.3.6.0",
	"name":"Post-operative chemoradiotherapy in anal cancer, summary"
},
{
	"jumpto":"ENAS5092_7.3.1.3",
	"name":"Post-operative radiotherapy of PC, summary"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"Post-op radiotherapy, TETs"
},
{
	"jumpto":"ENAS5098_8.3.3.0",
	"name":"Post-op radiotherapy in TETs, summary"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"Post-orchiectomy staging [TS/T-NS]"
},
{
	"jumpto":"ENAS5639_2.1.0.0",
	"name":"Post-PV myelofibrosis diagnostic criteria [MPNs]"
},
{
	"jumpto":"ENAS5633_4.1.2.0",
	"name":"Post-remission consolidation [ALL]"
},
{
	"jumpto":"ENAS6339_11.7.0.0",
	"name":"Post-treatment: survivors of anticancer therapy [CVD]"
},
{
	"jumpto":"ENAS6339_8.1.0.0",
	"name":"Post-treatment: survivors of anticancer therapy [CVD]"
},
{
	"jumpto":"ENAS5271_4.6.1.0",
	"name":"Post-treatment evaluation, DLBCL"
},
{
	"jumpto":"ENAS6341_3.3.0.0",
	"name":"Posterior reversible encephalopathy syndrome [PCN]"
},
{
	"jumpto":"ENAS6235_4.4.5.2",
	"name":"Postmenopausal patients [EBC]"
},
{
	"jumpto":"ENAS5407_4.8.1.0",
	"name":"Postoperative chemoradiotherapy [Rectal CA]"
},
{
	"jumpto":"ENAS5407_4.8.2.0",
	"name":"Postoperative chemotherapy [Rectal CA]"
},
{
	"jumpto":"interactive_0002477",
	"name":"Postoperative management of DTC pts., tool"
},
{
	"jumpto":"interactive_0002480",
	"name":"Postoperative mgmt. of MTC pts., tool"
},
{
	"jumpto":"ENAS5407_9.3.6.0",
	"name":"Postoperative therapy, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5267_12.2.0.0",
	"name":"Potential for anticancer agents, summary [Extra]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Potential for anticancer agents [Extra]"
},
{
	"jumpto":"ENAS5304_5.14.6.0",
	"name":"Potentially curative surgery [mCRC]"
},
{
	"jumpto":"ENAS6344_8.5.2.0",
	"name":"PPGL, treatment summary [ACC]"
},
{
	"jumpto":"ENAS6344_5.2.2.1",
	"name":"PPGL, treatment [ACC]"
},
{
	"jumpto":"ENAS6344_6.2.1.0",
	"name":"PPGL [ACC]"
},
{
	"jumpto":"ENAS5639_2.1.0.0",
	"name":"PPV-MF diagnostic criteria [MPNs]"
},
{
	"jumpto":"interactive_0002842",
	"name":"Practical approach for CIPN assessment, interactive tool [PCN]"
},
{
	"jumpto":"ENAS6341_2.2.2.2",
	"name":"Practical approach for CIPN assessment [PCN]"
},
{
	"jumpto":"ENAS6341_4.1.2.2",
	"name":"Practical aspects of assessment, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.2.2.1",
	"name":"Practical aspects of assessment [PCN]"
},
{
	"jumpto":"interactive_0002841",
	"name":"Practical assessment of CRF, interactive tool"
},
{
	"jumpto":"ENAS6340_4.2.0.0",
	"name":"Practical assessment of CRF [CRF]"
},
{
	"jumpto":"ENAS5633_7.3.1.1",
	"name":"Pre-phase therapy, summary [ALL]"
},
{
	"jumpto":"ENAS6346_9.0.0.0",
	"name":"Precision medicine [ABC]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Prednisolone [PC]"
},
{
	"jumpto":"ENAS5639_7.5.4.0",
	"name":"Pregnancy, summary [MPNs]"
},
{
	"jumpto":"ENAS5639_6.4.0.0",
	"name":"Pregnancy [MPNs]"
},
{
	"jumpto":"ENAS6235_4.4.5.1",
	"name":"Premenopausal patients [EBC]"
},
{
	"jumpto":"ENAS5406_4.9.0.0",
	"name":"Preoperative cardiac evaluation, interactive tool [Early NSCLC]"
},
{
	"jumpto":"interactive_0001745",
	"name":"Preoperative cardiac evaluation, interactive tool [Early NSCLC]"
},
{
	"jumpto":"ENAS5407_9.3.5.1",
	"name":"Preoperative chemotherapy, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5406_4.7.0.0",
	"name":"Preoperative respiratory evaluation, interactive tool [Early NSCLC]"
},
{
	"jumpto":"interactive_0001744",
	"name":"Preoperative respiratory evaluation, interactive tool [Early NSCLC]"
},
{
	"jumpto":"ENAS6341_4.2.3.0",
	"name":"PRES, summary [PCN]"
},
{
	"jumpto":"ENAS5406_4.6.0.0",
	"name":"Pretreatment risk assessment [Early NSCLC]"
},
{
	"jumpto":"ENAS5268_2.8.0.0",
	"name":"Prev., anticipatory nausea and vomiting"
},
{
	"jumpto":"ENAS5268_2.6.0.0",
	"name":"Prev., ChT with low & minimal emetogenic potential [N/V]"
},
{
	"jumpto":"ENAS5268_2.5.0.0",
	"name":"Prev., multiple-day cisplatin ChT [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.6.0",
	"name":"Prev. by ChT with low & min. emetogenic pot., summary [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.5.0",
	"name":"Prev. by multiple-day cisplatin ChT, summary [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.8.0",
	"name":"Prev. of anticipatory nausea and vomiting, summary [N/V]"
},
{
	"jumpto":"ENAS5268_4.0.0.0",
	"name":"Prevention, acute CINV in children [N/V]"
},
{
	"jumpto":"ENAS5262_5.6.0.0",
	"name":"Prevention, catheter-induced thrombosis [CVC]"
},
{
	"jumpto":"ENAS5262_5.5.2.0",
	"name":"Prevention, catheter-related thrombosis [CVC]"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Prevention, CINV"
},
{
	"jumpto":"ENAS5262_4.4.0.0",
	"name":"Prevention, CVC-related infections"
},
{
	"jumpto":"ENAS5267_5.0.0.0",
	"name":"Prevention, extravasation [Extra]"
},
{
	"jumpto":"ENAS5268_2.9.0.0",
	"name":"Prevention, high-dose chemotherapy [N/V]"
},
{
	"jumpto":"ENAS5267_12.4.0.0",
	"name":"Prevention, summary [Extra]"
},
{
	"jumpto":"ENAS6365_6.4.2.1",
	"name":"Prevention and management of CTIBL [Bone health]"
},
{
	"jumpto":"ENAS6370_8.1.0.0",
	"name":"Prevention and screening, summary [Endometrial CA]"
},
{
	"jumpto":"ENAS6370_2.0.0.0",
	"name":"Prevention and screening [Endometrial CA]"
},
{
	"jumpto":"ENAS5647_14.5.0.0",
	"name":"Prevention and treatment of acute RT-induced diarrhea [Diarrh.]"
},
{
	"jumpto":"ENAS5647_20.12.4.0",
	"name":"Prevention and treatment of acute RT-induced diarrhoea, summary"
},
{
	"jumpto":"ENAS5268_2.2.1.0",
	"name":"Prevention by emetogenic ChT, overview [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.9.0",
	"name":"Prevention by high-dose chemotherapy, summary [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.2.1",
	"name":"Prevention by highly emetogenic ChT, summary [N/V]"
},
{
	"jumpto":"ENAS5268_2.4.1.0",
	"name":"Prevention by MEC, overview [N/V]"
},
{
	"jumpto":"ENAS5268_6.1.4.1",
	"name":"Prevention by MEC, summary [N/V]"
},
{
	"jumpto":"ENAS5268_6.3.0.0",
	"name":"Prevention of acute CINV in children, summary [N/V]"
},
{
	"jumpto":"ENAS5262_6.4.5.0",
	"name":"Prevention of catheter-induced thrombosis, summary [CVC]"
},
{
	"jumpto":"ENAS6341_4.1.3.0",
	"name":"Prevention of CIPN, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.3.1.0",
	"name":"Prevention of CIPN [PCN]"
},
{
	"jumpto":"ENAS5262_6.3.4.0",
	"name":"Prevention of CVC-related infections, summary [CVC]"
},
{
	"jumpto":"ENAS5268_3.1.0.0",
	"name":"Prevention of RINV, overview [N/V]"
},
{
	"jumpto":"ENAS5268_6.2.1.0",
	"name":"Prevention of RINV, summary [N/V]"
},
{
	"jumpto":"ENAS5265_4.2.0.0",
	"name":"Prevention of VTE, medical patients"
},
{
	"jumpto":"ENAS5265_4.1.0.0",
	"name":"Prevention of VTE, surgical patients"
},
{
	"jumpto":"ENAS5265_8.3.2.0",
	"name":"Prevention of VTE in medical patients, summary"
},
{
	"jumpto":"ENAS5265_8.3.1.0",
	"name":"Prevention of VTE in surgical patients, summary"
},
{
	"jumpto":"ENAS6339_4.2.0.0",
	"name":"Prevention with CV therapeutics [CVD]"
},
{
	"jumpto":"ENAS5263_10.1.0.0",
	"name":"Preventive measures, overview [Mucosa]"
},
{
	"jumpto":"ENAS6235_7.3.6.0",
	"name":"Primary (neoadjuvant) systemic therapy, summary [EBC]"
},
{
	"jumpto":"ENAS6235_4.4.8.0",
	"name":"Primary (neoadjuvant) systemic therapy [EBC]"
},
{
	"jumpto":"ENAS5098_8.3.6.0",
	"name":"Primary/induction chemotherapy, summary [TETs]"
},
{
	"jumpto":"ENAS5062_4.3.0.0",
	"name":"Primary abdomino-perineal excision (APE)"
},
{
	"jumpto":"ENAS5278_2.4.0.0",
	"name":"Primary central nervous system lymphoma (PCNSL)"
},
{
	"jumpto":"ENAS5646_4.4.1.0",
	"name":"Primary cutaneous CD30+ LPDS, overview [PCLs]"
},
{
	"jumpto":"ENAS5646_4.7.0.0",
	"name":"Primary cutaneous peripheral T cell lymphoma-not otherwise specified [PCLs]"
},
{
	"jumpto":"ENAS5278_2.6.0.0",
	"name":"Primary diffuse large B-cell lymphoma of the bone (PBoL)"
},
{
	"jumpto":"ENAS5278_2.5.0.0",
	"name":"Primary diffuse large B-cell lymphoma of the breast (PBL)"
},
{
	"jumpto":"ENAS5269_4.2.0.0",
	"name":"Primary G-CSF prophylaxis, algo. [FN]"
},
{
	"jumpto":"ENAS5278_2.2.0.0",
	"name":"Primary mediastinal large B-cell lymphoma (PMBCL)"
},
{
	"jumpto":"ENAS5096_4.6.3.0",
	"name":"Primary penile tumour, treatment algorithm [Interactive tool]"
},
{
	"jumpto":"ENAS6339_11.3.0.0",
	"name":"Primary prevention therapy [CVD]"
},
{
	"jumpto":"ENAS6339_4.1.0.0",
	"name":"Primary prevention therapy [CVD]"
},
{
	"jumpto":"ENAS5269_6.3.1.0",
	"name":"Primary prophylaxis, summary [FN]"
},
{
	"jumpto":"ENAS5269_4.1.0.0",
	"name":"Primary prophylaxis [FN]"
},
{
	"jumpto":"ENAS5278_2.3.0.0",
	"name":"Primary testicular lymphoma (PTL)"
},
{
	"jumpto":"ENAS6369_4.2.1.0",
	"name":"Primary treatment, local/locoregional disease [Cervical CA]"
},
{
	"jumpto":"ENAS6369_8.3.1.0",
	"name":"Primary treatment, summary [Cervical CA]"
},
{
	"jumpto":"ENAS6228_5.2.3.1",
	"name":"Primary tumour management, summary [TC]"
},
{
	"jumpto":"ENAS6340_2.0.0.0",
	"name":"Principles of care [CRF]"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Probiotics [Mucosa]"
},
{
	"jumpto":"ENAS5267_12.3.0.0",
	"name":"Procedure-related risk factors, summary [Extra]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Procedure-related risk factors [Extra]"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"Proctoscopy"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Proctoscopy, risk assessment"
},
{
	"jumpto":"ENAS5645_11.6.0.0",
	"name":"Prognosis, summary"
},
{
	"jumpto":"ENAS5645_9.0.0.0",
	"name":"Prognosis [HL]"
},
{
	"jumpto":"ENAS5649_5.0.0.0",
	"name":"Prognostication of Wm [WM]"
},
{
	"jumpto":"ENAS6367_7.2.1.0",
	"name":"Prognostic factors, summary [NEOC]"
},
{
	"jumpto":"ENAS6367_3.1.0.0",
	"name":"Prognostic factors [NEOC]"
},
{
	"jumpto":"ENAS5097_4.5.2.0",
	"name":"Prognostic score, relapsing TS/ T-NS"
},
{
	"jumpto":"ENAS6341_3.6.0.0",
	"name":"Progressive multifocal leukoencephalopathy [PCN]"
},
{
	"jumpto":"ENAS5615_7.1.0.0",
	"name":"Prophylactic bilateral mastectomy [BRCA]"
},
{
	"jumpto":"ENAS5615_7.2.0.0",
	"name":"Prophylactic bilateral mastectomy [BRCA]"
},
{
	"jumpto":"ENAS5615_7.3.0.0",
	"name":"Prophylactic bilateral salpingo-oophorectomy [BRCA]"
},
{
	"jumpto":"ENAS5071_4.2.0.0",
	"name":"Prophylactic cranial irradiation (PCI)[SCLC]"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"Prophylactic irradiation [TETs]"
},
{
	"jumpto":"ENAS5615_7.1.0.0",
	"name":"Prophylactic surgery, overview [BRCA]"
},
{
	"jumpto":"ENAS5263_11.3.0.0",
	"name":"Prophylactic systematic gastrostomy [Mucosa]"
},
{
	"jumpto":"interactive_0002840",
	"name":"Proposed monitoring and management approach for patients undergoing potentially cardiotoxic anticancer therapy, interactive tool [CVD]"
},
{
	"jumpto":"ENAS6339_3.1.2.0",
	"name":"Proposed monitoring and management approach for patients undergoing potentially cardiotoxic anticancer therapy [CVD]"
},
{
	"jumpto":"ENAS6341_4.1.4.8",
	"name":"PROSPECT, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.4.8.0",
	"name":"PROSPECT [PCN]"
},
{
	"jumpto":"ENAS6365_6.2.0.0",
	"name":"Prostate cancer [Bone health]"
},
{
	"jumpto":"ENAS6365_5.5.4.0",
	"name":"Prostate cancer [Bone health]"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"Prostate specific antigen"
},
{
	"jumpto":"ENAS6343_5.3.3.8",
	"name":"PRRT [GEP-NENs]"
},
{
	"jumpto":"ENAS5643_6.3.8.0",
	"name":"PS 2 and beyond, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5643_4.8.0.0",
	"name":"PS 2 and beyond [mNSCLC]"
},
{
	"jumpto":"ENAS5092_6.0.0.0",
	"name":"PSA, PC follow-up [PC]"
},
{
	"jumpto":"ENAS5092_3.1.0.0",
	"name":"PSA in risk assessment of PC"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"PSA [PC]"
},
{
	"jumpto":"ENAS5283_7.0.0.0",
	"name":"Psychological support, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.6.0.0",
	"name":"Psychological support, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS6340_6.4.5.0",
	"name":"Psychosocial interventions, summary [CRF]"
},
{
	"jumpto":"ENAS6340_5.4.0.0",
	"name":"Psychosocial interventions [CRF]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"PTA and BCoG [Mucosa]"
},
{
	"jumpto":"ENAS5646_4.7.0.0",
	"name":"PTCL-NOS [PCLs]"
},
{
	"jumpto":"ENAS5277_4.2.0.0",
	"name":"PTCL Mgmt.: Front-line & relapsed, interactive tool"
},
{
	"jumpto":"ENAS5097_4.7.0.0",
	"name":"Pulmonary [TS/T-NS]"
},
{
	"jumpto":"ENAS5639_3.2.1.0",
	"name":"PV, first-line treatment [MPNs]"
},
{
	"jumpto":"ENAS5639_3.2.2.0",
	"name":"PV, second-line treatment [MPNs]"
},
{
	"jumpto":"ENAS5639_7.2.1.1",
	"name":"PV first-line treatment, summary [MPNs]"
},
{
	"jumpto":"ENAS5639_7.2.1.2",
	"name":"PV second-line treatment, summary [MPNs]"
},
{
	"jumpto":"ENAS5639_3.2.3.0",
	"name":"PV treatment, interactive tool [MPNs]"
},
{
	"jumpto":"interactive_0002110",
	"name":"PV treatment algorithm, interactive tool"
},
{
	"jumpto":"ENAS5062_8.4.0.0",
	"name":"Quality of life in anal cancer, summary"
},
{
	"jumpto":"ENAS5304_5.12.0.0",
	"name":"Radiation techniques [mCRC]"
},
{
	"jumpto":"ENAS5062_4.4.2.0",
	"name":"Radiation Therapy Oncology Group (RTOG)"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"Radical cystectomy [BC]"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Radical gastrectomy, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Radical gastrectomy in stage IB–III gastric cancer, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Radical oesophagectomy, surgical technique (Oes CA)"
},
{
	"jumpto":"ENAS6228_2.3.2.2",
	"name":"Radioactive iodine administration in DTC pts., tool [TC]"
},
{
	"jumpto":"ENAS5304_5.12.0.0",
	"name":"Radioembolisation [mCRC]"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Radiofrequency ablation (RFA) [mCRC]"
},
{
	"jumpto":"ENAS5285_6.1.1.0",
	"name":"Radiofrequency ablation [RCC]"
},
{
	"jumpto":"ENAS5304_2.0.0.0",
	"name":"Radiological imaging [mCRC]"
},
{
	"jumpto":"ENAS5643_6.2.2.0",
	"name":"Radiology, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5643_3.3.0.0",
	"name":"Radiology [mNSCLC]"
},
{
	"jumpto":"ENAS6344_6.2.4.0",
	"name":"Radionuclide therapy [ACC]"
},
{
	"jumpto":"ENAS6365_5.3.0.0",
	"name":"Radionuclide therapy [Bone health]"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Radiotherapy, advanced pancreatic cancer"
},
{
	"jumpto":"ENAS5098_5.9.0.0",
	"name":"Radiotherapy, definitive [TETs]"
},
{
	"jumpto":"ENAS5068_5.6.2.0",
	"name":"Radiotherapy, locally advanced pancreatic cancer"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"Radiotherapy, post-op [TETs]"
},
{
	"jumpto":"ENAS5277_4.7.0.0",
	"name":"Radiotherapy, PTCL"
},
{
	"jumpto":"ENAS5285_6.2.2.8",
	"name":"Radiotherapy, role [RCC]"
},
{
	"jumpto":"ENAS5284_7.3.2.1",
	"name":"Radiotherapy, summary [Bil]"
},
{
	"jumpto":"ENAS5285_9.4.2.3",
	"name":"Radiotherapy, summary [RCC]"
},
{
	"jumpto":"ENAS5062_4.8.0.0",
	"name":"Radiotherapy, supportive care"
},
{
	"jumpto":"ENAS5062_4.8.0.0",
	"name":"Radiotherapy, toxicity"
},
{
	"jumpto":"ENAS5647_10.2.0.0",
	"name":"Radiotherapy-induced acute diarrhoea"
},
{
	"jumpto":"ENAS5647_10.3.0.0",
	"name":"Radiotherapy-induced chronic diarrhoea"
},
{
	"jumpto":"ENAS5647_20.8.0.0",
	"name":"Radiotherapy-induced diarrhoea, summary"
},
{
	"jumpto":"ENAS5268_3.2.0.0",
	"name":"Radiotherapy emetic risk levels [N/V]"
},
{
	"jumpto":"ENAS5407_9.3.4.0",
	"name":"Radiotherapy field sizes, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5407_4.6.0.0",
	"name":"Radiotherapy field sizes [Rectal CA]"
},
{
	"jumpto":"ENAS5086_7.4.3.1",
	"name":"Radiotherapy in MPM, summary"
},
{
	"jumpto":"ENAS5096_7.3.2.0",
	"name":"Radiotherapy in PenCa, summary"
},
{
	"jumpto":"ENAS5277_7.3.5.0",
	"name":"Radiotherapy in PTCL, summary"
},
{
	"jumpto":"ENAS5284_4.4.1.0",
	"name":"Radiotherapy [Bil]"
},
{
	"jumpto":"ENAS5304_5.3.0.0",
	"name":"Radiotherapy [mCRC]"
},
{
	"jumpto":"ENAS5068_5.6.1.0",
	"name":"Radiotherapy [Pancr]"
},
{
	"jumpto":"ENAS5096_4.2.0.0",
	"name":"Radiotherapy [PenCa]"
},
{
	"jumpto":"ENAS6228_3.3.3.0",
	"name":"Radiotherapy [TC]"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"Radiotherapy [TETs]"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"Radiotherapy [TS/T-NS]"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"Radium-223 [PC]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Radium-223, side effects [PC]"
},
{
	"jumpto":"interactive_0002474",
	"name":"RAI administration in DTC patients"
},
{
	"jumpto":"ENAS6228_2.3.2.2",
	"name":"RAI administration in DTC pts., tool [TC]"
},
{
	"jumpto":"ENAS5279_3.2.0.0",
	"name":"RAI system [CLL]"
},
{
	"jumpto":"ENAS6228_5.2.3.2",
	"name":"RAI therapy of primary DTC tumour, summary [TC]"
},
{
	"jumpto":"ENAS5086_5.1.0.0",
	"name":"Raltitrexed, MPM therapy, Combination doublet chemotherapy"
},
{
	"jumpto":"ENAS5410_4.2.6.1",
	"name":"Rare immune-related toxicities, summary [irAEs]"
},
{
	"jumpto":"ENAS5304_8.5.1.0",
	"name":"RAS, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"RAS analysis [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.9.0",
	"name":"RAS mutant disease [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.1.0",
	"name":"RAS mutation status [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.1.0",
	"name":"RAS mutation [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.9.0",
	"name":"RAS wild-type disease [mCRC]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Raynaud syndrome [Extra]"
},
{
	"jumpto":"ENAS5094_4.2.0.0",
	"name":"RC [BC]"
},
{
	"jumpto":"ENAS5407_9.3.5.2",
	"name":"Reassessment after preop chemoradiotherapy, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5407_4.7.2.1",
	"name":"Reassessment after preoperative (chemo) radiotherapy [Rectal CA]"
},
{
	"jumpto":"ENAS6365_5.5.12.0",
	"name":"Rebound osteolysis after denosumab [Bone health]"
},
{
	"jumpto":"ENAS5409_13.7.0.0",
	"name":"Rechallenge, summary [IRs]"
},
{
	"jumpto":"ENAS5409_10.0.0.0",
	"name":"Rechallenge [IRs]"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"RECIST [TETs]"
},
{
	"jumpto":"ENAS5263_11.4.0.0",
	"name":"Recommendations, targeted therapy-associated stomatitis [Mucosa]"
},
{
	"jumpto":"interactive_0002837",
	"name":"Recommendations for adjuvant treatment of stage II colon cancer, interactive tool [LCC]"
},
{
	"jumpto":"interactive_0002839",
	"name":"Recommendations for adjuvant treatment of stage III colon cancer, interactive tool [LCC]"
},
{
	"jumpto":"interactive_0002838",
	"name":"Recommendations for follow-up after curative resection, interactive tool [LCC]"
},
{
	"jumpto":"ENAS5646_4.2.2.0",
	"name":"Recommendations for the treatment of MF [PCLs]"
},
{
	"jumpto":"interactive_0002096",
	"name":"Recommendations for the treatment of MF [tool]"
},
{
	"jumpto":"ENAS5646_4.3.2.0",
	"name":"Recommendations for the treatment of SS [PCLs]"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Rectal cancer, diagnosis"
},
{
	"jumpto":"ENAS5407_3.6.3.0",
	"name":"Rectal cancer, histopathology"
},
{
	"jumpto":"ENAS5407_4.1.0.0",
	"name":"Rectal cancer, management of local/locoregional disease"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Rectal cancer, molecular biology"
},
{
	"jumpto":"ENAS5407_2.1.0.0",
	"name":"Rectal cancer, pathology"
},
{
	"jumpto":"ENAS5407_3.6.2.0",
	"name":"Rectal cancer, stage grouping"
},
{
	"jumpto":"ENAS5407_3.5.0.0",
	"name":"Rectal cancer, subclassification of T3 stage"
},
{
	"jumpto":"ENAS5407_3.4.0.0",
	"name":"Rectal cancer, TNM staging"
},
{
	"jumpto":"ENAS5407_2.2.0.0",
	"name":"Rectal cancer diagnosis interactive tool"
},
{
	"jumpto":"ENAS5407_3.1.0.0",
	"name":"Rectal cancer staging"
},
{
	"jumpto":"ENAS5407_3.2.0.0",
	"name":"Rectal cancer staging, interactive tool"
},
{
	"jumpto":"interactive_0001756",
	"name":"Rectal cancer surveillance and follow-up [tool]"
},
{
	"jumpto":"ENAS5407_4.1.0.0",
	"name":"Rectal cancer treatment, interactive tool"
},
{
	"jumpto":"interactive_0001749",
	"name":"Rectal cancer treatment of local recurrence [tool]"
},
{
	"jumpto":"interactive_0001747",
	"name":"Rectal cancer treatment recommendations [tool]"
},
{
	"jumpto":"interactive_0001751",
	"name":"Rectal cancer Tx of metastatic disease [tool]"
},
{
	"jumpto":"ENAS5071_5.0.0.0",
	"name":"Recurrence, SCLC"
},
{
	"jumpto":"ENAS5407_4.4.0.0",
	"name":"Recurrence risk according to postop histology [Rectal CA]"
},
{
	"jumpto":"ENAS5265_5.4.0.0",
	"name":"Recurrent VTE, treatment"
},
{
	"jumpto":"ENAS5265_8.4.4.0",
	"name":"Recurrent VTE treatment, summary"
},
{
	"jumpto":"ENAS5648_9.2.0.0",
	"name":"Red blood cell transfusions, summary [Anaemia]"
},
{
	"jumpto":"ENAS5648_4.0.0.0",
	"name":"Red blood cell transfusions [Anaemia]"
},
{
	"jumpto":"ENAS5615_9.1.0.0",
	"name":"Referral for BRCA testing, summary"
},
{
	"jumpto":"ENAS5268_2.7.0.0",
	"name":"Refractory emesis [N/V]"
},
{
	"jumpto":"ENAS5635_7.3.4.0",
	"name":"Refractory or relapsed AML, summary"
},
{
	"jumpto":"ENAS5635_4.4.0.0",
	"name":"Refractory or relapsed AML, treatment"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Refractory patients"
},
{
	"jumpto":"ENAS6338_7.2.3.0",
	"name":"Regimen & duration of adjuvant treatment [LCC]"
},
{
	"jumpto":"ENAS5304_5.14.5.0",
	"name":"Regorafenib [mCRC]"
},
{
	"jumpto":"ENAS5271_7.4.2.1",
	"name":"Relapsed and refractory DLBCL, summary"
},
{
	"jumpto":"ENAS5273_5.6.0.0",
	"name":"Relapsed disease, FL"
},
{
	"jumpto":"ENAS5649_6.3.1.0",
	"name":"Relapsed disease, overview [WM]"
},
{
	"jumpto":"ENAS5645_11.3.4.0",
	"name":"Relapsed disease, summary"
},
{
	"jumpto":"ENAS5649_10.3.3.0",
	"name":"Relapsed disease, summary [WM]"
},
{
	"jumpto":"ENAS5645_6.4.0.0",
	"name":"Relapsed disease, treatment of cHL"
},
{
	"jumpto":"ENAS5273_8.3.3.0",
	"name":"Relapsed disease in FL, summary"
},
{
	"jumpto":"ENAS5408_7.3.5.0",
	"name":"Relapsed disease in MCL, summary"
},
{
	"jumpto":"ENAS5408_4.6.0.0",
	"name":"Relapsed disease [MCL]"
},
{
	"jumpto":"ENAS5645_11.4.3.0",
	"name":"Relapsed NLPHL, summary"
},
{
	"jumpto":"ENAS5645_7.3.0.0",
	"name":"Relapsed NLPHL, treatment of NLPHL"
},
{
	"jumpto":"ENAS5633_4.2.1.0",
	"name":"Relapsed or refractory ALL"
},
{
	"jumpto":"ENAS5633_4.2.4.0",
	"name":"Relapsed or refractory ALL, chemotherapy"
},
{
	"jumpto":"ENAS5633_4.2.2.0",
	"name":"Relapsed or refractory ALL, diagnostic work-up"
},
{
	"jumpto":"ENAS5633_4.2.5.0",
	"name":"Relapsed or refractory ALL, Ph+ ALL"
},
{
	"jumpto":"ENAS5633_7.3.2.1",
	"name":"Relapsed or refractory ALL, summary [ALL]"
},
{
	"jumpto":"ENAS5633_7.3.2.2",
	"name":"Relapsed or refractory ALL, treatment"
},
{
	"jumpto":"ENAS5633_4.2.3.0",
	"name":"Relapsed or refractory ALL, treatment principles"
},
{
	"jumpto":"ENAS5633_7.3.2.1",
	"name":"Relapsed or refractory ALL diagnsotic work-up, summary [ALL]"
},
{
	"jumpto":"ENAS6366_202011278",
	"name":"Relapsed ovarian cancer and surgery for palliation [EOC]"
},
{
	"jumpto":"ENAS5279_4.2.3.2",
	"name":"Relapse treatment, interactive tool"
},
{
	"jumpto":"ENAS5269_5.9.4.0",
	"name":"Remission induction chemotherapy [FN]"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"Renal cell tumors, WHO classification"
},
{
	"jumpto":"ENAS5410_4.2.6.4",
	"name":"Renal toxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.4.1",
	"name":"Renal toxicity [irAEs]"
},
{
	"jumpto":"ENAS5097_4.7.0.0",
	"name":"Renal toxicity [TS/T-NS]"
},
{
	"jumpto":"ENAS5644_6.0.0.0",
	"name":"Research in personalised therapy for HCC"
},
{
	"jumpto":"ENAS5644_8.5.0.0",
	"name":"Research in personalised therapy for HCC, summary"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Resectable TETs, treatment algorithm [TETs]"
},
{
	"jumpto":"ENAS5639_7.5.2.0",
	"name":"Resistance or intolerance to 1st-line cytoreductive agents, summary [MPNs]"
},
{
	"jumpto":"ENAS5639_6.2.0.0",
	"name":"Resistance or intolerance to first-line cytoreductive agents [MPNs]"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Resistant patients with early relapse"
},
{
	"jumpto":"ENAS5269_5.10.2.0",
	"name":"Response assessment, algo. [FN]"
},
{
	"jumpto":"ENAS5407_4.7.2.1",
	"name":"Response assessment after preoperative (chemo) radiotherapy [Rectal CA]"
},
{
	"jumpto":"ENAS5649_7.2.0.0",
	"name":"Response categories and criteria [WM]"
},
{
	"jumpto":"ENAS5279_4.3.0.0",
	"name":"Response evaluation, CLL"
},
{
	"jumpto":"ENAS5271_4.6.1.0",
	"name":"Response evaluation, DLBCL"
},
{
	"jumpto":"ENAS5278_4.7.0.0",
	"name":"Response evaluation, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5273_5.8.0.0",
	"name":"Response evaluation, FL"
},
{
	"jumpto":"ENAS5280_4.3.0.0",
	"name":"Response evaluation, HCL"
},
{
	"jumpto":"ENAS5649_7.1.0.0",
	"name":"Response evaluation, overview [WM]"
},
{
	"jumpto":"ENAS5645_11.5.0.0",
	"name":"Response evaluation, summary"
},
{
	"jumpto":"ENAS6366_2020112731",
	"name":"Response evaluation, summary [EOC]"
},
{
	"jumpto":"ENAS5640_12.3.0.0",
	"name":"Response evaluation, summary [MM]"
},
{
	"jumpto":"ENAS5285_9.6.0.0",
	"name":"Response evaluation, summary [RCC]"
},
{
	"jumpto":"ENAS5649_10.4.0.0",
	"name":"Response evaluation, summary [WM]"
},
{
	"jumpto":"ENAS6342_5.1.0.0",
	"name":"Response evaluation and follow-up, general considerations [MZLs]"
},
{
	"jumpto":"ENAS6342_5.3.0.0",
	"name":"Response evaluation and follow-up, SMZL [MZLs]"
},
{
	"jumpto":"ENAS5304_8.8.0.0",
	"name":"Response evaluation and follow-up, summary [mCRC]"
},
{
	"jumpto":"ENAS6342_7.4.0.0",
	"name":"Response evaluation and follow-up, summary [MZLs]"
},
{
	"jumpto":"ENAS5277_7.5.0.0",
	"name":"Response evaluation and follow-up in PTCL, summary"
},
{
	"jumpto":"ENAS5304_7.0.0.0",
	"name":"Response evaluation and follow-up [mCRC]"
},
{
	"jumpto":"ENAS6342_5.1.0.0",
	"name":"Response evaluation and follow-up [MZLs]"
},
{
	"jumpto":"ENAS6367_6.1.1.0",
	"name":"Response evaluation and follow-up [NEOC]"
},
{
	"jumpto":"ENAS5277_6.0.0.0",
	"name":"Response evaluation and follow up, PTCL"
},
{
	"jumpto":"ENAS5098_5.10.0.0",
	"name":"Response evaluation criteria [TETs]"
},
{
	"jumpto":"ENAS5271_7.3.4.0",
	"name":"Response evaluation in DLBCL, summary"
},
{
	"jumpto":"ENAS5278_7.3.7.0",
	"name":"Response evaluation in DLBCL-PMBCL, summary"
},
{
	"jumpto":"ENAS5273_8.3.5.0",
	"name":"Response evaluation in FL, summary"
},
{
	"jumpto":"ENAS5280_7.3.3.0",
	"name":"Response evaluation in HCL, summary"
},
{
	"jumpto":"ENAS5408_7.3.6.0",
	"name":"Response evaluation in MCL, summary"
},
{
	"jumpto":"ENAS6366_2020112717",
	"name":"Response evaluation [EOC]"
},
{
	"jumpto":"ENAS5645_8.0.0.0",
	"name":"Response evaluation [HL]"
},
{
	"jumpto":"ENAS5408_4.7.0.0",
	"name":"Response evaluation [MCL]"
},
{
	"jumpto":"ENAS5285_8.0.0.0",
	"name":"Response evaluation [RCC]"
},
{
	"jumpto":"ENAS5279_7.3.3.0",
	"name":"Response revaluation in CLL, summary"
},
{
	"jumpto":"ENAS5062_8.5.0.0",
	"name":"Response to treatment evaluation in anal cancer, summary"
},
{
	"jumpto":"ENAS5633_4.1.2.0",
	"name":"Results of induction therapy [ALL]"
},
{
	"jumpto":"ENAS5646_3.4.0.0",
	"name":"Revised clinical staging system for MF/SS [PCLs]"
},
{
	"jumpto":"ENAS5646_3.3.0.0",
	"name":"Revised TNMB classification of MF/SS [PCLs]"
},
{
	"jumpto":"ENAS5410_4.2.6.3",
	"name":"Rheumatological toxicity, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.3.1",
	"name":"Rheumatological toxicity [irAEs]"
},
{
	"jumpto":"ENAS6235_4.3.1.6",
	"name":"Risk-reducing mastectomy [EBC]"
},
{
	"jumpto":"ENAS5407_9.3.1.1",
	"name":"Risk adapted treatment of rectal cancer, summary"
},
{
	"jumpto":"ENAS5407_4.3.1.0",
	"name":"Risk adapted treatment [Rectal CA]"
},
{
	"jumpto":"ENAS5407_9.3.1.1",
	"name":"Risk adapted Tx, summary [Rectal CA]"
},
{
	"jumpto":"ENAS5283_3.1.0.0",
	"name":"Risk assessment (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_3.1.0.0",
	"name":"Risk assessment (Oes CA)"
},
{
	"jumpto":"ENAS5279_3.1.0.0",
	"name":"Risk assessment, CLL"
},
{
	"jumpto":"ENAS5271_3.1.0.0",
	"name":"Risk assessment, DLBCL"
},
{
	"jumpto":"ENAS5278_3.1.0.0",
	"name":"Risk assessment, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5278_3.1.0.0",
	"name":"Risk assessment, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5273_4.1.0.0",
	"name":"Risk assessment, FL"
},
{
	"jumpto":"ENAS5406_4.6.0.0",
	"name":"Risk assessment, pretreatment [Early NSCLC]"
},
{
	"jumpto":"ENAS5277_3.0.0.0",
	"name":"Risk assessment, PTCL"
},
{
	"jumpto":"ENAS5407_3.1.0.0",
	"name":"Risk assessment, rectal CA"
},
{
	"jumpto":"ENAS5284_7.2.0.0",
	"name":"Risk assessment, summary [Bil]"
},
{
	"jumpto":"ENAS6338_9.5.1.0",
	"name":"Risk assessment, summary [LCC]"
},
{
	"jumpto":"ENAS5263_14.8.6.0",
	"name":"Risk assessment, summary [Mucosa]"
},
{
	"jumpto":"ENAS5285_9.3.0.0",
	"name":"Risk assessment, summary [RCC]"
},
{
	"jumpto":"ENAS5633_3.1.0.0",
	"name":"Risk assessment and prognostic factors [ALL]"
},
{
	"jumpto":"ENAS5284_3.1.0.0",
	"name":"Risk assessment [Bil]"
},
{
	"jumpto":"ENAS6338_6.1.0.0",
	"name":"Risk assessment [LCC]"
},
{
	"jumpto":"ENAS5408_3.1.0.0",
	"name":"Risk assessment [MCL]"
},
{
	"jumpto":"ENAS5263_9.6.0.0",
	"name":"Risk assessment [Mucosa]"
},
{
	"jumpto":"ENAS5285_5.2.1.1",
	"name":"Risk assessment [RCC]"
},
{
	"jumpto":"ENAS5268_6.2.2.0",
	"name":"Risk classification, summary [N/V]"
},
{
	"jumpto":"ENAS5268_3.3.0.0",
	"name":"Risk classification [N/V]"
},
{
	"jumpto":"ENAS5262_5.2.0.0",
	"name":"Risk factors, catheter-induced thrombosis [CVC]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Risk factors, extravasation [Extra]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Risk factors, patient-related [Extra]"
},
{
	"jumpto":"ENAS5267_4.0.0.0",
	"name":"Risk factors, procedure-related [Extra]"
},
{
	"jumpto":"ENAS5267_12.3.0.0",
	"name":"Risk factors, summary [Extra]"
},
{
	"jumpto":"ENAS5265_2.1.0.0",
	"name":"Risk factors, VTE [VTE]"
},
{
	"jumpto":"ENAS5265_8.1.0.0",
	"name":"Risk factors for VTE, summary"
},
{
	"jumpto":"ENAS5262_6.4.2.0",
	"name":"Risk factors of catheter-induced thrombosis, summary [CVC]"
},
{
	"jumpto":"ENAS6341_2.6.2.0",
	"name":"Risk factors [PCN]"
},
{
	"jumpto":"ENAS6370_4.3.0.0",
	"name":"Risk groups [Endometrial CA]"
},
{
	"jumpto":"ENAS5615_6.0.0.0",
	"name":"Risk modifiers [BRCA]"
},
{
	"jumpto":"ENAS6338_6.3.0.0",
	"name":"Risk of complications from adjuvant treatment [LCC]"
},
{
	"jumpto":"ENAS5407_9.3.2.0",
	"name":"Risk of recurrence of rectal cancer, summary"
},
{
	"jumpto":"ENAS5615_9.3.1.0",
	"name":"Risk reduction non surical options, summary [BRCA]"
},
{
	"jumpto":"ENAS5615_9.3.2.0",
	"name":"Risk reduction surical options, summary [BRCA]"
},
{
	"jumpto":"ENAS5280_3.0.0.0",
	"name":"Risk stratification, HCL"
},
{
	"jumpto":"ENAS5409_11.2.3.0",
	"name":"Rituximab [IRs]"
},
{
	"jumpto":"ENAS5268_2.2.2.0",
	"name":"Rolapitant [N/V]"
},
{
	"jumpto":"ENAS5285_6.2.2.8",
	"name":"Role, bisphosphonates [RCC]"
},
{
	"jumpto":"ENAS5285_6.2.2.8",
	"name":"Role, radiotherapy [RCC]"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Role, surgery and local therapy"
},
{
	"jumpto":"ENAS5643_4.22.0.0",
	"name":"Role invasive proced. in stage IV NSCLC"
},
{
	"jumpto":"ENAS5647_16.0.0.0",
	"name":"Role of diet: nutritional strategies during acute and chronic diarrhoea [Diarrh.]"
},
{
	"jumpto":"ENAS5279_4.2.4.0",
	"name":"Role of HSCT"
},
{
	"jumpto":"ENAS5279_7.3.2.4",
	"name":"Role of HSCT, summary"
},
{
	"jumpto":"ENAS5643_6.3.22.0",
	"name":"Role of minimally invasive procedures in stage IV NSCLC, summary"
},
{
	"jumpto":"ENAS5643_4.23.0.0",
	"name":"Role of palliative care in stage IV NSCLC"
},
{
	"jumpto":"ENAS5643_6.3.23.0",
	"name":"Role of palliative care in stage IV NSCLC, summary"
},
{
	"jumpto":"ENAS5285_9.4.2.3",
	"name":"Role of radiotherapy and bisphosphonates, summary [RCC]"
},
{
	"jumpto":"ENAS5643_4.16.0.0",
	"name":"Role of RT in stage IV NSCLC"
},
{
	"jumpto":"ENAS5643_6.3.16.0",
	"name":"Role of RT in stage IV NSCLC, summary"
},
{
	"jumpto":"ENAS5285_9.4.2.1",
	"name":"Role of surgery and local therapy, summary [RCC]"
},
{
	"jumpto":"ENAS5643_4.19.0.0",
	"name":"Role of surgery in stage IV NSCLC"
},
{
	"jumpto":"ENAS5643_6.3.19.0",
	"name":"Role of surgery in stage IV NSCLC"
},
{
	"jumpto":"ENAS5268_6.1.3.1",
	"name":"Route of administration of antiemetics, summary [N/V]"
},
{
	"jumpto":"ENAS5269_6.3.2.0",
	"name":"Route of application of G-CSF, summary [FN]"
},
{
	"jumpto":"ENAS5269_6.3.2.0",
	"name":"Route of application of pegfilgrastim, summary [FN]"
},
{
	"jumpto":"ENAS6370_5.4.2.0",
	"name":"RT for primary tumours [Endometrial CA]"
},
{
	"jumpto":"ENAS6370_5.4.3.0",
	"name":"RT for recurrence [Endometrial CA]"
},
{
	"jumpto":"ENAS6342_4.1.3.0",
	"name":"RT in localised EMZL: Recommended doses and schedules at different sites [MZLs]"
},
{
	"jumpto":"ENAS6235_4.3.2.0",
	"name":"RT [EBC]"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"RT [PC]"
},
{
	"jumpto":"ENAS5098_5.5.0.0",
	"name":"RT [TETs]"
},
{
	"jumpto":"ENAS5262_4.3.7.0",
	"name":"S. lugdunensis [CVC]"
},
{
	"jumpto":"ENAS6341_2.5.3.0",
	"name":"Safety and prevention information [PCN]"
},
{
	"jumpto":"ENAS5268_6.1.3.1",
	"name":"Safety of antiemetics, summary [N/V]"
},
{
	"jumpto":"ENAS6365_5.5.8.0",
	"name":"Safety of BTAs [Bone health]"
},
{
	"jumpto":"ENAS5282_6.0.0.0",
	"name":"Salvage surgery (Oes CA)"
},
{
	"jumpto":"ENAS5062_4.9.0.0",
	"name":"Salvage surgical treatment, anal cancer"
},
{
	"jumpto":"ENAS5062_8.3.8.0",
	"name":"Salvage surgical treatment in anal cancer, summary"
},
{
	"jumpto":"ENAS5097_7.3.4.0",
	"name":"Salvage treatment, summary [TS/T-NS]"
},
{
	"jumpto":"ENAS5097_4.5.1.0",
	"name":"Salvage treatment, TS/ T-NS"
},
{
	"jumpto":"ENAS6367_2020113041",
	"name":"SCCOHTs, management of advanced disease [NEOC]"
},
{
	"jumpto":"ENAS6367_4.3.1.0",
	"name":"SCCOHTs, management of early stages [NEOC]"
},
{
	"jumpto":"ENAS6367_3.2.4.0",
	"name":"SCCOHTs, staging [NEOC]"
},
{
	"jumpto":"ENAS5268_6.1.3.1",
	"name":"Schedule of antiemetics, summary [N/V]"
},
{
	"jumpto":"ENAS5269_6.3.2.0",
	"name":"Schedule of G-CSF, summary [FN]"
},
{
	"jumpto":"ENAS5269_6.3.2.0",
	"name":"Schedule of pegfilgrastim, summary [FN]"
},
{
	"jumpto":"ENAS5410_3.1.3.2",
	"name":"Schematic of body surface area [irAEs]"
},
{
	"jumpto":"ENAS5071_6.5.0.0",
	"name":"SCLC follow-up, summary"
},
{
	"jumpto":"ENAS6341_4.1.4.7",
	"name":"Scrambler therapy, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.4.7.0",
	"name":"Scrambler therapy [PCN]"
},
{
	"jumpto":"ENAS6340_6.3.0.0",
	"name":"Screening and risk assessment, summary [CRF]"
},
{
	"jumpto":"ENAS6340_4.1.0.0",
	"name":"Screening and risk assessment [CRF]"
},
{
	"jumpto":"ENAS6339_3.1.1.0",
	"name":"Screening before anticancer therapy [CVD]"
},
{
	"jumpto":"ENAS6339_11.2.0.0",
	"name":"Screening before anticancer therapy [CVD]"
},
{
	"jumpto":"ENAS5406_2.0.0.0",
	"name":"Screening [Early NSCLC]"
},
{
	"jumpto":"ENAS6341_4.1.4.9",
	"name":"SCS, summary [PCN]"
},
{
	"jumpto":"ENAS6367_5.2.0.0",
	"name":"SCSTs, management of advanced disease [NEOC]"
},
{
	"jumpto":"ENAS6367_4.2.1.0",
	"name":"SCSTs, management of early stages [NEOC]"
},
{
	"jumpto":"ENAS6367_6.1.2.0",
	"name":"SCSTs, response evaluation and follow-up [NEOC]"
},
{
	"jumpto":"ENAS6367_3.2.3.0",
	"name":"SCSTs, staging [NEOC]"
},
{
	"jumpto":"ENAS5268_2.9.0.0",
	"name":"SCT [N/V]"
},
{
	"jumpto":"ENAS5283_4.6.0.0",
	"name":"Second- and further-line treatment (Gastric cancer)"
},
{
	"jumpto":"ENAS5283_8.3.4.0",
	"name":"Second- and further-line treatment, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5636_8.4.2.0",
	"name":"Second- and third-generation TKIs, summary [CML]"
},
{
	"jumpto":"ENAS5636_5.2.0.0",
	"name":"Second- and third-generation TKIs [CML]"
},
{
	"jumpto":"ENAS5304_8.6.10.0",
	"name":"Second-line therapy, summary [mCRC]"
},
{
	"jumpto":"ENAS5637_10.5.4.0",
	"name":"Second-line treat. of anaemia, summary [MDS]"
},
{
	"jumpto":"ENAS5637_10.4.5.0",
	"name":"Second-line treatment, summary [MDS]"
},
{
	"jumpto":"ENAS5285_9.4.2.2",
	"name":"Second-line treatment, summary [RCC]"
},
{
	"jumpto":"ENAS5637_5.5.0.0",
	"name":"Second-line treatment [MDS]"
},
{
	"jumpto":"ENAS5285_6.2.2.5",
	"name":"Second-line treatment [RCC]"
},
{
	"jumpto":"ENAS5643_6.3.10.0",
	"name":"Second-line Tx. of NSCLC w/o oncogenic driver, summary"
},
{
	"jumpto":"ENAS5269_6.3.1.0",
	"name":"Secondary prophylaxis, summary [FN]"
},
{
	"jumpto":"ENAS5269_4.1.0.0",
	"name":"Secondary prophylaxis [FN]"
},
{
	"jumpto":"ENAS5304_5.3.0.0",
	"name":"Selective internal radiotherapy (SIRT) [mCRC]"
},
{
	"jumpto":"ENAS5644_8.3.7.0",
	"name":"Selective internal radiotherapy, summary [HCC]"
},
{
	"jumpto":"ENAS5062_3.1.0.0",
	"name":"Sentinel lymph node biopsy"
},
{
	"jumpto":"ENAS6228_5.2.4.1",
	"name":"Serum Tg, summary [TC]"
},
{
	"jumpto":"ENAS6228_5.2.4.1",
	"name":"Serum thyroglobulin, summary [TC]"
},
{
	"jumpto":"ENAS6228_2.4.4.0",
	"name":"Serum thyroglobulin Serum Tg [TC]"
},
{
	"jumpto":"ENAS5267_12.7.0.0",
	"name":"Severe tissue damage, summary [Extra]"
},
{
	"jumpto":"ENAS5267_8.0.0.0",
	"name":"Severe tissue damage, surgical mgmt. [Extra]"
},
{
	"jumpto":"ENAS5086_5.4.1.0",
	"name":"Short course radiotherapy, MPM"
},
{
	"jumpto":"ENAS6343_8.3.3.0",
	"name":"SI-NET, summary [GEP-NENs]"
},
{
	"jumpto":"ENAS5283_8.5.0.0",
	"name":"Signet cell tumours, summary (Gastric cancer)"
},
{
	"jumpto":"interactive_0002109",
	"name":"Simplified diagnostic alorithms for MPNS, interactive tool"
},
{
	"jumpto":"ENAS5268_2.1.0.0",
	"name":"Single IV antineoplastics [N/V]"
},
{
	"jumpto":"ENAS5092_4.3.2.0",
	"name":"Sipleucel-T [PC]"
},
{
	"jumpto":"ENAS5092_4.1.0.0",
	"name":"Sipuleucel-T [PC]"
},
{
	"jumpto":"ENAS5410_4.2.1.2",
	"name":"Skin toxicities diagnosis & pathology, summary [irAEs]"
},
{
	"jumpto":"ENAS6369_4.2.2.0",
	"name":"SLN dissection in cervical cancer [Cervical CA]"
},
{
	"jumpto":"ENAS6343_4.3.1.0",
	"name":"Small intestinal NETs [GEP-NENs]"
},
{
	"jumpto":"ENAS5071_5.0.0.0",
	"name":"Smoking cessation counselling, SCLC"
},
{
	"jumpto":"ENAS5640_5.1.0.0",
	"name":"Smouldering myeloma, front-line treatment [MM]"
},
{
	"jumpto":"ENAS5640_12.4.1.0",
	"name":"Smouldering myeloma treatment, summary [MM]"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Sodium thiosulfate [Extra]"
},
{
	"jumpto":"ENAS5640_12.7.2.0",
	"name":"Solitary plasmacytoma management in MM, summary"
},
{
	"jumpto":"ENAS5647_14.3.3.0",
	"name":"Somatostatin analogues (octreotide) [Diarrh.]"
},
{
	"jumpto":"ENAS5268_5.2.0.0",
	"name":"Somatostatin analogues [N/V]"
},
{
	"jumpto":"ENAS5285_6.2.2.3",
	"name":"Sorafenib [RCC]"
},
{
	"jumpto":"ENAS5271_7.3.3.0",
	"name":"Special considerations for some DLBCLs"
},
{
	"jumpto":"ENAS6365_6.6.0.0",
	"name":"Special considerations in the elderly [Bone health]"
},
{
	"jumpto":"ENAS5639_7.5.1.0",
	"name":"Special situations, summary [MPNs]"
},
{
	"jumpto":"ENAS5639_6.1.0.0",
	"name":"Special situations [MPNs]"
},
{
	"jumpto":"ENAS5647_20.10.0.0",
	"name":"Specific clinical manifestations, summary [Diarrh.]"
},
{
	"jumpto":"ENAS5647_12.1.0.0",
	"name":"Specific clinical manifestations [Diarrh.]"
},
{
	"jumpto":"ENAS5269_5.9.1.0",
	"name":"Specific indications, overview [FN]"
},
{
	"jumpto":"ENAS5269_6.4.6.1",
	"name":"Specific indications, summary [FN]"
},
{
	"jumpto":"ENAS5267_12.6.3.0",
	"name":"Specific measures, summary [Extra]"
},
{
	"jumpto":"ENAS5267_7.3.0.0",
	"name":"Specific measures [Extra]"
},
{
	"jumpto":"ENAS6346_11.0.0.0",
	"name":"Specific populations [ABC]"
},
{
	"jumpto":"ENAS6346_10.0.0.0",
	"name":"Specific sites of metastases [ABC]"
},
{
	"jumpto":"ENAS5283_8.5.0.0",
	"name":"Specific situations, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5407_3.6.4.0",
	"name":"Specimen grading in mesorectal excision [Rectal CA]"
},
{
	"jumpto":"ENAS5062_4.8.0.0",
	"name":"Sperm banking"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Spinal cord compression, metastatic PC"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Spinal cord compression [PC]"
},
{
	"jumpto":"ENAS6341_2.4.9.0",
	"name":"Spinal cord stimulation [PCN]"
},
{
	"jumpto":"ENAS6365_6.5.0.0",
	"name":"Spinal metastases [Bone health]"
},
{
	"jumpto":"ENAS5280_4.5.0.0",
	"name":"Splenectomy, HCL"
},
{
	"jumpto":"ENAS5280_7.3.5.0",
	"name":"Splenectomy in HCL, summary"
},
{
	"jumpto":"ENAS5639_3.4.4.0",
	"name":"Splenomegaly and extramedullary haematopoiesis, treatment [MPNs]"
},
{
	"jumpto":"ENAS5639_7.2.3.2",
	"name":"Splenomegaly and extramedullary haematopoiesis treatment, summary [MPNs]"
},
{
	"jumpto":"ENAS5646_4.5.0.0",
	"name":"SPTCL [PCLs]"
},
{
	"jumpto":"ENAS5282_2.0.0.0",
	"name":"Squamous cell carcinomas (Oes CA)"
},
{
	"jumpto":"ENAS5282_4.1.5.0",
	"name":"Squamous cell carcinomas, management (Oes CA)"
},
{
	"jumpto":"ENAS6369_2.2.0.0",
	"name":"Squamous cell carcinoma [Cervical CA]"
},
{
	"jumpto":"ENAS6343_5.3.3.2",
	"name":"SSAs [GEP-NENs]"
},
{
	"jumpto":"ENAS5285_5.2.1.2",
	"name":"SSIGN score [RCC]"
},
{
	"jumpto":"ENAS5407_3.6.2.0",
	"name":"Stage grouping, rectal cancer"
},
{
	"jumpto":"ENAS5645_11.4.1.0",
	"name":"Stage IA without risk factors, summary"
},
{
	"jumpto":"ENAS5645_7.1.0.0",
	"name":"Stage IA without risk factors, treatment of NLPHL"
},
{
	"jumpto":"ENAS6338_9.6.2.0",
	"name":"Stage II disease, summary [LCC]"
},
{
	"jumpto":"ENAS6370_5.2.4.0",
	"name":"Stage II endometrial cancer [Endometrial CA]"
},
{
	"jumpto":"ENAS6338_9.6.1.0",
	"name":"Stage III disease, summary [LCC]"
},
{
	"jumpto":"ENAS5406_4.8.0.0",
	"name":"Stage I lung CA with emphysema, interactive tool [Early NSCLC]"
},
{
	"jumpto":"ENAS5283_3.1.0.0",
	"name":"Staging (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_3.1.0.0",
	"name":"Staging (Oes CA)"
},
{
	"jumpto":"ENAS5068_3.0.0.0",
	"name":"Staging (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5279_3.1.0.0",
	"name":"Staging, CLL"
},
{
	"jumpto":"ENAS5271_3.1.0.0",
	"name":"Staging, DLBCL"
},
{
	"jumpto":"ENAS5278_3.1.0.0",
	"name":"Staging, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5278_3.1.0.0",
	"name":"Staging, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5273_4.1.0.0",
	"name":"Staging, FL"
},
{
	"jumpto":"ENAS5280_3.0.0.0",
	"name":"Staging, HCL"
},
{
	"jumpto":"ENAS5277_3.0.0.0",
	"name":"Staging, PTCL"
},
{
	"jumpto":"ENAS5407_3.1.0.0",
	"name":"Staging, rectal CA"
},
{
	"jumpto":"ENAS5071_3.1.0.0",
	"name":"Staging, SCLC"
},
{
	"jumpto":"ENAS5284_7.2.0.0",
	"name":"Staging, summary [Bil]"
},
{
	"jumpto":"ENAS6366_2020112722",
	"name":"Staging, summary [EOC]"
},
{
	"jumpto":"ENAS6371_7.2.1.0",
	"name":"Staging, summary [GTD]"
},
{
	"jumpto":"ENAS5263_14.8.1.0",
	"name":"Staging, summary [Mucosa]"
},
{
	"jumpto":"ENAS6367_7.2.2.0",
	"name":"Staging, summary [NEOC]"
},
{
	"jumpto":"ENAS5285_9.3.0.0",
	"name":"Staging, summary [RCC]"
},
{
	"jumpto":"ENAS6344_4.1.0.0",
	"name":"Staging and risk assessment, ACC [ACC]"
},
{
	"jumpto":"ENAS5406_4.1.0.0",
	"name":"Staging and risk assessment, NSCLC [Early NSCLC]"
},
{
	"jumpto":"ENAS5646_3.1.0.0",
	"name":"Staging and risk assessment, overview [PCLs]"
},
{
	"jumpto":"ENAS5278_3.9.0.0",
	"name":"Staging and risk assessment, PBL"
},
{
	"jumpto":"ENAS5278_3.8.1.0",
	"name":"Staging and risk assessment, PCNSL"
},
{
	"jumpto":"ENAS5278_3.6.0.0",
	"name":"Staging and risk assessment, PMBCL"
},
{
	"jumpto":"ENAS6344_4.2.0.0",
	"name":"Staging and risk assessment, PPGL [ACC]"
},
{
	"jumpto":"ENAS5278_3.7.0.0",
	"name":"Staging and risk assessment, PTL"
},
{
	"jumpto":"ENAS5645_11.2.0.0",
	"name":"Staging and risk assessment, summary"
},
{
	"jumpto":"ENAS5283_8.2.0.0",
	"name":"Staging and risk assessment, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_7.2.0.0",
	"name":"Staging and risk assessment, summary (Oes CA)"
},
{
	"jumpto":"ENAS6344_8.3.0.0",
	"name":"Staging and risk assessment, summary [ACC]"
},
{
	"jumpto":"ENAS6369_8.2.0.0",
	"name":"Staging and risk assessment, summary [Cervical CA]"
},
{
	"jumpto":"ENAS6370_8.3.0.0",
	"name":"Staging and risk assessment, summary [Endometrial CA]"
},
{
	"jumpto":"ENAS6343_8.2.0.0",
	"name":"Staging and risk assessment, summary [GEP-NENs]"
},
{
	"jumpto":"ENAS5644_8.2.0.0",
	"name":"Staging and risk assessment, summary [HCC]"
},
{
	"jumpto":"ENAS5640_12.2.0.0",
	"name":"Staging and risk assessment, summary [MM]"
},
{
	"jumpto":"ENAS5643_6.2.1.0",
	"name":"Staging and risk assessment, summary [mNSCLC]"
},
{
	"jumpto":"ENAS6342_7.2.0.0",
	"name":"Staging and risk assessment, summary [MZLs]"
},
{
	"jumpto":"ENAS6367_7.2.1.0",
	"name":"Staging and risk assessment, summary [NEOC]"
},
{
	"jumpto":"ENAS5646_7.2.0.0",
	"name":"Staging and risk assessment, summary [PCLs]"
},
{
	"jumpto":"ENAS5098_8.2.0.0",
	"name":"Staging and risk assessment, summary [TETs]"
},
{
	"jumpto":"ENAS5649_10.2.0.0",
	"name":"Staging and risk assessment, summary [WM]"
},
{
	"jumpto":"ENAS6235_7.2.0.0",
	"name":"Staging and risk assessment, summmary [EBC]"
},
{
	"jumpto":"ENAS5279_7.2.0.0",
	"name":"Staging and risk assessment of CLL, summary"
},
{
	"jumpto":"ENAS5271_7.2.0.0",
	"name":"Staging and risk assessment of DLBCL, summary"
},
{
	"jumpto":"ENAS5278_7.2.1.0",
	"name":"Staging and risk assessment of DLBCL-PMBCL, summary"
},
{
	"jumpto":"ENAS5273_8.2.0.0",
	"name":"Staging and risk assessment of FL, summary"
},
{
	"jumpto":"ENAS5408_7.2.1.0",
	"name":"Staging and risk assessment of MCL, summary"
},
{
	"jumpto":"ENAS5278_7.2.5.0",
	"name":"Staging and risk assessment of PBL, summary"
},
{
	"jumpto":"ENAS5278_7.2.6.0",
	"name":"Staging and risk assessment of PBoL, summary"
},
{
	"jumpto":"ENAS5092_7.2.0.0",
	"name":"Staging and risk assessment of PC, summary"
},
{
	"jumpto":"ENAS5278_7.2.4.0",
	"name":"Staging and risk assessment of PCNSL, summary"
},
{
	"jumpto":"ENAS5278_7.2.2.0",
	"name":"Staging and risk assessment of PMBCL, summary"
},
{
	"jumpto":"ENAS5277_7.2.0.0",
	"name":"Staging and risk assessment of PTCL, summary"
},
{
	"jumpto":"ENAS5278_7.2.3.0",
	"name":"Staging and risk assessment of PTL, summary"
},
{
	"jumpto":"ENAS5407_9.2.1.0",
	"name":"Staging and risk assessment of rectal cancer, summary"
},
{
	"jumpto":"ENAS6344_4.1.0.0",
	"name":"Staging and risk assessment [ACC]"
},
{
	"jumpto":"ENAS6369_3.0.0.0",
	"name":"Staging and risk assessment [Cervical CA]"
},
{
	"jumpto":"ENAS6235_3.0.0.0",
	"name":"Staging and risk assessment [EBC]"
},
{
	"jumpto":"ENAS6370_4.1.0.0",
	"name":"Staging and risk assessment [Endometrial CA]"
},
{
	"jumpto":"ENAS5644_3.1.0.0",
	"name":"Staging and risk assessment [HCC]"
},
{
	"jumpto":"ENAS5645_3.0.0.0",
	"name":"Staging and risk assessment [HL]"
},
{
	"jumpto":"ENAS5643_3.1.0.0",
	"name":"Staging and risk assessment [mNSCLC]"
},
{
	"jumpto":"ENAS6342_3.1.1.0",
	"name":"Staging and risk assessment [MZLs]"
},
{
	"jumpto":"ENAS6367_3.1.0.0",
	"name":"Staging and risk assessment [NEOC]"
},
{
	"jumpto":"ENAS6228_2.2.1.0",
	"name":"Staging and risk assessment [TC]"
},
{
	"jumpto":"ENAS5649_3.0.0.0",
	"name":"Staging and risk assessment [WM]"
},
{
	"jumpto":"ENAS5280_7.2.0.0",
	"name":"Staging and risk stratification of HCL, summary"
},
{
	"jumpto":"ENAS5643_3.5.0.0",
	"name":"Staging and stage grouping UICC TNM 8 [mNSCLC]"
},
{
	"jumpto":"ENAS5646_3.2.0.0",
	"name":"Staging evaluation in patients with MF/SS [PCLs]"
},
{
	"jumpto":"ENAS6371_7.2.2.0",
	"name":"Staging investigations and treatment stratification after a molar pregnancy, summary [GTD]"
},
{
	"jumpto":"ENAS6371_3.2.1.0",
	"name":"Staging investigations and treatment stratification after a molar pregnancy [GTD]"
},
{
	"jumpto":"ENAS6371_7.2.3.0",
	"name":"Staging investigations for CC and PSTT/ETT, summary [GTD]"
},
{
	"jumpto":"ENAS6371_3.3.0.0",
	"name":"Staging investigations for CC and PSTT/ETT [GTD]"
},
{
	"jumpto":"ENAS6229_3.0.0.0",
	"name":"Staging of bronchial and thymic NETs, TNM [NETs]"
},
{
	"jumpto":"ENAS6370_4.2.0.0",
	"name":"Staging of endometrial cancer [Endometrial CA]"
},
{
	"jumpto":"ENAS5086_7.3.0.0",
	"name":"Staging of MPM, summary"
},
{
	"jumpto":"ENAS5068_8.2.0.0",
	"name":"Staging of pancreatic cancer, summary"
},
{
	"jumpto":"ENAS5096_7.2.0.0",
	"name":"Staging of PenCa, summary"
},
{
	"jumpto":"ENAS5071_6.2.0.0",
	"name":"Staging of SCLC, summary"
},
{
	"jumpto":"ENAS5279_3.2.0.0",
	"name":"Staging systems for CLL"
},
{
	"jumpto":"ENAS5098_4.1.0.0",
	"name":"Staging TETs"
},
{
	"jumpto":"ENAS5284_3.1.0.0",
	"name":"Staging [Bil]"
},
{
	"jumpto":"ENAS6366_202011273",
	"name":"Staging [EOC]"
},
{
	"jumpto":"ENAS6371_3.1.0.0",
	"name":"Staging [GTD]"
},
{
	"jumpto":"ENAS5408_3.1.0.0",
	"name":"Staging [MCL]"
},
{
	"jumpto":"ENAS5263_9.1.0.0",
	"name":"Staging [Mucosa]"
},
{
	"jumpto":"ENAS6367_3.2.1.0",
	"name":"Staging [NEOC]"
},
{
	"jumpto":"ENAS6229_3.0.0.0",
	"name":"Staging [NETs]"
},
{
	"jumpto":"ENAS5304_5.11.0.0",
	"name":"Standard treatment algorithm, oligometastatic disease [mCRC]"
},
{
	"jumpto":"ENAS5262_6.3.3.6",
	"name":"Staphylococcus aureus, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.8.0",
	"name":"Staphylococcus aureus [CVC]"
},
{
	"jumpto":"ENAS5262_6.3.3.5",
	"name":"Staphylococcus coagulase-negative, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.7.0",
	"name":"Staphylococcus coagulase-negative [CVC]"
},
{
	"jumpto":"ENAS5285_2.0.0.0",
	"name":"Stauf­fer’s syn­drome [RCC]"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Steatorrhoea (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5277_4.8.0.0",
	"name":"Stem cell transplantation, PTCL"
},
{
	"jumpto":"ENAS5633_7.3.1.7",
	"name":"Stem cell transplantation, summary [ALL]"
},
{
	"jumpto":"ENAS5639_7.2.3.3",
	"name":"Stem cell transplantation, summary [MPNs]"
},
{
	"jumpto":"ENAS5277_7.3.6.0",
	"name":"Stem cell transplantation in PTCL, summary"
},
{
	"jumpto":"ENAS5633_4.1.7.0",
	"name":"Stem cell transplantation [ALL]"
},
{
	"jumpto":"ENAS5639_3.4.5.0",
	"name":"Stem cell transplantation [MPNs]"
},
{
	"jumpto":"ENAS5268_2.9.0.0",
	"name":"Stem cell transplantation [N/V]"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Stent, advanced pancreatic cancer"
},
{
	"jumpto":"ENAS5267_9.2.0.0",
	"name":"Steps, CVAD extravasation"
},
{
	"jumpto":"ENAS5267_7.4.0.0",
	"name":"Steps, peripheral line extravasation"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Stereotactic ablative body radiotherapy (SBRT) [mCRC]"
},
{
	"jumpto":"ENAS5406_5.1.3.0",
	"name":"Stereotactic body radiotherapy [Early NSCLC]"
},
{
	"jumpto":"ENAS5647_14.3.5.0",
	"name":"Steroids [Diarrh.]"
},
{
	"jumpto":"ENAS5263_11.4.0.0",
	"name":"Steroids [Mucosa]"
},
{
	"jumpto":"ENAS5410_3.1.2.0",
	"name":"Stevens John­son syndrome [irAEs]"
},
{
	"jumpto":"ENAS5263_14.1.0.0",
	"name":"Stomatitis, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.5.0.0",
	"name":"Stomatitis in targeted therapy, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_6.0.0.0",
	"name":"Stomatitis in targeted therapy [Mucosa]"
},
{
	"jumpto":"ENAS5263_2.0.0.0",
	"name":"Stomatitis [Mucosa]"
},
{
	"jumpto":"ENAS6341_4.2.8.0",
	"name":"Stroke and vasculopathy, summary [PCN]"
},
{
	"jumpto":"ENAS6341_3.8.0.0",
	"name":"Stroke and vasculopathy [PCN]"
},
{
	"jumpto":"ENAS6365_4.2.0.0",
	"name":"Structural imaging [Bone health]"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Sub-total gastrectomy, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5646_7.3.5.0",
	"name":"Subcut. panniculitis-like T cell lymphomas, summary [PCLs]"
},
{
	"jumpto":"ENAS5646_4.5.0.0",
	"name":"Subcutaneous panniculitis-like T cell lymphomas [PCLs]"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"Succinate dehydrogenase-deficient RCCs"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Sucralfate enemas [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Sucralfate mouthwash [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.3.0",
	"name":"Sulfasalazine [Mucosa]"
},
{
	"jumpto":"ENAS5649_10.1.0.0",
	"name":"Summary of recommendations"
},
{
	"jumpto":"ENAS5283_8.1.0.0",
	"name":"Summary of recommendations (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_7.1.0.0",
	"name":"Summary of recommendations (Oes CA)"
},
{
	"jumpto":"ENAS5062_8.1.0.0",
	"name":"Summary of recommendations, anal cancer"
},
{
	"jumpto":"ENAS5284_7.1.0.0",
	"name":"Summary of recommendations, biliary cancer"
},
{
	"jumpto":"ENAS5279_7.1.0.0",
	"name":"Summary of recommendations, CLL"
},
{
	"jumpto":"ENAS5262_6.1.0.0",
	"name":"Summary of recommendations, CVC"
},
{
	"jumpto":"ENAS5647_20.1.0.0",
	"name":"Summary of recommendations, diarrhoea"
},
{
	"jumpto":"ENAS5271_7.1.0.0",
	"name":"Summary of recommendations, DLBCL"
},
{
	"jumpto":"ENAS5278_7.1.1.0",
	"name":"Summary of recommendations, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5267_12.1.0.0",
	"name":"Summary of recommendations, Extra"
},
{
	"jumpto":"ENAS5273_8.1.0.0",
	"name":"Summary of recommendations, FL"
},
{
	"jumpto":"ENAS5269_6.1.0.0",
	"name":"Summary of recommendations, FN"
},
{
	"jumpto":"ENAS5280_7.1.0.0",
	"name":"Summary of recommendations, HCL"
},
{
	"jumpto":"ENAS6232_4.1.1.0",
	"name":"Summary of recommendations, HDGC [Hereditary GC]"
},
{
	"jumpto":"ENAS5263_14.1.0.0",
	"name":"Summary of recommendations, Mucosa"
},
{
	"jumpto":"ENAS5268_6.1.1.0",
	"name":"Summary of recommendations, N/V"
},
{
	"jumpto":"ENAS5277_7.1.0.0",
	"name":"Summary of recommendations, PTCL"
},
{
	"jumpto":"ENAS5285_9.1.0.0",
	"name":"Summary of recommendations, RCC"
},
{
	"jumpto":"ENAS5071_6.1.0.0",
	"name":"Summary of recommendations, SCLC"
},
{
	"jumpto":"ENAS6340_6.1.0.0",
	"name":"Summary of recommendations, summary [CRF]"
},
{
	"jumpto":"ENAS6341_4.1.1.0",
	"name":"Summary of recommendations, summary [PCN]"
},
{
	"jumpto":"ENAS5098_8.1.0.0",
	"name":"Summary of recommendations, TETs"
},
{
	"jumpto":"ENAS5265_8.1.0.0",
	"name":"Summary of recommendations, VTE"
},
{
	"jumpto":"ENAS6344_8.1.0.0",
	"name":"Summary of recommendations [ACC]"
},
{
	"jumpto":"ENAS5633_7.1.2.0",
	"name":"Summary of recommendations [ALL]"
},
{
	"jumpto":"ENAS5635_7.1.0.0",
	"name":"Summary of recommendations [AML]"
},
{
	"jumpto":"ENAS5648_9.1.1.1",
	"name":"Summary of recommendations [Anaemia]"
},
{
	"jumpto":"ENAS5636_8.1.0.0",
	"name":"Summary of recommendations [CML]"
},
{
	"jumpto":"ENAS6339_11.1.0.0",
	"name":"Summary of recommendations [CVD]"
},
{
	"jumpto":"ENAS6343_8.1.0.0",
	"name":"Summary of recommendations [GEP-NENs]"
},
{
	"jumpto":"ENAS5645_11.1.0.0",
	"name":"Summary of recommendations [HL]"
},
{
	"jumpto":"ENAS6338_9.1.1.0",
	"name":"Summary of recommendations [LCC]"
},
{
	"jumpto":"ENAS6233_4.1.1.0",
	"name":"Summary of recommendations [LS]"
},
{
	"jumpto":"ENAS5408_7.1.0.0",
	"name":"Summary of recommendations [MCL]"
},
{
	"jumpto":"ENAS5304_8.1.0.0",
	"name":"Summary of recommendations [mCRC]"
},
{
	"jumpto":"ENAS5637_10.1.0.0",
	"name":"Summary of recommendations [MDS]"
},
{
	"jumpto":"ENAS5640_12.1.0.0",
	"name":"Summary of recommendations [MM]"
},
{
	"jumpto":"ENAS5643_6.1.1.0",
	"name":"Summary of recommendations [mNSCLC]"
},
{
	"jumpto":"ENAS5639_7.1.0.0",
	"name":"Summary of recommendations [MPNs]"
},
{
	"jumpto":"ENAS6229_6.1.0.0",
	"name":"Summary of recommendations [NETs]"
},
{
	"jumpto":"ENAS5646_7.1.0.0",
	"name":"Summary of recommendations [PCLs]"
},
{
	"jumpto":"ENAS6228_5.1.0.0",
	"name":"Summary of recommendations [TC]"
},
{
	"jumpto":"ENAS5645_11.1.0.0",
	"name":"Summary recommendations for for Hodgkin lymphoma"
},
{
	"jumpto":"ENAS5644_8.1.1.0",
	"name":"Summary recommendations for hepatocellular carcinoma, summary [HCC]"
},
{
	"jumpto":"ENAS5649_10.1.0.0",
	"name":"Summary recommendations for waldenstrom's macroglobulinaemia"
},
{
	"jumpto":"ENAS6343_5.3.3.5",
	"name":"Sunitinib [GEP-NENs]"
},
{
	"jumpto":"ENAS5285_6.2.2.3",
	"name":"Sunitinib [RCC]"
},
{
	"jumpto":"ENAS5068_4.1.0.0",
	"name":"Superior mesenteric artery (SMA)"
},
{
	"jumpto":"ENAS6346_13.0.0.0",
	"name":"Supportive and palliative care [ABC]"
},
{
	"jumpto":"ENAS5068_5.7.1.0",
	"name":"Supportive care (Pancreatic Cancer)"
},
{
	"jumpto":"ENAS5637_10.6.0.0",
	"name":"Supportive care and chelation therapy, summary [MDS]"
},
{
	"jumpto":"ENAS5637_7.0.0.0",
	"name":"Supportive care and chelation therapy in MDS"
},
{
	"jumpto":"ENAS5640_9.2.0.0",
	"name":"Supportive care for anaemia, BM failures and infections [MM]"
},
{
	"jumpto":"ENAS5640_12.8.2.0",
	"name":"Supportive care for anaemia, summary [MM]"
},
{
	"jumpto":"ENAS5640_12.8.1.0",
	"name":"Supportive care for bone disease & spinal cord compression, summary [MM]"
},
{
	"jumpto":"ENAS5640_9.1.0.0",
	"name":"Supportive care for bone disease & spinal cord compression [MM]"
},
{
	"jumpto":"ENAS5640_12.8.2.0",
	"name":"Supportive care for bone marrow failure, summary [MM]"
},
{
	"jumpto":"ENAS5640_12.8.2.0",
	"name":"Supportive care for infections, summary [MM]"
},
{
	"jumpto":"ENAS5640_12.8.1.0",
	"name":"Supportive care for MM, summary"
},
{
	"jumpto":"ENAS5640_12.8.3.0",
	"name":"Supportive care for renal failure, summary [MM]"
},
{
	"jumpto":"ENAS5640_9.3.0.0",
	"name":"Supportive care for renal failure [MM]"
},
{
	"jumpto":"ENAS5640_12.8.4.0",
	"name":"Supportive care for VTE, summary [MM]"
},
{
	"jumpto":"ENAS5640_9.4.0.0",
	"name":"Supportive care for VTE [MM]"
},
{
	"jumpto":"ENAS5062_8.3.7.0",
	"name":"Supportive care in anal cancer, summary"
},
{
	"jumpto":"ENAS6341_4.1.5.0",
	"name":"Supportive measures for safety and self-management, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.5.1.0",
	"name":"Supportive measures for safety and self-management [PCN]"
},
{
	"jumpto":"ENAS5280_4.8.0.0",
	"name":"Supportive treatment, HCL"
},
{
	"jumpto":"ENAS5280_7.3.8.0",
	"name":"Supportive treatment of HCL, summary"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Surgery, management (Gastric cancer)"
},
{
	"jumpto":"ENAS6369_4.2.1.0",
	"name":"Surgery, primary Tx of local/locoregional disease [Cervical CA]"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Surgery, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS6344_8.4.1.0",
	"name":"Surgery, summary [ACC]"
},
{
	"jumpto":"ENAS6235_7.3.2.0",
	"name":"Surgery, summary [EBC]"
},
{
	"jumpto":"ENAS6370_8.4.2.0",
	"name":"Surgery, summary [Endometrial CA]"
},
{
	"jumpto":"ENAS6366_2020112724",
	"name":"Surgery, summary [EOC]"
},
{
	"jumpto":"ENAS5639_7.5.6.0",
	"name":"Surgery, summary [MPNs]"
},
{
	"jumpto":"ENAS6228_5.2.3.1",
	"name":"Surgery, summary [TC]"
},
{
	"jumpto":"ENAS6235_4.3.1.7",
	"name":"Surgery after primary systemic therapy [EBC]"
},
{
	"jumpto":"ENAS6344_6.1.5.0",
	"name":"Surgery and local therapies [ACC]"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Surgery and local therapy, role"
},
{
	"jumpto":"ENAS6235_4.3.1.4",
	"name":"Surgery for in situ malignancy [EBC]"
},
{
	"jumpto":"ENAS6343_5.1.0.0",
	"name":"Surgery for metastatic disease [GEP-NENs]"
},
{
	"jumpto":"ENAS5062_8.3.2.0",
	"name":"Surgery in anal cancer, summary"
},
{
	"jumpto":"ENAS5086_7.4.4.0",
	"name":"Surgery in MPM, summary"
},
{
	"jumpto":"ENAS6344_6.2.3.0",
	"name":"Surgery [ACC]"
},
{
	"jumpto":"ENAS5615_8.1.0.0",
	"name":"Surgery [BRCA]"
},
{
	"jumpto":"ENAS6235_4.3.1.1",
	"name":"Surgery [EBC]"
},
{
	"jumpto":"ENAS6370_5.2.1.0",
	"name":"Surgery [Endometrial CA]"
},
{
	"jumpto":"ENAS6366_202011276",
	"name":"Surgery [EOC]"
},
{
	"jumpto":"ENAS5304_5.2.1.0",
	"name":"Surgery [mCRC]"
},
{
	"jumpto":"ENAS5639_6.6.0.0",
	"name":"Surgery [MPNs]"
},
{
	"jumpto":"interactive_0002852",
	"name":"Surgical approach in SI-NETS, interactive tool"
},
{
	"jumpto":"interactive_0002852",
	"name":"Surgical approach in SI-NETS [GEP-NENs]"
},
{
	"jumpto":"ENAS6343_4.3.2.0",
	"name":"Surgical approach in SI-NETS [GEP-NENs]"
},
{
	"jumpto":"interactive_0002851",
	"name":"Surgical approach in sporadic PAN-NETS, interactive tool"
},
{
	"jumpto":"ENAS6343_4.2.2.0",
	"name":"Surgical approach in sporadic PAN-NETS, interactive tool [GEP-NENs]"
},
{
	"jumpto":"ENAS6343_4.2.2.0",
	"name":"Surgical approach in sporadic PAN-NETS [GEP-NENs]"
},
{
	"jumpto":"ENAS5304_5.4.0.0",
	"name":"Surgical criteria [mCRC]"
},
{
	"jumpto":"ENAS5267_12.7.0.0",
	"name":"Surgical debridement, summary [Extra]"
},
{
	"jumpto":"ENAS5267_8.0.0.0",
	"name":"Surgical debridement [Extra]"
},
{
	"jumpto":"ENAS6228_2.3.1.2",
	"name":"Surgical management of DTC pts., tool [TC]"
},
{
	"jumpto":"ENAS6344_5.1.1.0",
	"name":"Surgical management of locoregional disease [ACC]"
},
{
	"jumpto":"ENAS6228_5.2.3.1",
	"name":"Surgical management of primary tumour, summary [TC]"
},
{
	"jumpto":"ENAS5267_8.0.0.0",
	"name":"Surgical mgmt., severe tissue damage [Extra]"
},
{
	"jumpto":"ENAS5267_12.7.0.0",
	"name":"Surgical mgmt., summary [Extra]"
},
{
	"jumpto":"ENAS6232_4.2.3.0",
	"name":"Surgical mgmt. in patients at high risk for PC, summary [Hereditary GC]"
},
{
	"jumpto":"ENAS6232_3.3.0.0",
	"name":"Surgical mgmt. in patients at high risk for PC [Hereditary GC]"
},
{
	"jumpto":"ENAS5265_4.1.0.0",
	"name":"Surgical patients, prevention of VTE"
},
{
	"jumpto":"ENAS5283_4.3.1.0",
	"name":"Surgical resection, management (Gastric cancer)"
},
{
	"jumpto":"ENAS5304_8.6.2.2",
	"name":"Surgical resection, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.2.2.0",
	"name":"Surgical resection [mCRC]"
},
{
	"jumpto":"ENAS6369_4.2.3.0",
	"name":"Surgical therapy of the uterus [Cervical CA]"
},
{
	"jumpto":"ENAS5406_5.1.1.0",
	"name":"Surgical treatment, stage I and II [Early NSCLC]"
},
{
	"jumpto":"ENAS5098_5.4.0.0",
	"name":"Surgical treatment, TETs"
},
{
	"jumpto":"ENAS5615_9.4.1.0",
	"name":"Surgical treatment of breast cancer in BRCA, summary [BRCA]"
},
{
	"jumpto":"ENAS5096_7.3.1.0",
	"name":"Surgical treatment of PenCa, summary"
},
{
	"jumpto":"ENAS5098_8.3.2.0",
	"name":"Surgical treatment of TETs, summary"
},
{
	"jumpto":"ENAS5407_8.2.0.0",
	"name":"Surveillance and follow-up, tool [Rectal CA]"
},
{
	"jumpto":"ENAS6232_4.1.2.0",
	"name":"Surveillance and risk reduction, summary [Hereditary GC]"
},
{
	"jumpto":"ENAS6233_4.2.1.2",
	"name":"Surveillance and risk reduction, summary [LS]"
},
{
	"jumpto":"ENAS6233_4.1.2.0",
	"name":"Surveillance and risk reduction, summary [LS]"
},
{
	"jumpto":"ENAS6233_4.2.2.2",
	"name":"Surveillance and risk reduction, summary [LS]"
},
{
	"jumpto":"ENAS6232_2.2.2.0",
	"name":"Surveillance and risk reduction [Hereditary GC]"
},
{
	"jumpto":"ENAS6232_2.4.2.0",
	"name":"Surveillance and risk reduction [Hereditary GC]"
},
{
	"jumpto":"ENAS6232_2.5.2.0",
	"name":"Surveillance and risk reduction [Hereditary GC]"
},
{
	"jumpto":"ENAS6233_3.2.2.0",
	"name":"Surveillance and risk reduction [LS]"
},
{
	"jumpto":"ENAS6233_3.1.2.1",
	"name":"Surveillance and risk reduction [LS]"
},
{
	"jumpto":"ENAS6233_2.2.0.0",
	"name":"Surveillance and risk reduction [LS]"
},
{
	"jumpto":"ENAS6339_5.5.0.0",
	"name":"Surveillance biomarker in adjuvant trastuzumab treatment [CVD]"
},
{
	"jumpto":"ENAS6339_11.4.4.0",
	"name":"Surveillance biomarker in adjuvant trastuzumab treatment [CVD]"
},
{
	"jumpto":"ENAS6339_11.4.2.0",
	"name":"Surveillance for risk stratification in asymptomatic patients [CVD]"
},
{
	"jumpto":"ENAS6339_5.3.0.0",
	"name":"Surveillance for risk stratification in asymptomatic patients [CVD]"
},
{
	"jumpto":"ENAS6339_5.4.0.0",
	"name":"Surveillance in adjuvant trastuzumab treatment [CVD]"
},
{
	"jumpto":"ENAS6339_11.4.3.0",
	"name":"Surveillance in adjuvant trastuzumab treatment [CVD]"
},
{
	"jumpto":"ENAS6339_11.4.5.0",
	"name":"Surveillance in metastatic disease of anti-HER2-based treatment [CVD]"
},
{
	"jumpto":"ENAS6339_5.6.0.0",
	"name":"Surveillance in metastatic disease of anti-HER2-based treatment [CVD]"
},
{
	"jumpto":"ENAS6232_4.2.2.0",
	"name":"Surveillance of high-risk patients, summary [Hereditary GC]"
},
{
	"jumpto":"ENAS6232_3.2.0.0",
	"name":"Surveillance of high-risk patients [Hereditary GC]"
},
{
	"jumpto":"ENAS5096_6.3.0.0",
	"name":"Surveillance [PenCa]"
},
{
	"jumpto":"ENAS5098_4.2.0.0",
	"name":"Survival rates, TETs"
},
{
	"jumpto":"ENAS5285_9.6.0.0",
	"name":"Survivorship, summary [RCC]"
},
{
	"jumpto":"ENAS5285_8.0.0.0",
	"name":"Survivorship [RCC]"
},
{
	"jumpto":"ENAS5269_6.4.6.6",
	"name":"Suspected meningitis, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.6.0",
	"name":"Suspected meningitis [FN]"
},
{
	"jumpto":"ENAS5269_6.4.6.5",
	"name":"Suspected viral infection, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.5.0",
	"name":"Suspected viral infection [FN]"
},
{
	"jumpto":"ENAS5410_3.1.2.0",
	"name":"Sweet syndrome [irAEs]"
},
{
	"jumpto":"ENAS5640_5.2.2.0",
	"name":"Symptomatic MM front-line treatment, interactive tool"
},
{
	"jumpto":"interactive_0002130",
	"name":"Symptomatic MM front-line treatment, interactive tool"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Symptoms (Pancreatic Cancer)"
},
{
	"jumpto":"ENAS5263_11.1.0.0",
	"name":"Systematic enteral nutrition, emergent data [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.3.0.0",
	"name":"Systematic enteral nutrition, emergent data [Mucosa]"
},
{
	"jumpto":"ENAS5098_5.4.0.0",
	"name":"Systematic lymphadenectomy [TETs]"
},
{
	"jumpto":"ENAS6341_1.0.0.0",
	"name":"Systemic anticancer therapy-induced peripheral and central neurotoxicity [PCN]"
},
{
	"jumpto":"ENAS5284_7.3.2.2",
	"name":"Systemic chemotherapy, summary [Bil]"
},
{
	"jumpto":"ENAS5284_4.4.2.0",
	"name":"Systemic chemotherapy [Bil]"
},
{
	"jumpto":"ENAS6344_6.2.5.0",
	"name":"Systemic ChT [ACC]"
},
{
	"jumpto":"ENAS6343_5.3.3.6",
	"name":"Systemic ChT [GEP-NENs]"
},
{
	"jumpto":"ENAS5304_5.7.0.0",
	"name":"Systemic perioperative therapy [mCRC]"
},
{
	"jumpto":"ENAS5644_5.1.1.0",
	"name":"Systemic therapies for advanced HCC"
},
{
	"jumpto":"ENAS5644_8.4.1.1",
	"name":"Systemic therapies for advanced HCC, summary"
},
{
	"jumpto":"ENAS5304_5.14.8.0",
	"name":"Systemic therapy choices [mCRC]"
},
{
	"jumpto":"interactive_0002856",
	"name":"Systemic therapy in GEP-NENS, interactive tool"
},
{
	"jumpto":"ENAS6343_5.3.3.7",
	"name":"Systemic therapy in GEP-NENS [GEP-NENs]"
},
{
	"jumpto":"interactive_0002856",
	"name":"Systemic therapy in GEP-NENS [GEP-NENs]"
},
{
	"jumpto":"ENAS6228_5.4.5.3",
	"name":"Systemic therapy of advanced/metastatic MTC, summary [TC]"
},
{
	"jumpto":"ENAS6370_5.4.4.0",
	"name":"Systemic therapy [Endometrial CA]"
},
{
	"jumpto":"ENAS5285_6.2.2.2",
	"name":"Systemic treatment, algorithm [RCC]"
},
{
	"jumpto":"ENAS5285_6.2.2.1",
	"name":"Systemic treatment, overview [RCC]"
},
{
	"jumpto":"ENAS5285_9.4.2.2",
	"name":"Systemic treatment, summary [RCC]"
},
{
	"jumpto":"ENAS6235_4.4.2.0",
	"name":"Systemic treatment for EBC subtypes [EBC]"
},
{
	"jumpto":"ENAS5615_9.4.2.0",
	"name":"Systemic treatment of breast cancer in BRCA, summary [BRCA]"
},
{
	"jumpto":"ENAS5615_8.2.0.0",
	"name":"Systemic treatment [BRCA]"
},
{
	"jumpto":"ENAS5646_4.3.1.0",
	"name":"S�zary syndrome, overview [PCLs]"
},
{
	"jumpto":"ENAS5646_7.3.3.0",
	"name":"S�zary syndrome, summary [PCLs]"
},
{
	"jumpto":"ENAS5097_4.4.2.0",
	"name":"T-NS, standard treatment strategies"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"T-NS treatment, for high-risk stage I"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"T-NS treatment, for low-risk stage I"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"T-NS treatment, for stage IIA/IIB marker-negative disease"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"T-NS treatment, for stage IIA/IIB marker-positive disease"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"T-NS treatment, for stage IS/ II/III"
},
{
	"jumpto":"ENAS5097_4.4.1.0",
	"name":"T-NS treatment, overview"
},
{
	"jumpto":"ENAS5097_7.3.2.0",
	"name":"T-NS treatment, summary"
},
{
	"jumpto":"ENAS5285_9.4.1.1",
	"name":"T1 tumours (&lt;7 cm), summary [RCC]"
},
{
	"jumpto":"ENAS5285_6.1.1.0",
	"name":"T1 tumours (&lt;7 cm) [RCC]"
},
{
	"jumpto":"ENAS5285_9.4.1.2",
	"name":"T2 tumours (&gt;7 cm), summary [RCC]"
},
{
	"jumpto":"ENAS5285_6.1.2.0",
	"name":"T2 tumours (&gt;7 cm) [RCC]"
},
{
	"jumpto":"ENAS5644_8.4.1.2",
	"name":"Targeted first-line therapies, summary [HCC]"
},
{
	"jumpto":"ENAS5644_5.1.2.0",
	"name":"Targeted first-line therapies [HCC]"
},
{
	"jumpto":"ENAS5644_8.4.1.3",
	"name":"Targeted second-line therapies, summary [HCC]"
},
{
	"jumpto":"ENAS5644_5.1.3.0",
	"name":"Targeted second-line therapies [HCC]"
},
{
	"jumpto":"ENAS5633_7.3.1.6",
	"name":"Targeted therapies, summary [ALL]"
},
{
	"jumpto":"ENAS6344_6.2.6.0",
	"name":"Targeted therapies [ACC]"
},
{
	"jumpto":"ENAS6366_2020112712",
	"name":"Targeted therapy, primary ovarian cancer [EOC]"
},
{
	"jumpto":"ENAS6366_2020112715",
	"name":"Targeted therapy, recurrent ovarian cancer [EOC]"
},
{
	"jumpto":"ENAS5263_11.4.0.0",
	"name":"Targeted therapy-associated stomatitis, recommendations [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.8.5.0",
	"name":"Targeted therapy-associated stomatitis grading, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_9.5.0.0",
	"name":"Targeted therapy-associated stomatitis grading [Mucosa]"
},
{
	"jumpto":"ENAS5647_20.5.0.0",
	"name":"Targeted therapy-induced diarrhoea, summary"
},
{
	"jumpto":"ENAS6366_2020112726",
	"name":"Targeted therapy in primary ovarian cancer, summary [EOC]"
},
{
	"jumpto":"ENAS6366_2020112729",
	"name":"Targeted therapy in recurrent ovarian CA, summary [EOC]"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"Taurolidine [CVC]"
},
{
	"jumpto":"ENAS5062_4.11.0.0",
	"name":"Taxanes [Anal cancr]"
},
{
	"jumpto":"ENAS5647_6.2.1.0",
	"name":"Taxanes [Diarrh.]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Taxanes [Extra]"
},
{
	"jumpto":"ENAS5409_11.1.4.0",
	"name":"Taxanes [IRs]"
},
{
	"jumpto":"ENAS5268_2.9.0.0",
	"name":"TBI [N/V]"
},
{
	"jumpto":"ENAS5263_5.0.0.0",
	"name":"Tegafur [Mucosa]"
},
{
	"jumpto":"ENAS5285_6.2.2.4",
	"name":"Temsirolimus [RCC]"
},
{
	"jumpto":"ENAS5263_14.1.0.0",
	"name":"Terminology, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_2.0.0.0",
	"name":"Terminology [Mucosa]"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"Testicular germ cell tumour (TGCT) [TS/T-NS]"
},
{
	"jumpto":"ENAS5098_5.12.0.0",
	"name":"TET chemotherapy agents"
},
{
	"jumpto":"ENAS5098_8.5.0.0",
	"name":"TETs follow-up, summary"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"TGF-α [mCRC]"
},
{
	"jumpto":"ENAS5645_6.1.3.0",
	"name":"The ABVD regimen, limited-stage disease [HL]"
},
{
	"jumpto":"ENAS5645_6.1.4.0",
	"name":"The BEACOPPescalated regimen, limited-stage disease [HL]"
},
{
	"jumpto":"ENAS5280_4.10.0.0",
	"name":"Therapeutic algo. for HCL-V, interactive tool"
},
{
	"jumpto":"ENAS5645_6.2.2.0",
	"name":"Therapeutic algo. for intermediate-stage HL in patients ≤ 60 years, interactive tool"
},
{
	"jumpto":"ENAS5273_5.3.2.0",
	"name":"Therapeutic algorithm, interactive tool"
},
{
	"jumpto":"ENAS5645_6.3.2.0",
	"name":"Therapeutic algorithm for newly diagnosed, advanced-stage Hodgkin lymphoma in patients ≤ 60 years"
},
{
	"jumpto":"ENAS5645_6.1.2.0",
	"name":"Therapeutic algorithm for newly diagnosed, limited-stage Hodgkin lymphoma in patients ≤ 60 years"
},
{
	"jumpto":"ENAS5647_14.1.0.0",
	"name":"Therapeutic approach for diarrhoea mgmt., interactive tool"
},
{
	"jumpto":"interactive_0002211",
	"name":"Therapeutic approach for diarrhoea mgmt., interactive tool"
},
{
	"jumpto":"interactive_0002853",
	"name":"Therapeutic approach in NETS with CS, interactive tool"
},
{
	"jumpto":"interactive_0002853",
	"name":"Therapeutic approach in NETS with CS [GEP-NENs]"
},
{
	"jumpto":"ENAS6343_5.3.2.2",
	"name":"Therapeutic approach in NETS with CS [GEP-NENs]"
},
{
	"jumpto":"ENAS5098_5.2.0.0",
	"name":"Therapeutic strategies, thymic carcinoma [TETs]"
},
{
	"jumpto":"ENAS5098_5.2.0.0",
	"name":"Therapeutic strategies, thymoma [TETs]"
},
{
	"jumpto":"ENAS5304_8.6.8.0",
	"name":"Therapeutic strategy, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Therapeutic strategy [mCRC]"
},
{
	"jumpto":"ENAS5644_8.3.4.0",
	"name":"Thermal tumour ablation, summary [HCC]"
},
{
	"jumpto":"ENAS5644_4.6.0.0",
	"name":"Thermal tumour ablation [HCC]"
},
{
	"jumpto":"ENAS5304_8.6.11.0",
	"name":"Third-line therapy, summary [mCRC]"
},
{
	"jumpto":"ENAS5285_9.4.2.2",
	"name":"Third-line treatment, summary [RCC]"
},
{
	"jumpto":"ENAS5285_6.2.2.6",
	"name":"Third-line treatment [RCC]"
},
{
	"jumpto":"ENAS5265_5.1.2.0",
	"name":"Thrombolytic therapy, acute treatment [VTE]"
},
{
	"jumpto":"ENAS5098_5.4.0.0",
	"name":"Thymectomy [TETs]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Thymic carcinomas [TETs]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Thymic epithelial tumours (TETs)"
},
{
	"jumpto":"ENAS6229_4.1.2.0",
	"name":"Thymic NETs, treatment [NETs]"
},
{
	"jumpto":"ENAS6229_2.3.0.0",
	"name":"Thymic NETs [NETs]"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"Thymidylate synthase (TS) activity [mCRC]"
},
{
	"jumpto":"ENAS5098_2.0.0.0",
	"name":"Thymomas [TETs]"
},
{
	"jumpto":"interactive_0001763",
	"name":"Thyroid function, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.2.1.2",
	"name":"Thyroid function monitoring, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_3.2.1.3",
	"name":"Thyroid function – TSH, interactive tool [irAEs]"
},
{
	"jumpto":"ENAS5410_4.2.2.1",
	"name":"Thyroid gland disorders, summary [irAEs]"
},
{
	"jumpto":"ENAS5410_3.2.1.1",
	"name":"Thyroid gland disorders [irAEs]"
},
{
	"jumpto":"ENAS6228_2.2.2.0",
	"name":"Thyroid gland UICC TNM 8 staging system [TC]"
},
{
	"jumpto":"ENAS6338_9.6.3.0",
	"name":"Timing of adjuvant ChT, summary [LCC]"
},
{
	"jumpto":"ENAS6338_7.3.3.0",
	"name":"Timing of adjuvant ChT [LCC]"
},
{
	"jumpto":"ENAS5262_5.5.1.0",
	"name":"Tinzaparin [CVC]"
},
{
	"jumpto":"ENAS5304_8.3.0.0",
	"name":"Tissue handling, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_8.4.0.0",
	"name":"Tissue selection for biomarker testing, summary [mCRC]"
},
{
	"jumpto":"ENAS5407_3.6.2.0",
	"name":"TNM pathological classification [Rectal CA]"
},
{
	"jumpto":"ENAS5283_3.2.0.0",
	"name":"TNM staging (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_3.2.0.0",
	"name":"TNM staging (Oes CA)"
},
{
	"jumpto":"ENAS5407_3.4.0.0",
	"name":"TNM staging, rectal cancer"
},
{
	"jumpto":"ENAS5071_3.2.0.0",
	"name":"TNM staging, SCLC"
},
{
	"jumpto":"ENAS5098_4.3.0.0",
	"name":"TNM staging, TETs"
},
{
	"jumpto":"ENAS6229_3.0.0.0",
	"name":"TNM staging classification system of NETs of the lung [NETs]"
},
{
	"jumpto":"ENAS5406_4.4.0.0",
	"name":"TNM staging [Early NSCLC]"
},
{
	"jumpto":"ENAS5285_5.1.0.0",
	"name":"TNM staging [RCC]"
},
{
	"jumpto":"ENAS5304_5.3.0.0",
	"name":"Toolbox of ablative treatments [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.5.0",
	"name":"Toolbox of LATs, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.12.0.0",
	"name":"Toolbox of LATs [mCRC]"
},
{
	"jumpto":"ENAS5267_7.5.0.0",
	"name":"Topical DMSO [Extra]"
},
{
	"jumpto":"ENAS6341_4.1.4.3",
	"name":"Topical local intervention, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.4.3.0",
	"name":"Topical local intervention [PCN]"
},
{
	"jumpto":"ENAS5263_11.4.0.0",
	"name":"Topical [Mucosa]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Topoisomerase II inhibitors [Extra]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Topoisomerase I inhibitors [Extra]"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Topotecan, second-line treatment [SCLC]"
},
{
	"jumpto":"ENAS5268_2.9.0.0",
	"name":"Total body irradiation [N/V]"
},
{
	"jumpto":"ENAS5268_3.3.0.0",
	"name":"Total nodal irradiation [N/V]"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"Total testosterone [TS/T-NS]"
},
{
	"jumpto":"ENAS5304_8.5.4.0",
	"name":"Toxicity biomarkers, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"Toxicity biomarkers [mCRC]"
},
{
	"jumpto":"ENAS5282_7.2.0.0",
	"name":"Tracheo-bronchoscopy, summary (Oes CA)"
},
{
	"jumpto":"ENAS5262_4.3.8.0",
	"name":"Trans-oesophageal echocardiogram [CVC]"
},
{
	"jumpto":"ENAS5304_5.3.0.0",
	"name":"Transarterial chemoembolisation (TACE) [mCRC]"
},
{
	"jumpto":"ENAS5644_8.3.6.0",
	"name":"Transarterial chemoembolisation, summary [HCC]"
},
{
	"jumpto":"ENAS5644_4.9.0.0",
	"name":"Transarterial chemoembolisation [HCC]"
},
{
	"jumpto":"ENAS5644_4.8.0.0",
	"name":"Transarterial therapies [HCC]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Transdermal fentanyl [Mucosa]"
},
{
	"jumpto":"ENAS5304_4.2.5.0",
	"name":"Transforming growth factor-α [mCRC]"
},
{
	"jumpto":"ENAS5282_4.1.3.0",
	"name":"Transthoracic oesophagectomy, surgical technique (Oes CA)"
},
{
	"jumpto":"ENAS5094_2.0.0.0",
	"name":"Transurethral resection of the bladder tumour (TURBT)"
},
{
	"jumpto":"ENAS5409_11.2.4.0",
	"name":"Trastuzumab [IRs]"
},
{
	"jumpto":"interactive_0002174",
	"name":"Treat. for stage IV lung CA with EGFR-activating mutation, interactive tool"
},
{
	"jumpto":"interactive_0002172",
	"name":"Treat. for stage IV NSCC with molecular tests negative, interactive tool"
},
{
	"jumpto":"ENAS6346_15.4.0.0",
	"name":"Treat. of ER-positive/HER2-negative ABC, interactive tool"
},
{
	"jumpto":"interactive_0002861",
	"name":"Treat. of ER-positive/HER2-negative ABC, interactive tool"
},
{
	"jumpto":"ENAS5282_4.1.2.0",
	"name":"Treat. of local/ locoregional Oes CA, interactive tool"
},
{
	"jumpto":"interactive_0002176",
	"name":"Treat. of stage IV lung CA with ALK translocation, interactive tool"
},
{
	"jumpto":"interactive_0002178",
	"name":"Treat. of stage IV lung CA with BRAF V600 mutation, interactive tool"
},
{
	"jumpto":"interactive_0002177",
	"name":"Treat. of stage IV lung CA with ROS1 translocation, interactive tool"
},
{
	"jumpto":"ENAS5283_4.1.0.0",
	"name":"Treatment (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_4.1.1.0",
	"name":"Treatment (Oes CA)"
},
{
	"jumpto":"ENAS5633_4.1.1.0",
	"name":"Treatment, ALL [ALL]"
},
{
	"jumpto":"ENAS5262_5.4.0.0",
	"name":"Treatment, catheter-induced thrombosis [CVC]"
},
{
	"jumpto":"ENAS5262_5.5.1.0",
	"name":"Treatment, catheter-related thrombosis [CVC]"
},
{
	"jumpto":"ENAS5279_4.1.0.0",
	"name":"Treatment, CLL"
},
{
	"jumpto":"ENAS5271_4.4.0.0",
	"name":"Treatment, CNS prophylaxis (DLBCL)"
},
{
	"jumpto":"ENAS5262_4.3.1.0",
	"name":"Treatment, CVC infections"
},
{
	"jumpto":"ENAS5271_4.1.0.0",
	"name":"Treatment, DLBCL"
},
{
	"jumpto":"ENAS5278_4.1.0.0",
	"name":"Treatment, DLBCL-PMBCL"
},
{
	"jumpto":"ENAS5407_4.3.2.0",
	"name":"Treatment, early rectal cancer not suitable for local excision"
},
{
	"jumpto":"ENAS5304_5.14.10.4",
	"name":"Treatment, elderly patients [mCRC]"
},
{
	"jumpto":"ENAS6342_7.3.1.0",
	"name":"Treatment, EMZL, summary [MZLs]"
},
{
	"jumpto":"ENAS6342_4.1.1.1",
	"name":"Treatment, EMZL [MZLs]"
},
{
	"jumpto":"ENAS5304_5.14.10.2",
	"name":"Treatment, fit patients with symptomatic disease [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Treatment, fit patients [mCRC]"
},
{
	"jumpto":"ENAS5273_5.1.1.0",
	"name":"Treatment, FL"
},
{
	"jumpto":"ENAS5280_4.1.0.0",
	"name":"Treatment, HCL"
},
{
	"jumpto":"ENAS5407_4.3.3.0",
	"name":"Treatment, intermediate/more locally advanced rectal cancer"
},
{
	"jumpto":"ENAS5284_4.1.0.0",
	"name":"Treatment, introduction [Bil]"
},
{
	"jumpto":"ENAS5071_4.2.0.0",
	"name":"Treatment, localised disease [SCLC]"
},
{
	"jumpto":"ENAS5406_5.2.1.0",
	"name":"Treatment, locally advanced (stage III) NSCLC [Early NSCLC]"
},
{
	"jumpto":"ENAS5407_4.3.4.0",
	"name":"Treatment, locally advanced rectal cancer"
},
{
	"jumpto":"ENAS5285_6.2.1.0",
	"name":"Treatment, management of metastatic disease [RCC]"
},
{
	"jumpto":"ENAS5304_5.14.1.0",
	"name":"Treatment, metastatic disease [mCRC]"
},
{
	"jumpto":"ENAS5285_6.1.1.0",
	"name":"Treatment, mgmt. of local/ locoregional disease [RCC]"
},
{
	"jumpto":"ENAS6342_7.3.3.0",
	"name":"Treatment, NMZL, summary [MZLs]"
},
{
	"jumpto":"ENAS6342_4.3.0.0",
	"name":"Treatment, NMZL [MZLs]"
},
{
	"jumpto":"ENAS5285_6.2.2.7",
	"name":"Treatment, non-clear cell histology [RCC]"
},
{
	"jumpto":"ENAS5406_5.1.1.0",
	"name":"Treatment, NSCLC stages I and II [Early NSCLC]"
},
{
	"jumpto":"ENAS5646_4.1.0.0",
	"name":"Treatment, overview [PCLs]"
},
{
	"jumpto":"ENAS5278_4.5.0.0",
	"name":"Treatment, PBL"
},
{
	"jumpto":"ENAS5278_4.6.0.0",
	"name":"Treatment, PBoL"
},
{
	"jumpto":"ENAS5278_4.4.0.0",
	"name":"Treatment, PCNSL"
},
{
	"jumpto":"ENAS5278_4.2.0.0",
	"name":"Treatment, PMBCL"
},
{
	"jumpto":"ENAS5277_4.1.0.0",
	"name":"Treatment, PTCL"
},
{
	"jumpto":"ENAS5278_4.3.0.0",
	"name":"Treatment, PTL"
},
{
	"jumpto":"ENAS5407_4.2.0.0",
	"name":"Treatment, rectal cancer without distant mets. [Rectal CA]"
},
{
	"jumpto":"ENAS5407_4.3.5.0",
	"name":"Treatment, rectal tumours with threatened resection margin [Rectal CA]"
},
{
	"jumpto":"ENAS5265_5.4.0.0",
	"name":"Treatment, recurrent VTE"
},
{
	"jumpto":"ENAS5271_5.2.2.0",
	"name":"Treatment, response evaluation and FU (DLBCL)"
},
{
	"jumpto":"ENAS5271_7.4.2.2",
	"name":"Treatment, response evaluation and FU in DLBCL, summary"
},
{
	"jumpto":"ENAS6342_7.3.2.0",
	"name":"Treatment, SMZL, summary [MZLs]"
},
{
	"jumpto":"ENAS6342_4.2.0.0",
	"name":"Treatment, SMZL [MZLs]"
},
{
	"jumpto":"ENAS5271_4.5.0.0",
	"name":"Treatment, special considerations for some DLBCLs"
},
{
	"jumpto":"ENAS5406_5.1.1.0",
	"name":"Treatment, stage II [Early NSCLC]"
},
{
	"jumpto":"ENAS5406_5.1.1.0",
	"name":"Treatment, stage I [Early NSCLC]"
},
{
	"jumpto":"ENAS5283_8.3.1.1",
	"name":"Treatment, summary (Gastric cancer)"
},
{
	"jumpto":"ENAS5282_7.3.1.1",
	"name":"Treatment, summary (Oes CA)"
},
{
	"jumpto":"ENAS6365_8.4.0.0",
	"name":"Treatment, summary [Bone health]"
},
{
	"jumpto":"ENAS6235_7.3.1.0",
	"name":"Treatment, summary [EBC]"
},
{
	"jumpto":"ENAS6370_8.4.1.0",
	"name":"Treatment, summary [Endometrial CA]"
},
{
	"jumpto":"ENAS6371_7.3.1.0",
	"name":"Treatment, summary [GTD]"
},
{
	"jumpto":"ENAS5304_8.6.1.0",
	"name":"Treatment, summary [mCRC]"
},
{
	"jumpto":"ENAS6342_7.3.1.0",
	"name":"Treatment, summary [MZLs]"
},
{
	"jumpto":"ENAS5646_7.3.1.0",
	"name":"Treatment, summary [PCLs]"
},
{
	"jumpto":"ENAS5304_5.14.10.3",
	"name":"Treatment, unfit patients [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Treatment, unfit patients [mCRC]"
},
{
	"jumpto":"ENAS5407_4.3.1.0",
	"name":"Treatment, very early rectal cancer"
},
{
	"jumpto":"ENAS5071_4.1.0.0",
	"name":"Treatment algorithm, SCLC"
},
{
	"jumpto":"interactive_0002878",
	"name":"Treatment algorithm for cervical cancer, interactive tool"
},
{
	"jumpto":"ENAS6369_4.1.0.0",
	"name":"Treatment algorithm for cervical cancer, interactive tool"
},
{
	"jumpto":"interactive_0002843",
	"name":"Treatment algorithm for localised gastric MZL, interactive tool"
},
{
	"jumpto":"ENAS6342_4.1.1.2",
	"name":"Treatment algorithm for localised gastric MZL [MZLs]"
},
{
	"jumpto":"ENAS5649_6.2.3.0",
	"name":"Treatment algorithm for patients with newly diagnosed Wm"
},
{
	"jumpto":"ENAS5649_6.3.2.0",
	"name":"Treatment algorithm for patients with relapsed and refractory Wm"
},
{
	"jumpto":"ENAS5643_4.6.2.0",
	"name":"Treatment algorithm for stage IV SCC, interactive tool"
},
{
	"jumpto":"interactive_0002171",
	"name":"Treatment algorithm for stage IV SCC, interactive tool"
},
{
	"jumpto":"interactive_0002844",
	"name":"Treatment algorithms for advanced gastric MZL and non-gastric EMZL, interactive tool"
},
{
	"jumpto":"ENAS6342_4.1.1.3",
	"name":"Treatment algorithms for advanced gastric MZL and non-gastric EMZL [MZLs]"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Treatment algorithms [TETs]"
},
{
	"jumpto":"ENAS5647_14.3.1.0",
	"name":"Treatment approaches for diarrhea"
},
{
	"jumpto":"ENAS5647_20.12.2.0",
	"name":"Treatment approaches for diarrhoea, summary"
},
{
	"jumpto":"ENAS5262_6.3.3.4",
	"name":"Treatment duration, summary [CVC]"
},
{
	"jumpto":"ENAS5262_4.3.6.0",
	"name":"Treatment duration [CVC]"
},
{
	"jumpto":"ENAS5280_4.7.0.0",
	"name":"Treatment during pregnancy, HCL"
},
{
	"jumpto":"ENAS5649_6.2.3.0",
	"name":"Treatment for newly diagnosed Wm"
},
{
	"jumpto":"interactive_0002091",
	"name":"Treatment for patients with newly diagnosed WM [tool]"
},
{
	"jumpto":"ENAS5649_6.3.2.0",
	"name":"Treatment for relapsed and refractory Wm"
},
{
	"jumpto":"ENAS6343_8.4.3.1",
	"name":"Treatment for symptom control, summary [GEP-NENs]"
},
{
	"jumpto":"ENAS6343_5.3.2.1",
	"name":"Treatment for symptom control [GEP-NENs]"
},
{
	"jumpto":"ENAS5062_8.3.5.0",
	"name":"Treatment in elderly with anal cancer, summary"
},
{
	"jumpto":"interactive_0002857",
	"name":"Treatment of ACC amenable to complete resection, interactive tool"
},
{
	"jumpto":"interactive_0002858",
	"name":"Treatment of ACC amenable to complete resection, interactive tool"
},
{
	"jumpto":"ENAS6344_5.1.2.2",
	"name":"Treatment of ACC amenable to complete resection, interactive tool [ACC]"
},
{
	"jumpto":"ENAS6344_5.1.2.2",
	"name":"Treatment of ACC amenable to complete resection [ACC]"
},
{
	"jumpto":"interactive_0002857",
	"name":"Treatment of ACC amenable to complete resection [ACC]"
},
{
	"jumpto":"ENAS6338_9.3.1.0",
	"name":"Treatment of adenocarcinomas presenting in adenomas, summary [LCC]"
},
{
	"jumpto":"ENAS6338_4.1.1.0",
	"name":"Treatment of adenocarcinomas presenting in adenomas [LCC]"
},
{
	"jumpto":"ENAS5279_4.2.1.0",
	"name":"Treatment of advanced-stage disease, CLL"
},
{
	"jumpto":"ENAS5279_7.3.2.1",
	"name":"Treatment of advanced-stage disease in CLL, summary"
},
{
	"jumpto":"interactive_0002859",
	"name":"Treatment of advanced ACC, interactive tool"
},
{
	"jumpto":"ENAS6344_6.1.2.0",
	"name":"Treatment of advanced ACC, interactive tool [ACC]"
},
{
	"jumpto":"interactive_0002859",
	"name":"Treatment of advanced ACC [ACC]"
},
{
	"jumpto":"ENAS6344_6.1.2.0",
	"name":"Treatment of advanced ACC [ACC]"
},
{
	"jumpto":"ENAS6229_4.2.0.0",
	"name":"Treatment of advanced metastatic bronchial and thymic NETs [NETs]"
},
{
	"jumpto":"interactive_0002860",
	"name":"Treatment of advanced PPGL, interactive tool"
},
{
	"jumpto":"ENAS6344_6.2.2.0",
	"name":"Treatment of advanced PPGL, interactive tool [ACC]"
},
{
	"jumpto":"ENAS6344_6.2.2.0",
	"name":"Treatment of advanced PPGL [ACC]"
},
{
	"jumpto":"interactive_0002860",
	"name":"Treatment of advanced PPGL [ACC]"
},
{
	"jumpto":"ENAS5098_5.7.0.0",
	"name":"Treatment of advanced TETs"
},
{
	"jumpto":"ENAS5643_4.12.1.1",
	"name":"Treatment of ALK-rearranged NSCLC"
},
{
	"jumpto":"ENAS5643_6.3.12.1",
	"name":"Treatment of ALK-rearranged NSCLC, summary"
},
{
	"jumpto":"ENAS5637_10.5.2.0",
	"name":"Treatment of anaemia, summary [MDS]"
},
{
	"jumpto":"ENAS5643_4.14.1.0",
	"name":"Treatment of BRAF-mutated NSCLC"
},
{
	"jumpto":"ENAS5643_6.3.14.0",
	"name":"Treatment of BRAF-mutated NSCLC, summary"
},
{
	"jumpto":"ENAS6229_4.1.1.0",
	"name":"Treatment of bronchial NETs [NETs]"
},
{
	"jumpto":"ENAS5262_6.4.4.0",
	"name":"Treatment of catheter-induced thrombosis, summary [CVC]"
},
{
	"jumpto":"ENAS5645_6.1.1.0",
	"name":"Treatment of cHL, limited-stage disease [HL]"
},
{
	"jumpto":"ENAS5645_11.3.1.0",
	"name":"Treatment of cHL, summary"
},
{
	"jumpto":"ENAS5647_14.6.0.0",
	"name":"Treatment of chronic RT-induced diarrhoea"
},
{
	"jumpto":"ENAS5647_20.12.5.0",
	"name":"Treatment of chronic RT-induced diarrhoea, summary"
},
{
	"jumpto":"ENAS6341_4.1.4.1",
	"name":"Treatment of CIPN, summary [PCN]"
},
{
	"jumpto":"ENAS6341_2.4.1.0",
	"name":"Treatment of CIPN [PCN]"
},
{
	"jumpto":"ENAS5279_4.2.5.0",
	"name":"Treatment of CLL, complications"
},
{
	"jumpto":"ENAS5279_4.2.2.1",
	"name":"Treatment of CLL, front-line"
},
{
	"jumpto":"ENAS5279_7.3.1.0",
	"name":"Treatment of CLL, summary"
},
{
	"jumpto":"ENAS5279_7.3.2.5",
	"name":"Treatment of CLL complications, summary"
},
{
	"jumpto":"ENAS5092_7.3.2.2",
	"name":"Treatment of CRPC, summary [PC]"
},
{
	"jumpto":"ENAS5262_6.3.3.1",
	"name":"Treatment of CVC infections, summary"
},
{
	"jumpto":"ENAS5271_7.3.1.0",
	"name":"Treatment of DLBCL, summary"
},
{
	"jumpto":"ENAS5278_7.3.1.0",
	"name":"Treatment of DLBCL-PMBCL, summary"
},
{
	"jumpto":"ENAS5279_7.3.1.0",
	"name":"Treatment of early-stage disease in CLL, summary"
},
{
	"jumpto":"ENAS5407_9.3.1.2",
	"name":"Treatment of early rectal cancer not suitable for local excision, summary"
},
{
	"jumpto":"ENAS5279_4.1.0.0",
	"name":"Treatment of early stage disease, CLL"
},
{
	"jumpto":"ENAS5643_4.11.1.1",
	"name":"Treatment of EGFR-mutated NSCLC"
},
{
	"jumpto":"ENAS5643_6.3.11.1",
	"name":"Treatment of EGFR-mutated NSCLC, summary"
},
{
	"jumpto":"ENAS5408_7.3.3.0",
	"name":"Treatment of elderly patients of MCL, summary"
},
{
	"jumpto":"ENAS5408_4.4.0.0",
	"name":"Treatment of elderly patients [MCL]"
},
{
	"jumpto":"ENAS5273_8.3.1.0",
	"name":"Treatment of FL, Summary"
},
{
	"jumpto":"ENAS5280_7.3.1.0",
	"name":"Treatment of HCL, summary"
},
{
	"jumpto":"ENAS5280_4.9.0.0",
	"name":"Treatment of HCL-V"
},
{
	"jumpto":"ENAS5280_7.3.9.0",
	"name":"Treatment of HCL-V, summary"
},
{
	"jumpto":"interactive_0002863",
	"name":"Treatment of HER2-positive ABC, interactive tool"
},
{
	"jumpto":"ENAS6346_15.5.0.0",
	"name":"Treatment of HER2-positive ABC, interactive tool"
},
{
	"jumpto":"ENAS5637_8.3.0.0",
	"name":"Treatment of high-risk MDS, interactive tool"
},
{
	"jumpto":"interactive_0002133",
	"name":"Treatment of high-risk MDS, interactive tool"
},
{
	"jumpto":"ENAS6339_4.3.0.0",
	"name":"Treatment of hyperlipidaemia during anticancer therapy [CVD]"
},
{
	"jumpto":"ENAS5647_20.12.3.0",
	"name":"Treatment of immunotherapy-induced diarrhoea and colitis, summary"
},
{
	"jumpto":"ENAS5647_14.4.0.0",
	"name":"Treatment of immunotherapy-induced diarrhoea and colitis [Diarrh.]"
},
{
	"jumpto":"ENAS5407_9.3.1.3",
	"name":"Treatment of intermediate rectal cancer, summary"
},
{
	"jumpto":"ENAS6346_15.3.0.0",
	"name":"Treatment of LABC, interactive tool"
},
{
	"jumpto":"interactive_0002108",
	"name":"Treatment of LABC, interactive tool"
},
{
	"jumpto":"ENAS5071_6.3.1.0",
	"name":"Treatment of localised SCLC, summary"
},
{
	"jumpto":"ENAS5407_9.3.1.4",
	"name":"Treatment of locally advanced rectal cancer, summary"
},
{
	"jumpto":"ENAS5407_5.2.0.0",
	"name":"Treatment of local recurrence of rectal cancer, tool [Rectal CA]"
},
{
	"jumpto":"interactive_0002132",
	"name":"Treatment of low-risk MDS, interactive tool"
},
{
	"jumpto":"ENAS5637_8.2.0.0",
	"name":"Treatment of low-risk MDS, interactive tool"
},
{
	"jumpto":"ENAS5408_7.3.1.0",
	"name":"Treatment of MCL, summary"
},
{
	"jumpto":"ENAS5304_8.6.7.0",
	"name":"Treatment of metastatic disease, summary [mCRC]"
},
{
	"jumpto":"ENAS5407_6.2.0.0",
	"name":"Treatment of metastatic disease, tool [Rectal CA]"
},
{
	"jumpto":"ENAS5068_8.3.6.0",
	"name":"Treatment of metastatic pancreatic cancer, summary"
},
{
	"jumpto":"ENAS5071_6.3.2.0",
	"name":"Treatment of metastatic SCLC, summary"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Treatment of metastatic TETs, interactive tool"
},
{
	"jumpto":"ENAS5094_9.3.2.0",
	"name":"Treatment of MIBC, summary"
},
{
	"jumpto":"ENAS5086_7.4.1.0",
	"name":"Treatment of MPM, summary"
},
{
	"jumpto":"ENAS5637_10.5.5.0",
	"name":"Treatment of neutropenia and thrombocytopenia, summary [MDS]"
},
{
	"jumpto":"ENAS5637_6.5.0.0",
	"name":"Treatment of neutropenia and thrombocytopenia [MDS]"
},
{
	"jumpto":"ENAS5633_4.1.1.0",
	"name":"Treatment of newly diagnosed ALL [ALL]"
},
{
	"jumpto":"ENAS5645_7.1.0.0",
	"name":"Treatment of NLPHL"
},
{
	"jumpto":"ENAS5645_11.4.1.0",
	"name":"Treatment of NLPHL, summary"
},
{
	"jumpto":"ENAS5094_9.3.1.0",
	"name":"Treatment of NMIBC, summary"
},
{
	"jumpto":"ENAS5068_8.3.5.0",
	"name":"Treatment of non-resectable pancreatic cancer, summary"
},
{
	"jumpto":"ENAS5643_6.3.15.0",
	"name":"Treatment of NSCLC with other actionable oncogenic drivers, summary"
},
{
	"jumpto":"ENAS5643_4.15.0.0",
	"name":"Treatment of NSCLC with other onco. Drivers"
},
{
	"jumpto":"ENAS5643_6.3.20.0",
	"name":"Treatment of oligometastatic disease, summary [mNSCLC]"
},
{
	"jumpto":"ENAS5278_7.3.5.0",
	"name":"Treatment of PBL, summary"
},
{
	"jumpto":"ENAS5278_7.3.6.0",
	"name":"Treatment of PBoL, summary"
},
{
	"jumpto":"ENAS5278_7.3.4.0",
	"name":"Treatment of PCNSL, summary"
},
{
	"jumpto":"ENAS5096_7.3.1.0",
	"name":"Treatment of PenCa, summary"
},
{
	"jumpto":"ENAS5278_7.3.2.0",
	"name":"Treatment of PMBCL, summary"
},
{
	"jumpto":"ENAS6344_5.2.2.2",
	"name":"Treatment of PPGL amenable to complete resection, interactive tool [ACC]"
},
{
	"jumpto":"ENAS6344_5.2.2.2",
	"name":"Treatment of PPGL amenable to complete resection [ACC]"
},
{
	"jumpto":"interactive_0002858",
	"name":"Treatment of PPGL amenable to complete resection [ACC]"
},
{
	"jumpto":"ENAS6366_2020112724",
	"name":"Treatment of primary ovarian cancer, summary [EOC]"
},
{
	"jumpto":"ENAS5277_7.3.1.0",
	"name":"Treatment of PTCL, summary"
},
{
	"jumpto":"ENAS5278_7.3.3.0",
	"name":"Treatment of PTL, summary"
},
{
	"jumpto":"ENAS5098_5.11.0.0",
	"name":"Treatment of recurrences in TETs"
},
{
	"jumpto":"ENAS5098_8.3.9.0",
	"name":"Treatment of recurrences in TETs, summary"
},
{
	"jumpto":"ENAS6366_2020112714",
	"name":"Treatment of recurrent ovarian cancer [EOC]"
},
{
	"jumpto":"ENAS5265_8.4.4.0",
	"name":"Treatment of recurrent VTE, summary"
},
{
	"jumpto":"ENAS5640_8.2.0.0",
	"name":"Treatment of relapse, interactive tool"
},
{
	"jumpto":"interactive_0002131",
	"name":"Treatment of relapse, interactive tool"
},
{
	"jumpto":"ENAS5092_7.3.1.4",
	"name":"Treatment of relapse of PC, summary"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Treatment of resectable TETs, interactive tool"
},
{
	"jumpto":"ENAS5643_4.13.1.0",
	"name":"Treatment of ROS1-rearranged NSCLC"
},
{
	"jumpto":"ENAS5643_6.3.13.0",
	"name":"Treatment of ROS1-rearranged NSCLC, summary"
},
{
	"jumpto":"ENAS6229_4.1.2.0",
	"name":"Treatment of thymic NETs [NETs]"
},
{
	"jumpto":"ENAS6346_15.6.0.0",
	"name":"Treatment of triple negative ABC, interactive tool"
},
{
	"jumpto":"interactive_0002862",
	"name":"Treatment of triple negative ABC, interactive tool"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Treatment of unresectable TETs. Interactive tool"
},
{
	"jumpto":"ENAS5408_7.3.4.0",
	"name":"Treatment of younger patients of MCL, summary"
},
{
	"jumpto":"ENAS5408_4.5.0.0",
	"name":"Treatment of younger patients [MCL]"
},
{
	"jumpto":"ENAS6338_9.6.1.0",
	"name":"Treatment options, summary [LCC]"
},
{
	"jumpto":"ENAS5649_6.2.2.0",
	"name":"Treatment options in first line according to disease presentation [WM]"
},
{
	"jumpto":"ENAS5646_4.8.3.0",
	"name":"Treatment recommendations for initial management of PCLBCL-LT [PCLs]"
},
{
	"jumpto":"ENAS5646_4.8.2.0",
	"name":"Treatment recommendations for initial management of PCMZL and PCFCL [PCLs]"
},
{
	"jumpto":"ENAS5271_4.2.5.0",
	"name":"Treatment strategies, >2 relapses/ progressions (DLBCL)"
},
{
	"jumpto":"ENAS5271_4.2.1.0",
	"name":"Treatment strategies, DLBCL"
},
{
	"jumpto":"ENAS5271_4.2.3.0",
	"name":"Treatment strategies, elderly >60 years (DLBCL)"
},
{
	"jumpto":"ENAS5271_4.2.4.0",
	"name":"Treatment strategies, first relapse/ progression (DLBCL)"
},
{
	"jumpto":"ENAS5271_4.2.2.0",
	"name":"Treatment strategies, patients ≤60 years (DLBCL)"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Treatment stratification [mCRC]"
},
{
	"jumpto":"ENAS5271_4.3.0.0",
	"name":"Treatment stratified according to age, DLBCL"
},
{
	"jumpto":"ENAS5648_3.4.2.0",
	"name":"Treatment with IV iron, clinical evidence [Anaemia]"
},
{
	"jumpto":"ENAS6365_5.1.0.0",
	"name":"Treatment [Bone health]"
},
{
	"jumpto":"ENAS5615_8.1.0.0",
	"name":"Treatment [BRCA]"
},
{
	"jumpto":"ENAS6235_4.1.0.0",
	"name":"Treatment [EBC]"
},
{
	"jumpto":"ENAS6370_5.1.0.0",
	"name":"Treatment [Endometrial CA]"
},
{
	"jumpto":"ENAS6371_4.1.0.0",
	"name":"Treatment [GTD]"
},
{
	"jumpto":"ENAS5408_4.1.0.0",
	"name":"Treatment [MCL]"
},
{
	"jumpto":"ENAS5304_5.1.0.0",
	"name":"Treatment [mCRC]"
},
{
	"jumpto":"ENAS5304_5.1.0.0",
	"name":"Treatment [mCRC]"
},
{
	"jumpto":"ENAS6342_4.1.1.1",
	"name":"Treatment [MZLs]"
},
{
	"jumpto":"ENAS5304_5.14.5.0",
	"name":"Trifluridine/tipiracil [mCRC]"
},
{
	"jumpto":"ENAS5268_2.3.2.0",
	"name":"Tropisetron [N/V]"
},
{
	"jumpto":"ENAS5092_2.0.0.0",
	"name":"TRUS guided prostate biopsy [PC]"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"TS/T-NS, diagnosis"
},
{
	"jumpto":"ENAS5097_6.0.0.0",
	"name":"TS/T-NS, follow-up and surveillance"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"TS/T-NS, iso-chromosome 12p"
},
{
	"jumpto":"ENAS5097_5.0.0.0",
	"name":"TS/T-NS, personalised medicine"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"TS/T-NS, post-orchiectomy staging"
},
{
	"jumpto":"ENAS5097_4.3.2.0",
	"name":"TS/T-NS, standard treatment strategies"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"TS/T-NS, syncytiotrophoblasts"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"TS/T-NS, TNM staging"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"TS/T-NS, WHO classification"
},
{
	"jumpto":"ENAS5097_7.1.0.0",
	"name":"TS/T-NS diagnosis, summary"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"TS/T-NS staging"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"TS/T-NS staging, for metastatic disease"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"TS/T-NS staging, for stage I disease"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"TS/T-NS staging, IGCCCG prognostic groups"
},
{
	"jumpto":"ENAS5097_3.2.0.0",
	"name":"TS/T-NS staging, serum tumour markers"
},
{
	"jumpto":"ENAS5097_7.2.0.0",
	"name":"TS/T-NS staging, summary"
},
{
	"jumpto":"ENAS5097_4.1.0.0",
	"name":"TS/T-NS treatment"
},
{
	"jumpto":"ENAS5097_4.1.0.0",
	"name":"TS/T-NS treatment, chemotherapy regimens"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"TS/T-NS treatment, for stage I"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"TS/T-NS treatment, for stage IIA"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"TS/T-NS treatment, for stage IIB/ IIC"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"TS/T-NS treatment, for stage III"
},
{
	"jumpto":"ENAS5097_4.3.1.0",
	"name":"TS/T-NS treatment, overview"
},
{
	"jumpto":"ENAS5097_4.2.0.0",
	"name":"TS/T-NS treatment chemotherapy regimens, summary"
},
{
	"jumpto":"ENAS5097_4.6.0.0",
	"name":"TS/T-NS treatment in late relapse"
},
{
	"jumpto":"ENAS5097_4.7.0.0",
	"name":"TS/T-NS treatment in late toxicity"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"TS enhancer region (TSER) genotyping [mCRC]"
},
{
	"jumpto":"ENAS5097_7.3.1.0",
	"name":"TS treatment, summary"
},
{
	"jumpto":"ENAS5068_3.0.0.0",
	"name":"Tumor marker (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5071_3.3.0.0",
	"name":"Tumor stage grouping, SCLC"
},
{
	"jumpto":"ENAS5304_5.14.1.0",
	"name":"Tumour biology [mCRC]"
},
{
	"jumpto":"ENAS5273_7.3.0.0",
	"name":"Tumour burden: Low/high, interactive tool"
},
{
	"jumpto":"ENAS5304_5.14.1.0",
	"name":"Tumour burden [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Tumour marker measurements [mCRC]"
},
{
	"jumpto":"ENAS5097_3.1.0.0",
	"name":"Tumour markers in staging [TS/T-NS]"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"Tumour markers [TS/T-NS]"
},
{
	"jumpto":"ENAS5062_4.4.1.0",
	"name":"Tumour shrinkage"
},
{
	"jumpto":"ENAS5407_9.3.1.5",
	"name":"Tumours with threatened resection margin, summary"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"TURBT [BC]"
},
{
	"jumpto":"ENAS5643_4.2.0.0",
	"name":"Tx. of EGFR- & ALK-neg., PD-L1 ≥ 50% [mNSCLC]"
},
{
	"jumpto":"ENAS5643_4.3.0.0",
	"name":"Tx. of EGFR- & ALK-neg., regardless of PD-L1 [mNSCLC]"
},
{
	"jumpto":"ENAS5643_4.6.3.0",
	"name":"Tx. of stage IV NSCC: molecular tests negative, interactive tool"
},
{
	"jumpto":"ENAS5643_4.6.4.0",
	"name":"Tx. of stage IV NSCC: molecular tests positive, interactive tool"
},
{
	"jumpto":"interactive_0002173",
	"name":"Tx. of stage IV NSCC with molecular tests positive, interactive tool"
},
{
	"jumpto":"ENAS5280_7.3.7.0",
	"name":"Tx during pregnancy in HCL, summary"
},
{
	"jumpto":"interactive_0002095",
	"name":"Tx for advanced-stage HL in patients [tool]"
},
{
	"jumpto":"ENAS5645_6.3.2.0",
	"name":"Tx for advanced-stage HL in patients ≤ 60 yrs"
},
{
	"jumpto":"interactive_0002869",
	"name":"Tx for bone metastases & myeloma disease, interactive tool"
},
{
	"jumpto":"ENAS6365_5.5.2.0",
	"name":"Tx for bone metastases & myeloma disease, interactive tool"
},
{
	"jumpto":"interactive_0002094",
	"name":"Tx for intermediate-stage HL in patients [tool]"
},
{
	"jumpto":"ENAS5645_6.2.2.0",
	"name":"Tx for intermediate-stage HL in patients ≤ 60 yrs"
},
{
	"jumpto":"interactive_0002093",
	"name":"Tx for limited-stage HL in patients &le; 60 years [tool]"
},
{
	"jumpto":"ENAS5645_6.1.2.0",
	"name":"Tx for limited-stage HL in patients ≤ 60 yrs"
},
{
	"jumpto":"ENAS5643_4.12.1.2",
	"name":"Tx for stage IV lung CA with ALK translocation, interactive tool"
},
{
	"jumpto":"ENAS5643_4.14.2.0",
	"name":"Tx for stage IV lung CA with BRAF V600 mutation, interactive tool"
},
{
	"jumpto":"ENAS5643_4.11.1.2",
	"name":"Tx for stage IV lung CA with EGFR-activating mutation, interactive tool"
},
{
	"jumpto":"ENAS5643_4.13.2.0",
	"name":"Tx for stage IV lung CA with ROS1 translocation, interactive tool"
},
{
	"jumpto":"ENAS6366_202011276",
	"name":"Tx of primary ovarian cancer [EOC]"
},
{
	"jumpto":"ENAS6366_2020112728",
	"name":"Tx of recurrent ovarian CA, summary [EOC]"
},
{
	"jumpto":"ENAS5279_4.2.3.1",
	"name":"Tx of relapsed and refractory disease, CLL"
},
{
	"jumpto":"ENAS5279_7.3.2.3",
	"name":"Tx of relapsed and refractory disease in CLL, summary"
},
{
	"jumpto":"ENAS5280_4.4.1.0",
	"name":"Tx of replapse & refra. pts., HCL"
},
{
	"jumpto":"ENAS5280_7.3.4.0",
	"name":"Tx of replapse & refra. pts., summary"
},
{
	"jumpto":"ENAS5649_6.2.2.0",
	"name":"Tx options according to disease presentation [WM]"
},
{
	"jumpto":"ENAS5410_4.2.2.3",
	"name":"Type 1 diabetes mellitus, summary [irAEs]"
},
{
	"jumpto":"ENAS5068_5.7.2.0",
	"name":"Tyrosine kinase inhibitor (TKI)"
},
{
	"jumpto":"ENAS5633_4.1.6.3",
	"name":"Tyrosine kinase inhibitors in Ph+ ALL"
},
{
	"jumpto":"ENAS5633_4.1.6.4",
	"name":"Tyrosine kinase inhibitors in Ph-like ALL"
},
{
	"jumpto":"ENAS5644_3.2.0.0",
	"name":"UICC 8th edition staging system for HCC"
},
{
	"jumpto":"ENAS5285_5.2.1.3",
	"name":"UISS risk groups [RCC]"
},
{
	"jumpto":"ENAS5094_3.1.0.0",
	"name":"Ultrasonography [BC]"
},
{
	"jumpto":"ENAS5096_6.3.0.0",
	"name":"Ultrasound-guided FNAC biopsy [PenCa]"
},
{
	"jumpto":"ENAS5647_14.2.1.0",
	"name":"Uncomplicated diarrhea"
},
{
	"jumpto":"ENAS5304_8.6.12.2",
	"name":"Unfit patients, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.2.5",
	"name":"Unresectable colorectal liver metastases, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.8.0.0",
	"name":"Unresectable colorectal liver metastase [mCRC]"
},
{
	"jumpto":"ENAS5086_5.3.0.0",
	"name":"Unresectable mesothelioma, treatment recommendations"
},
{
	"jumpto":"ENAS5098_5.1.0.0",
	"name":"Unresectable TETs, treatment algorithm [TETs]"
},
{
	"jumpto":"ENAS5268_3.3.0.0",
	"name":"Upper body irradiation [N/V]"
},
{
	"jumpto":"ENAS5094_8.0.0.0",
	"name":"Urethral wash cytology [BC]"
},
{
	"jumpto":"ENAS5304_4.2.4.0",
	"name":"Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) [mCRC]"
},
{
	"jumpto":"ENAS5647_14.3.4.0",
	"name":"Uridine triacetate [Diarrh.]"
},
{
	"jumpto":"ENAS5304_8.6.12.1",
	"name":"Use of biologicals, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.6.0",
	"name":"Use of biologicals [mCRC]"
},
{
	"jumpto":"ENAS5304_8.6.12.1",
	"name":"Use of cytotoxics, summary [mCRC]"
},
{
	"jumpto":"ENAS5304_5.14.6.0",
	"name":"Use of cytotoxics [mCRC]"
},
{
	"jumpto":"ENAS6338_9.5.4.0",
	"name":"Use of personalised medicine, summary [LCC]"
},
{
	"jumpto":"ENAS6338_6.4.0.0",
	"name":"Use of personalised medicine [LCC]"
},
{
	"jumpto":"ENAS5262_4.3.3.0",
	"name":"Vancomycin [CVC]"
},
{
	"jumpto":"ENAS5269_5.9.7.0",
	"name":"Vancomycin [FN]"
},
{
	"jumpto":"ENAS5410_3.6.5.0",
	"name":"Vascular endothelial growth factor"
},
{
	"jumpto":"ENAS5304_5.14.2.0",
	"name":"Vascular endothelial growth factor (VEGF) [mCRC]"
},
{
	"jumpto":"ENAS5265_8.4.5.0",
	"name":"Vena cava filter, summary [VTE]"
},
{
	"jumpto":"ENAS5265_5.5.0.0",
	"name":"Vena cava filter [VTE]"
},
{
	"jumpto":"ENAS5648_3.3.4.0",
	"name":"Venous thromboembolic events [Anaemia]"
},
{
	"jumpto":"ENAS5096_3.1.0.0",
	"name":"Verrucous carcinoma [PenCa]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Vesicant [Extra]"
},
{
	"jumpto":"ENAS5269_6.4.6.5",
	"name":"Vesicular lesions, summary [FN]"
},
{
	"jumpto":"ENAS5269_5.9.5.0",
	"name":"Vesicular lesions [FN]"
},
{
	"jumpto":"ENAS5267_3.0.0.0",
	"name":"Vinca alkaloids [Extra]"
},
{
	"jumpto":"ENAS5071_4.3.2.0",
	"name":"Vincristine, second-line treatment [SCLC]"
},
{
	"jumpto":"ENAS5094_5.2.0.0",
	"name":"Vinflunine, second line treatment [BC]"
},
{
	"jumpto":"ENAS5410_3.6.5.0",
	"name":"Vogt-Koyanagi-Harada syndrome [irAEs]"
},
{
	"jumpto":"ENAS5410_3.6.5.0",
	"name":"Vogt-‍Koyanagi-‍Harada syn­drome [irAEs]"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"Von Hippel-Lindau gene alterations [RCC]"
},
{
	"jumpto":"ENAS5269_5.9.4.0",
	"name":"Voriconazole [FN]"
},
{
	"jumpto":"ENAS5265_2.1.0.0",
	"name":"VTE, risk factors [VTE]"
},
{
	"jumpto":"ENAS5648_9.1.1.4",
	"name":"VTE risk and ESA, summary [Anaemia]"
},
{
	"jumpto":"ENAS5265_8.1.0.0",
	"name":"VTE risk factors, summary"
},
{
	"jumpto":"ENAS5648_3.3.4.0",
	"name":"VTE risk [Anaemia]"
},
{
	"jumpto":"ENAS5265_5.1.1.0",
	"name":"VTE treatment, acute"
},
{
	"jumpto":"ENAS5265_5.2.0.0",
	"name":"VTE treatment, long-term"
},
{
	"jumpto":"ENAS5062_2.2.0.0",
	"name":"Vulval intra-epithelial neoplasis (VIN)"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Weight loss (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5646_2.2.0.0",
	"name":"WHO-EORTC classification [PCLs]"
},
{
	"jumpto":"ENAS5285_3.0.0.0",
	"name":"WHO classification, renal cell tumors"
},
{
	"jumpto":"ENAS6229_2.2.0.0",
	"name":"WHO classification of bronchial NETs [NETs]"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"Whole exome analyses [mCRC]"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"Whole genome analyses [mCRC]"
},
{
	"jumpto":"ENAS5068_2.0.0.0",
	"name":"Whole genome sequencing (Pancreatic cancer)"
},
{
	"jumpto":"ENAS5304_4.2.6.0",
	"name":"Whole transcriptome analyses [mCRC]"
},
{
	"jumpto":"ENAS5263_9.2.0.0",
	"name":"WHO scale, oral mucositis [Mucosa]"
},
{
	"jumpto":"ENAS5263_14.8.2.0",
	"name":"WHO scale, summary [Mucosa]"
},
{
	"jumpto":"ENAS5263_11.2.2.0",
	"name":"Zinc supplements [Mucosa]"
},
{
	"jumpto":"ENAS5092_4.4.0.0",
	"name":"Zoledronate [PC]"
},
{
	"jumpto":"ENAS5285_6.2.2.8",
	"name":"Zoledronic acid [RCC]"
},
{
	"jumpto":"ENAS5304_5.14.7.0",
	"name":"Zurich treatment algorithm [mCRC]"
},
{
	"jumpto":"ENAS5097_2.0.0.0",
	"name":"α-fetoprotein [TS/T-NS]"
},
{
	"jumpto":"ENAS5283_4.3.3.1",
	"name":"≥ stage IB gastric cancer"
}
]